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Abstract
As the central function of PDEs within cells is to control the levels of the cyclic 
nucleotides, it was surprising to find that the PDE4A gene encoded a splice variant, called 
PDE4A7 (2EL) that is catalytic ally inactive. This protein was investigated further by 
firstly determining its intracellular localisation using the methods of siibcellular 
fractionation and Laser Scamiing Confocal Microscopy (LSCM). Interestingly, PDE4A7 
when over-expressed in COS-1 cells was found exclusively within the nuclear 
compartment. This was in contrast to that of the catalytically active long isoform, 
PDE4A4B, which was found to be extranuclear. Subcellular fractionation studies revealed 
that the major fraction of PDE4A4B was localised within the cytosolic (S2) fraction, 
whereas PDE4A7 was localised exclusively within the low speed particulate (PI) fraction. 
Therefore, despite sharing identical core regions, both PDE4A4B and PDE4A7 were found 
in completely different compartments. Using chimeric constructs, I firstly demonstrated 
that the central core was exclusively located to the particulate (PI) fraction even in the 
absence of the PDE4A7 N-terminal region. Secondly, I demonstrated that replacing the C- 
terminal of PDE4A7 with 19 amino acids from the C-terminal region that is common to all 
the active PDE4As was enough to cause re-distribution of a fraction of the PDE4A7 central 
core to the cytosolic (S2) fraction. These analyses established that the cytosolic targeting 
observed with the active PDE4A enzymes can be attributed to a small portion of sequence 
located within their C-teiminal regions.
In Chapter 4, the yeast two hybrid screening procedure was used to try and identify 
binding partners for PDE4A7. Proteins identified as potential binding partners for 
PDE4A7 included; CREB binding protein (CBP), RanBPM9 and niRNA from the 
KIAA0160 gene. However, upon further analysis I demonstrated that both CBP and 
RanBPM9 were false positives generated from the yeast two-hybrid screen. The 
interaction between PDE4A7 and the mRNA from the KIAA0160 gene has yet to be re­
evaluated.
In Chapter 5, I used the methods of gene microarray and RT-PCR to address 
whether the functional role of PDE4A7 within the nucleus was to control the expression 
levels of other genes. Gene microarray results demonstrated that the expression levels of a 
large number of genes changed in response to the over-expression of PDE4A7. Next, RT- 
PCR was used in an attempt to verify a small number of these changes. However, RT-PCR 
analysis did not support the changes observed with gene microaixay. It was concluded that 
microanay had generated false positive data for these particular genes.
As yet the basis for the nuclear targeting of PDE4A7 and the function of this 
protein within this compartment remains to be elucidated.
Finally, in Chapter 6, I performed partial characterisation studies on a novel 
PDE4A isofoim, called HSPDE4A11. Transient expression of HSPDE4A11 in COS-7 
cells allowed the detection of a llSkD a protein in both the soluble and particulate 
fractions. The soluble and particulate forms of HSPDE4A11 exhibited similar Km values 
for cAMP hydrolysis (~2.5pM) and Vmax values.
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IChapter 1 
General Introduction
1.1 Cyclic nucleotide signalling pathways
1.1.1 Generation and detection of cAMP
Cyclic adenosine monophosphate (cAMP) was first discovered in 1957 [Sutherland 
et al., 1958] and cyclic guanosine monophosphate (cGMP) was first identified as an 
important signalling molecule in 1963 by Ashman [Ashman et al., 1963]. Since their 
discovery both cAMP and cGMP have been found to regulate a wide range of different 
cellular processes including neurotransmission, glycogenolysis, transcription, and 
inflammatory processes [Verne et al., 1973; Montminy, 1997; Torphy, 1998] and cAMP 
has also been shown to regulate cell growth and differentiation [Lui, 1982]. The production 
and detection of cAMP will be discussed in brief, followed by an Tn depth’ discussion of 
the targeting and regulation of phosphodiesterases (PDEs), which are the enzymes that 
catalyse the hydrolysis of these cyclic nucleotides.
1.1.2 G protein coupled receptors
The events preceding the production of cAMP include a ligand such as a hormone 
or neurotransmitter binding to its cognate G protein coupled receptor (GPCR), which then 
stimulates Gsa to activate adenylyl cyclase and produce cAMP (cAMP signalling pathway 
is illustrated in figure 1.1). This process is discussed in more depth below.
Although over 1000 GPCRs exist, each share a common general structure 
composed of an extracellular N-tenninal followed by seven transmembrane domains that 
are coimected by tinee extracellular and three intracellular loops and end with a 
cytoplasmic C-terminal tail [Gether et al., 1998; Hamm, 1998]. Prior to activation, G 
proteins exist as heterodimers composed of an a  subunit (which bears the guanine 
nucleotide site) associated with a (3y subunit dimer. After ligand binding, GPCRs undergo 
a confoiinational change that exposes residues capable of interacting with particular G 
proteins. The N-teiminal region of Gsa can then interact with residues in the third 
cytoplasmic loop of the activated GPCR [Martin et al., 1996]. This interaction results in a 
confonnational change in the G proteins that results in the exchange of GDP for GTP in
1
the a  subunit. The Gsa subunit dissociates from the Gpy subunit dimer and goes on to 
activate adenylyl cyclase and Gpy can also go on and activate downstream effectors 
[Gether and Ulrik, 2000; Hamm, 1998]. It should also be noted that there are different G a 
subunits that can serve to activate or inhibit adenylyl cyclase. De-activation of this process 
ensues when GTP is hydrolysed back to GDP by the intrinsic GTPase activity of the Gsa 
subunit. There are of course additional mechanisms that de-activate GPCR signals which 
are reviewed elsewhere [Bunemaim and Hosey, 1999].
1.1.3 Adenylyl cyclase
The adenylyl cyclase enzyme family consists of nine isoforms that all catalyse 
cAMP from ATP when activated by Gsa-GTP. However, regulation of these enzymes is 
by no means a simple process as they can also be regulated by PKA, PKC, calcium (Ca^^), 
calcium/calmodulin (CaUCaM), Gia and Gpy in an isoform-specific fashion [Hanoune et 
al., 2001; Patel et al., 2001].
Each adenylyl cyclase isofonn demonstrates a common overall structme consisting 
of two transmembrane domains (Ml and M2) that are each composed of six 
transmembrane domains and two large cytoplasmic loops (Cl and C2), which can be 
further sub-divided into the regions of C la , C ip, C2a and C2p (figure 1.1) [Hurley, 1999; 
Tesmer et al., 1998]. The C la  and C2a regions form the catalytic site of adenylyl cyclase. 
The C2a region provides the site of interaction for Gsa and Gpy [Tang and Gilman, 1995; 
Yan, Huang et al., 1997]. The C lp region provides the domain that mediates the 
regulation of certain adenylyl cyclase isoforms by PKA, calcium, Ca^’^ /CaM etc (as 
described above) [Tesmer and Sprang, 1998]. The effect this regulation has on enzyme 
activity depends on the isoform. Forskolin can activate all the adenylyl cyclases, except 
AC-IX, by stabilizing the interactions between the two cytoplasmic domains [Sunahara et 
al., 1997]. The differences found in cAMP responsiveness in different tissues can be 
accounted for by different expression patterns of the differentially regulated adenylyl 
cyclases (Table 1.1). The main intracellular detector of cAMP is the cAMP-dependent 
protein kinase (PKA) [Taylor, Knighton et al., 1992] other targets regulated by cAMP 
include cyclic nucleotide gated ion chamiels [Pedarzani and Storm, 1995] and the GTP 
exchange proteins of Epac [de Rooij, Zwartkruis et al., 1998; Kawasaki, Springett et al., 
1998].
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1.1.4 Protein Kinase A
The most extensively studied intracellular receptor of cAMP is PKA. In its inactive 
state, PKA exists as a heterotetramer composed of two catalytic subunits (C) bound to a 
regulatory subunit dimer (R). When four molecules of cAMP bind to the regulatory 
subunit dimer, a confonnational change ensues, which causes dissociation of the enzyme 
into an R subunit and two C subunits that can phosphorylate substrate proteins on serine or 
threonine residues in an RRXS/T motif {figure L I )  [reviewed in Skalhegg and Tasken, 
2000 and the substrates of PKA are reviewed in Shabb, 2001]. Multiple isofonns of both 
the R and C subunits exist, leading to different isoforms that possess different biochemical 
characteristics. The R subunits are encoded by lour different genes (RIa, Rip, R lla  and 
RIip) [Lee et al., 1983; Scott et a l, 1987] with alternative splice variants reported for RIa 
[Solberg et a l, 1997]. Tluee different genes (Ca, Cp and Cy) encode the C subunit with 
alternative splice variants reported for both C a and Cp [Chiivia et a l, 1988]. The PKAÏ 
holoenzymes (RIa and Rip) exist as soluble species and are activated by weak cAMP 
signals, whereas PKAII (R lla and RIIP) associate with the particulate fraction of the cell 
and are activated only by high and persistent cAMP signals [Taylor et a l, 1992]. R Ia and 
R lla  are ubiquitously expressed whereas RIip has been found expressed predominantly in 
endocrine, brain, fat and reproductive tissues [Taylor et a l, 1992].
PKAII is localised to specific intracellular locations by associating with targeting 
proteins called A-kinase anchoring proteins (AKAPs). AKAPs are a family of proteins 
that demonstrate little sequence similarity to each other but all possess a RII binding 
domain [Feliciello et a l, 2001; Michel and Scott, 2002]. This domain is an amphipathic 
helix that binds to the first 30 amino acids in the N-tenninal of the RII subunit dimer, a 
region that is also responsible for promoting the dimerization of the RII subunits [Li and 
Rubin, 1995; Newlon et a l, 1997]. Each AKAP contains a unique targeting domain, 
responsible for directing the PKA holoenzymes to the appropriate cellular location 
[Colledge and Scott, 1999]. Most AKAPs preferentially bind to the RII subunits of PKA. 
However, recently a family of dual function AKAPs, capable of binding to both RI and RII 
subunit dimers, have been identified [Banky et a l, 2000; Feliciello et a l, 2001].
1.1.5 cAMP signalling independent from PKA
cAMP can activate the small GTPases of Rapl and Rap2 in a PKA-independent 
manner by directly activating the guanine nucleotide exchange factor (GEF) Epac 
(exchange protein directly activated by cAMP) [de Rooij et al., 1998; Kawasaki et al., 
1998], The Epac family consists of thiee members: Epacl, Epac2 and Repac (for related 
to Epac) [de Rooij et al., 2000]. The N-tenninals of Epacl and Epac2 contain one and two 
cAMP binding sites respectively, which, in the absence of cAMP act as an inhibitory 
domain to these proteins. Upon the binding of cAMP to these domains, a conformational 
change ensues that allows the GEF domain, located in the C-terminal catalytic site, to 
specifically activate both the Rapl and Rap2 GTPases [de Rooij et a l, 2000]. Also located 
within the N-teiminal of Epacl is a DEP domain (for Disheveled, Egl-10 and pleckstrin 
[Ponting and Bork, 1996]), found responsible for the membrane localisation of this protein 
[de Rooij et a l, 2000]. Repac lacks the cAMP binding domains and, as a result, remains 
constitutively active.
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Figure 1.1 cAMP signalling. cAMP generation begins with ligand binding to its 
cognate seven transmembrane domain receptor. The activated receptor stimulates 
the release of the Ga subunit from the py subunit dimer. Ga then diffuses along 
the membrane and interacts with adenylyl cyclase, which results in either 
activation or inhibition in the production of cAMP. If it is Gas, then cAMP will 
be produced, which then binds to the regulatory subunits of PKA causing the 
release of the catalytic subunits that can phosphorylate a number of other target 
proteins. cAMP degradation is catalysed by the phosphodiesterase enzymes.
1.2 Phosphodiesterase enzymes
PDE activity was first discovered in heai1 tissues, soon after the discovery of cAMP 
[Sutherland and Rail, 1958]. Following this, many other PDEs have since been discovered 
and characterised. These enzymes hydrolyse the 3’-5’ phosphodiester bond of either 
cAMP and/or cGMP to generate inactive 5’-nucleoside monophosphates. PDEs are 
encoded hy 21 different genes, the products of which are classified into 11 families based 
on primary amino acid sequence, substiate specificity, regulatory properties and their 
sensitivity to different inhibitors [reviewed in Houslay, 2001]. Further complexity arises 
within each family as a result of alternative mRNA 5’ splicing, which yields isofomis with 
unique N-terminal sequences. There are also members that rmdergo 5’ and 3’ mRNA 
splicing, which generate isoforms containing unique N- and C-terminal regions. This has 
been demonstrated for members of the PDEl and PDE4 enzyme families.
The unique N-tenninal sequence has been found to confer targeting and regulatory 
properties on these enzymes, for example the calmodulin-binding domains on PDEl 
enzymes, the GAP domains of PDE2, PDE5 and PDE6 and membrane association of 
PDE3s is mediated by their hydrophobic N-terminal portion. These various features are 
discussed in depth later. As PDEs can be regulated by other signals, they seiwe as a point 
of cross-talk between different signalling cascades [Conti et al. 1995; reviewed in Houslay, 
2001]. Despite the diversity of PDEs, they each share a degree o f structui'al homology. 
This relates to the catalytic domain, which is located towards the C-tenninus of all PDEs 
and is typically around 275 amino acids in size. This domain demonstrates a sequence 
homology of 80% between isoforms of the same gene family and 25-40% sequence 
identity between isoenzymes from different gene families [Charbonneau et al., 1986]. The 
catalytic core also contains a PDE-specifrc sequence motif of HD(X)2 H(X)4 N and two 
consensus Zn^'^-binding domains [Beavo, 1995].
Due to the large number of PDE enzymes, a system of nomenclature was developed 
for describing them [Beavo et al., 1994]. This can be demonstrated by using HSPDE4A4 
as an example where ‘HS’ indicates the species of origin in this case Homo sapiens, PDE4 
refers to the gene family, ‘A ’ refers to the gene and ‘4’ refers to the splice variant. A letter 
after the splice variant number refers to the GenBank report for a specific splice variant 
that has been cloned separately by two or more groups.
PDEs tightly control the levels of cAMP and cGMP during hormonal stimulation. 
The targeting of these enzymes to different cellular locations serves to channel cAMP or 
cGMP to the appropriate intracellular detector and can also keep the cAMP or cGMP
signal confined to a particular sub-compartment of the cell [Houslay and Milligan, 1997]. 
Therefore, PDEs have an important role in dictating the cellular response to hormone or 
neurotransmitter stimulation. Each of the 11 PDE families are discussed in more depth 
below with Table 1.2 summarising the general characteristics of each family.
1.2.1 PDE1 enzyme family
The existence of a calcium stimulated PDE was first identified in rat brain 
[Kakiuchi, 1970]. The PDEl family of enzymes are encoded by tlu*ee different genes: 
PDEIA, which encodes two splice variants (PDElAl and PDE1A2); PDEIB encodes one 
splice variant (PDEIB 1) and PDE 1C encodes five splice variants (PDBICI, PDE1C2, 
PDE1C3, PDE1C4 and PDE1C5) [Kakkar et al., 1999; Sonnenburg et a l, 1998]. The 
multiple splice variants of this family result hom alternative 5’ and 3’ mRNA splicing, 
generating enzymes with unique N- and C-termini. PDEl enzymes are able to hydrolyse 
both cAMP and cGMP, although the PDEIA and PDEIB 1 enzymes demonstrate a higher 
affinity for cGMP than cAMP, whereas the PDE 1C enzymes hydrolyse both these cyclic 
nucleotides equally well. PDEl enzymes are activated by the binding of Ca^V Calmodulin 
(Ca^^/CaM) to paired domains located within their N-tenninal regions. Their affinity for 
CaM differs for each of the PDEl isofonns [reviewed in Kakkar et al, 1999].
Phosphorylation of certain PDEl splice variants by either PKA or Cam kinase II 
reduces their affinity for CaM and results in a reduction of PDEl enzyme activity 
[Hashimoto et al., 1989; Sharma and Wang, 1985]. The PDEl enzyme family 
demonstrates a broad tissue distribution with the highest expression found in the testis, 
heart and neural tissues. These enzymes are postulated to have specific functional roles in 
neuronal functions as their expression is selective to particular brain areas including the 
cortex, regions of the hippocampus and the dentate gyrus [Juilfs et al., 1997; Van et al., 
1996].
1.2.2 PDE2 enzyme family
The PDE2 splice variants are encoded by a single gene called PDE2A. This gene 
encodes the tlnee splice variants of PDE2A1, PDE2A2 and PDE2A3, which are found 
distributed between the soluble and particulate fraction of cells [reviewed in Beavo, 1995]. 
PDE2 enzymes localised to the particulate fraction of cells contain hydrophobic N- 
teiminals, which may mediate membrane association. These enzymes can hydrolyse both 
cAMP (Km 15-30pM) and cGMP (Km 30-50pM), with affinity for nucleotide hydrolysis
increased by the binding of cGMP to allosteric non-catalytic cGMP sites located within the 
N-tenninal portion of PDE2s [Manganiello et al., 1990].
PDE2 expression is high within the adrenal cortex, olfactory neurons and a subset 
of goblet cells. These enzymes have been implicated as having important functional roles 
in catecholamine secretion [MacFarland et al., 1997], regulation of calcium chaimels 
[Hartzeli and Fischmeister, 1986] and olfactory signalling [Juilfs et al., 1997]. However, 
little is known about the functional role of this enzyme family.
1.2.3 PDE3 enzyme family
Both cAMP and cGMP can act as substi'ates for the PDE3 enzymes, therefore, both 
these nucleotides compete for hydrolysis by these enzymes. Nevertheless, cGMP 
hydrolysis is so low that this group of enzymes are effectively cAMP-specific. PDE3 
isoforms are encoded by the two genes of PDE3A and PDE3B [Meacci et al., 1992]. 
PDE3A is abundant in the cardiovascular system and airways [Harrison et al., 1986, 
MacPhee et al., 1986] and PDE3B is abundant in adipose tissue [Degerman et al., 1997]. 
These enzymes are found distributed between the soluble and particulate fractions of cells. 
Located within the N-terminal of PDE3s is a hydrophobic region of sequence that has been 
suggested to mediate membrane association [Shakur et al., 2000]. Both PDE3A and 
PDE3B can be phosphorylated and activated by PKA on sequence present within their N- 
termini [Manganiello et al., 1992]. In adipocytes, insulin promotes the phosphorylation 
and activation of PDE3B in a process involving insulin-receptor substrate-1 (IRS-1), 
phosphatidylinositol 3-kinase (PI3-K) and insulin-stimulated protein kinase (PDE3IK) 
[Rahn et al., 1996]. Activation of PDE3B lowers cAMP levels, which results in 
dephosphorylation and inactivation of hormone-sensitive lipase (HSL) coupled with a 
decrease in lipolysis in white fat (adipocytes) [Ralm et al., 1996]. PDE3 enzymes have 
also been implicated to have a role in processes such as cardiac function, platelet 
aggregation and regulation of blood pressure [reviewed in Beavo, 1995].
1.2.4 PDE4 enzyme family
The PDE4 enzyme family are encoded by the four genes of PDE4A, PDE4B, 
PDE4C and PDE4D and because the products of these genes, their localisation and 
regulation are reviewed in a later section (Section 1.4), they will be omitted hnm 
discussion in this overview section.
1.2.5 PDE5 enzyme family
PDE5 cDNA was first isolated from bovine lung [McAllister-Lucas et a l, 1993]. 
The PDE5 family of enzymes are encoded by a single gene called PDE5 A, which encodes 
for the two splice variants of PDE5A1 and PDE5A2 that are specific for the hydrolysis of 
cGMP [Loughney et a l, 1998; Kotera, Fujishige et ah, 1999; Stacey, Rulten et al., 1998]. 
Located within the N-tenninal portion of PDE5 are two high affinity, non-catalytic cGMP- 
binding sites (GAF domains) [Tuiko et ah, 1996]. Once cGMP occupies both of these 
sites, PDE5 can be phosphorylated by either PKA or PKG. Although no clear functional 
consequence for this has been identified [Thomas et al., 1992], it has been suggested that 
phosphorylation by these kinases may seiwe to up-regulate PDE5 activity.
PDE5 is expressed as a cytosolic species in platelets, spleen, limg and vascular 
smooth muscle cells (VSCM) [Loughney et ah, 1998; Stacey et ah, 1998]. Zaprinast and 
sildenafil are potent inhibitors of PDE5 enzymes, with sildenafil (Viagra) marketed for the 
treatment of male erectile dysfunction [Corbin and Francis, 1999; Gopal et al., 2001].
1.2.6 PDE6 enzyme family
PDE6 has been found localised to the rod and cone cells of the retina and has a 
major role in the process of visual signal transduction. PDE6 enzymes specifically 
hydrolyse cGMP and contain two allosteric cGMP binding sites (GAF domains) that are 
located within their N-terminal regions. These enzymes exist either as heterotetramers 
composed of variations in catalytic units, either of a  and p if in rod cells or as 
homotetramers consisting of two a ’ if  in cone cells. Each catalytic dimer is complexed 
with two inhibitory y-subunits when cGMP is bound [Aitemyev et al., 1998; Mou and 
Cote, 2001]. Soluble PDE6 contains an additional 8-subunit responsible for conferring 
solubility on the enzymes by masking their membrane binding motifs [Florio et al., 1996]. 
Following illumination, a photon activates rhodopsin, which promotes the GDP/GTP 
exchange of transducin. The GTP-bound a-subunit of transducin interacts with and 
releases the inhibitory y-subunits of PDE6, resulting in an increase in PDE6 activity. 
cGMP is hyrolysed, which causes the dissociation of cGMP from the cGMP-gated 
channels followed by their closure.
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1.2.7 PDB7 enzyme family
PDE7 was first discovered by a genetic screening procedure, which was developed 
in yeast to identify high affinity cAMP PDE cDNA clones. The PDE7 enzyme family 
demonstrates a high specificity for cAMP (Km 0.2-IpM) and are resistant to inhibition by 
a number of common PDE inhibitors. PDE7s are encoded by two genes: PDE7A [Bloom 
and Beavo, 1996; Han et al., 1997] and PDE7B [Gardner et al., 2000]. PDE7A encodes for 
three splice variants (PDE7A1, PDE7A2 and PDE7A3), which each possess unique N- 
tenninal regions. The N-terminal region of PDE7A1 and PDE7A2 impose differential 
intracellular targeting on these enzymes as PDE7A1 is found associated with both the 
soluble and particulate fractions of cardiac and skeletal muscle whereas PDE7A2, which 
possesses a hydrophobic N-tenninal region, promotes particulate association in these cells 
[Han et al., 1997].
Interest developed in PDE7A1 when it was found induced with the onset of T-cell 
activation. It has been suggested to play a crucial role in promoting T cell activation and 
proliferation [Li et al., 1997]. Recently PDE7A3 was also suggested to be actively 
involved in this process [Glavas et al., 2001].
PDE7B transcripts have been identified in the putamen, caudate nucleus, heart and 
skeletal muscle, but its functional role is yet unclear [Gardner et al., 2000].
1.2.8 PDE8 enzyme family
The PDE8 family of enzymes are encoded by the two genes, PDE8A [Fisher et al., 
1998; Soderling et al., 1998] and PDE8B [Hayashi et al., 1998]. The PDE8 enzymes are 
specific for the hydrolysis of cAMP (Km 70nM) and are resistant to inliibition by the non- 
selective (general) PDE inhibitor, IBMX. Located within the N-tenninal regions o f PDE8 
is a PAS domain (for Per, ARNT and Sim proteins, where this domain was originally 
identified), which in other proteins mediates homomeric and heteromeric protein-protein 
interactions [reviewed in Soderling and Beavo, 2000]. The function of the PAS domain in 
PDE8 is not yet known. PDE8A expression is most abundant in the testis, ovary, small 
intestine and colon [Fisher et al., 1998], whereas PDE8B is most highly expressed in the 
thyroid gland [Hayashi et al., 1998]. Again a functional role for PDE8 enzymes has yet to 
be established although, recently, the PDE8A1 splice variant was shown to be induced in 
response to T cell activation [Glavas et al., 2001].
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1.2.9 PDE9 enzyme family
PDE9 was first identified by bioinformatic screening of an expressed sequence tag 
(EST) database for entities having a PDE motif. The PDE9 family is composed of four 
splice variants encoded by the PDE9A gene generated as a result of alternative 5’ mRNA 
splicing [Fisher et al., 1997; Soderling et al., 1998]. cGMP is hyrolysed with high affinity 
by PDE9s (Km 70pM). They, like PDE8 are also insensitive to selective inhibitors such as 
sildenafil (PDE5), rolipram (PDE4) as well as the non-selective PDE inliibitor IBMX. 
PDE9 mRNA demonstrates a wide tissue distribution. As yet no functional role for PDE9 
is known [Guipponi et al., 1998] although it has been postulated that PDE9, with its high 
affinity for cGMP and broad tissue distribution, may serve to maintain the basal levels of 
cAMP.
1.2.10 PDE 10 enzyme family
PDEIO was identified using bioinformatics to search an EST database for entities 
having a PDE motif. To date, the PDEIO family contains two splice variants that are 
encoded by the PDEl DA gene (PDElOAl and PDE10A2) and are capable of hydrolysing 
both cAMP (Km 0.26p.M) and cGMP (Km 7.2pM) [Fujishige et al., 1999; Loughney et al. 
1999; Soderling et al., 1999]. These enzymes are inhibited by the non-selective PDE 
inhibitor of IBMX. Located within the N-tenninal of PDEIO are two domains that 
resemble the cGMP binding domains of PDE2, PDE5 and PDE6. However, as yet, any 
regulatory role they impose on PDEIO remains to be resolved [reviewed in Soderling and 
Beavo, 2000]. That cAMP can inhibit cGMP hydrolysis PDEIO led to their classification 
as the cAMP-inhibited cGMP PDEs. PDEIO mRNA has been identified in a number of 
tissues with abundance detected in the brain and testis [Fujishige et al., 1999].
1.2.11 PDE11 enzyme family
The PD E ll family was also discovered by bioinfoimatic screening of an Incyte 
database for entities containing a PDE motif. Three PDEl 1 splice variants are postulated 
to arise form the PDEl 1A gene, however, PDEl 1 A l is the only splice variant to have been 
characterised to date. P D E llA l can hydrolyse both cAMP (Km l.OdpM) and cGMP (Km 
0.52pM) and can be potently inhibited by dipyiidamole and IBMX [Fawcett et al., 2000]. 
Contained within the N-terminal region of PDEl 1 is a domain that is homologous to the 
cGMP-binding domain of PDE2, PDE5, PDE6 and PDEIO, as yet no regulatory role is
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known for this domain [Fawcett et al., 2000]. PD E ll A transcripts have been detected in 
skeletal muscle, prostate, kidney, liver, testis, pituitary and salivary glands, but the 
functional role of this enzyme remains to be elucidated [Yuasa et al., 2000].
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Table 1.2 Phosphodiesterase superfamily
PDE Family Genes Substrate
Specificity
Inhibitors Examples of 
Regulation
PDElHZZHZ
Ca^ VCaM
Binding
X
Catalytic
PDEIA
PDEIB
PDEIC
cAMP and 
cGMP
Nicardipine,
Methoxymethyl"
IBMX
Vinpocetine,
KS-505a
Stimulated by 
Ca*^  / calmodulin. 
Phosphorylated by 
PKAiPKG
PDE2
cGMP binding 
GAF domain
PDE2A cAMP and 
cGMP
EHNA
Catalytic
Stimulated by 
cGMP
PDE3
Transmembrane
Domain
PDE3A
PDE3B
cAMP and 
cGMP
Catalytic
Cilostimide,
Milrinone,
Enoximone,
cGMP can inhibit 
cAMP hydrolysis. 
Phosphorylated and 
activated by PKA 
and by insidin- 
dependent kinases.
PDE4
UCRl UCR2 Catalytic
PDE4A
PDE4B
PDE4C
PDE4D
cAMP Specific Rolipram,
Denbufylline
Phosphorylated by 
PKA and by 
ERK2
Long isoforms 
activated by 
phosphatidic add.
PDE5
cGMP binding 
GAF domain
PDE5A
PDE5B
cGMP Specific
Catalytic
Zaprinast
Sildenafil
Dipyridamole
cGMP binding 
results in
phosphorylation by 
PKA/PKG
PDE6
cGMP binding 
GAF domain Catalytic
PDE6A
PDE6B
PDE6C
cGMP Specific Zaprinast,
Dipyridamole
Stimulated by 
transducin, when 
activated by 
photons. Inhibited 
by y subunit.
PDE7 PDE7A
PDE7B
cAMP Specific None reported
Catalytic
None reported
PDE8
PAS
Domain
PDE8A
PDE8B
cAMP Specific Dipyridamole 
(Ki = 4.5|iM)
Catalytic
None reported
PDE9 PDE9A cGMP Specific SCH 518666 
Zaprinast
Catalytic
None reported
PDEIO
cGMP binding 
GAF domain??
PDEIOA cAMP and 
cGMP
None reported
Catalytic
None reported
P D E ll
cGMP binding 
GAF domain??
PDEll A cAMP and 
cGMP
Catalytic
Zaprinast,
Dipyridamole
None reported
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1.3 Compartmentalîsation of cAMP signalling
It was first realised that cAMP signalling could be confined to a particular 
subcellular compartment hom studies reporting that the activation of two receptors which 
both stimulated adenylyl cyclase could generate quite different cellular responses. The 
earlier examples of compartmentalised cAMP signalling was demonstrated by Keely 
[Keely, 1977] where the stimulation of rat heart with either epinephrine ((32 adrenoreceptor 
agonist) or prostaglandin E l (PGEl) led to an increase in cAMP levels and activation of 
PKA. However, only epinephrine was found to phosphorylate and activate glycogen 
phosphorylase. The most conclusive evidence was generated by studies performed by 
Hayes et al [Hayes et al., 1980], whereby stimulation of cultured rat myocytes with 
isoproterenol or PGEl led both to increases in cAMP and subsequent activation of PKA. 
However, only isoproterenol stimulation led to contractile activity and the phosphorylation 
of a number of proteins whereas PGEl stimulation resulted in no cellular response. These 
studies demonstrated that isoproterenol and epinephrine-mediated cAMP signalling occur 
in different compartments to the cAMP response generated by PG E l.
Several studies have illustrated the importance of PDEs in generating a 
compartmentalised response. For example, exposure o f one half of a hog ventricular 
myocyte to isoproterenol, led to increases in cAMP and activation o f PKA. This resulted 
in the phosphorylation and stimulation of TocaF L-type Ca^^ channels (within the vicinity 
of agonist stimulation), but had little effect on Ca^ "^  channels located in the other half of the 
cell [Jurevicius and Fiscluneister, 1996]. In contrast, treatment of one half of the cell with 
the non-selective PDE inhibitor IBMX, followed by isoproterenol stimulation resulted not 
only in the stimulation of Ca^^ channels locally, but also of those channels distant from the 
site o f agonist/inhibitor administration [Jurevicius and Fiscluneister, 1996]. This study 
demonstrated that PDEs ai’e important in constraining the diffusion of cAMP and keep it 
contained within a particular subcellular location.
Studies perfonned by Dousa [Dousa, 1999] have demonstrated that PDE3 and 
PDE4 enzymes can control distinct pools of cAMP in the mesangial cells of kidney 
glomeruli. Inliibition of PDE3 enzymes in these cells by treatment with the PDE3- 
selective inhibitor cilostamide caused increases in cAMP, which inhibited mitotic DNA 
synthesis [Matousovic et al., 1995]. hi contrast, the inhibition of PDE4 enzyme activity 
with the PDE4-selective inhibitor rolipram caused no effect on mitotic DNA synthesis. 
However, the rolipram-mediated increases in cAMP were found to inhibit the production
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of reactive oxygen metabolite (ROM), which has a pathogenic role in glomemlonephiitis 
[Chini et al., 1997]. hi contrast to this, PDE3 inliibition had no effect on ROM production.
Therefore, the cellular response resulting from ligands that increase cAMP levels 
depends on a number of factors, including the isofonns of adenylyl cyclase, PICA and PDE 
that are expressed by the cell and also on their localisation. For example, adenylyl cyclase 
can be localised to discrete regions of the plasma membrane, certain isofonns of PKA are 
anchored to specific cellular domains by interacting with AKAPs and PDE isofonns can 
associate with particular cellular compartments by interacting with different binding 
partners [Houslay and Milligan, 1997]. PDEs are important in maintaining steep cAMP 
gradients and preventing levels of this nucleotide from becoming uniform. They also 
channel cAMP so that only particular PKA isoforms become activated [Houslay and 
Milligan, 1997].
1.4 PDE4 Phosphodiesterases
The PDE4 family of enzymes are encoded by four genes: PDE4A (cliromosome 
19pl3.1) [Davis et al., 1989; Sullivan et al., 1998], PDE4B (clnomosome 1) [Szpirer et al.,
1995], PDE4C (clnomosome 19pl3.2) [Sullivan et al., 1999] and PDE4D (chromosome 5) 
[Szpirer et al., 1995]. Each of these genes encodes for multiple splice variants produced as 
a result of alternative 5’ mRNA splicing [reviewed in Houslay, 2001 and Muller et al.,
1996]]. PDE4A1 (RDI) was the first PDE to be cloned and was identified by screening a 
rat brain cDNA library using the product of the Drosophila melanogaster dunce gene as a 
probe [Davis et al., 1989]. All PDE4 isoenzymes specifically hyrolyse cAMP and are 
resistant to regulation by either Ca^VCaM or cGMP. The compound rolipram acts as a 
competitive inhibitor of PDE4s and interacts with their catalytic site.
The catalytic site of PDE4 is -320-350 amino acids in size and shows common
similarity to the other PDE enzyme classes [Charbomieau et al., 1986]. Located N-
terminal to the catalytic domain are two regions of conserved sequence referred to as
upstream conseiwed region 1 (UCRl) and 2 (UCR2), which are 60 amino acids and 80
amino acids in size, respectively {figure 1.2) [reviewed in Houslay, 2001]. There are two
splice junctions that generate active PDE4s and these detennine whether the product
enzyme will contain one or both of these UCRs {figure 1.2 and figure 1.3). Those
enzymes containing both UCRl and UCR2 are referred to as long isoforms, whereas those
that lack a UCRl, but contain a UCR2, are referred to as short isofonns {figure 1.2 and
figure 1.3). Additionally, there are enzymes such as PDE4A1 (RDI) and PDE4D2 that
lack a UCRl and are missing the N-tenninal portion of UCR2; these enzymes are referred
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to as super-short isoforms (figure 1.2 and figure 1.3). The two regions of hypervariable 
sequence that connect UCRl to UCR2 and UCR2 to the catalytic domain are referred to as 
linker region 1 and 2 (LRl and LR2), respectively [reviewed in Houslay, 2001]. LRl and 
LR2 demonstrate no sequence similarity between different sub-families.
That the UCRl and UCR2 domains have been evolutionary conserved suggests 
they are important to the functioning of these enzymes. 'Yeast two hybrid’ studies and 
'pull down assays’ using various portions of PDE4D3 cDNA have revealed that the C- 
terminal portion of UCRl can interact with the N-terminal portion of UCR2 [Beai*d et al., 
2000]. This interaction can be blocked by mutating the positively charged residues of Ai'g- 
98 and Arg-101 in the UCRl region to alanine, or by mutating the negatively charged 
residues of Glu-146, Glu-147 and Asp-149 in UCR2 to alanine, indicating these domains 
associate by electrostatic interactions [Beard et al., 2000]. Phosphorylation of Ser^ "^  in the 
UCRl domain was found to ablate the interaction between UCRl and UCR2 and alters the 
conformation of the catalytic unit. However this has no effect on enzyme activity [Beard 
et al., 2000]. The UCRl and UCR2 domains are postulated to form a module that 
regulates the PDE4 catalytic domain.
As well as possessing these highly conseiwed domains certain PDE4 isoforms also 
have a unique N-tenninal sequence, whieh confers distinct targeting and regulatory 
properties on the enzyme [Houslay, 1996; Michie et al., 1995]. The first evidence that a 
PDE could be targeted by virtue of its unique N-terminal sequence came from studies 
performed on the super-short PDE4A1 enzyme (RDI) [Shakur et al., 1993]. PDE4A1 
associates with the plasma membrane and golgi apparatus. However, the removal of the 25 
amino acid unique N-terminal, to generate Met^^-RDl, produced an enzyme that was 
entirely cytosolic [Scotland and Houslay, 1995; Shakur et al., 1993]. Additionally, Met^^- 
RDl was also found to have a Vmax twice that of PDE4A1. This suggested that the 
targeting and regulation of the activity o f PDEs could be imposed, in part, by their unique 
N-terminal regions. To further test this theory, the 25 amino acid N-terminal of PDE4A1 
was frised to the cytosolic enzyme of chloramphenicol acetyltransferase (CAT), which 
caused this normally soluble enzyme to become completely membrane-associated 
[Scotland and Houslay, 1995]. This provided the definitive evidence that the N-terminal 
region of PDEs direct their intracellular targeting. This has since been demonstrated for 
many other PDEs [Houslay et al., 1995].
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Figure 1.2 Schematic representation of PDE4 enzymes. This figure 
shows a schematic representation of a typical long PDE4 enzyme. The 
unique N-terminal is shown as a thick black line. The upstream conserved 
regions (UCRl and UCR2) are coloured in light grey, the linker regions 
(LRl and LR2) are shown in dark grey, the catalytic domain is shown in 
white and the C-terminal domain is shown in black. The positions of the 
splice junctions that are responsible for producing long, short and 
supershort isoforms are marked by arrows.
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Figure 1.3 PDE4 mRNA transcripts generated from the human PDE4A, 
PDE4B, PDE4C and PDE4D genes. This figure shows a diagrammatic 
illustration of the mRNA transcripts that are generated from the four PDE4 
gene groups. The initiator and termination codons are marked with white- 
filled and black-filled squares, respectively. The upstream conserved regions 
(UCRl and UCR2) are shown in light grey, the linker regions are shown in 
dark grey, the catalytic core is in white and the C-terminal domain is shown 
in black. The dashed line connecting transcripts D1 and D2 indicates the 
region of sequence in PDE4D1 that is spliced out in PDE4D2.
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1.4.1 PDE4A subfamily
There are five different splice variants encoded by both the human and rat PDE4A 
gene including PDE4A4B (PDE46) [Sullivan et al., 1998] (rodent homologue PDE4A5 
[McPhee et al., 1995]), PDE4A10 (so called in human and rat) [Rena et al., 2001] and 
PDE4A11 (TM3; unpublished), which are all long isoforms that each contain a unique N- 
temiinal sequence that is generated as a result of alternative 5’mRNA splicing. There is 
also the supershort isoform called PDE4A1, which lacks a UCRl and contains a truncated 
UCR2 [Davis et al., 1989; Sullivan et al., 1998] and the highly unusual N- and C- 
terminally truncated PDE4A7 (2EL) [Horton et al., 1995]. All the transcripts generated 
from the human PDE4A gene are shown schematically in figure 1.3. The rat RNPDE4A8 
(RPDE39) has no human or mouse homologue [Bolger et al., 1996].
PDE4A7 was isolated from a human T cell library and is devoid of catalytic 
activity [Horton et al., 1995]. It is the only PDE4 found to possess a unique N- and C- 
terminal domain due to alternative 5’ and 3’ mRNA splicing. The 34 base pair insert 
within the highly conseiwed catalytic domain is responsible for making this enzyme 
inactive and causes the fi*ameshift that results in the premature termination of the transcript 
[Horton et al., 1995]. The cellular function of PDE4A7 remains to be elucidated.
1.4.1.1 PDE4A localisation and targeting
The first evidence that PDEs could be targeted to specific subcellular compartments 
by virtue of sequence located within their unique N-terminals came from studies perfonned 
on PDE4A1 [Scotland and Houslay, 1995; Shakur et al., 1993]. PDE4A1 localises 
specifically to the membrane and golgi apparatus and is therefore associates exclusively 
with the particulate fi*action of cells [Pooley et al., 1997]. This is in contrast to the 
homologues PDE4A4B and PDE4A5, which are distributed between both the soluble and 
particulate fraction of cells [Huston et al. 1996; O’Connell et al., 1996]. The particulate 
localisation of these enzymes is governed in part by their proline-and arginine-rich N- 
terminal domains, which mediate their interaction with the SH3 domains of other proteins 
such as the SRC-related tyrosyl kinases LYN and FYN and the cytoskeletal protein fodrin 
[Huston et al., 1996; O,Cornell et al., 1996]. Deletion of the N-tenninal of PDE4A4B 
caused a notable loss o f this species from the membrane ruffles. However, did not 
completely ablate particulate association [Huston et al., 1996]. An additional proline- and 
arginine-rich domain has been identified in the LR2 region of PDE4A4B, which can also 
bind the SH3 domains of LYN and FYN, demonstrating that regions other than the unique
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N-terminal are responsible for directing PDEs to their cellular location [McPhee et al., 
1999]. This point was further reinforced with studies performed on the rat homologue 
PDE4A5, whereby the N-tenninal of UCR2 was found to be partly responsible for 
mediating the membrane association o f this enzyme [Beard et al., 2002]. Interestingly, the 
particulate PDE4A4B isoform demonstrates a higher affinity for rolipram than its soluble 
counterpart suggesting that the interaction of the PDE4A4B N-tenninal with SH3 domain 
containing proteins induces a confoimational change in the enzyme. Therefore, the N- 
tenninal not only mediates targeting of PDEs, but can also control the conformation of the 
catalytic unit, as indicated by changes in activity and in sensitivity to the selective inhibitor 
rolipram.
In cells undergoing apoptosis, the unique N-terminal region of PDE4A5 is cleaved 
by caspase 3, thus preventing its interaction with the SH3 domain of LYN. This results in 
a re-distribution of the PDE4A5 enzyme [Huston et al, 2000]. PDE4A5 has been reported 
to have a role in promoting cell suiwival, as over-expression of PDE4A5 in Rat-1 cells 
protected them against staurosporine-induced apoptosis [Huston et al., 2000].
The PDE4A10 and PDE4A4B long isofonns differ in sequence only at their unique 
N-termini yet are targeted differently and possess distinct kinetic properties. PDE4A10 is 
predominantly localised to the perinuclear region of COS-1 cells, whereas PDE4A4B 
predominates at the cell margins and cortical cyto skeleton [Huston et al., 1996; 0,Comiell 
et al., 1996; Rena et al., 2001]. Both these enzymes can associate with the SH3 domains of 
LYN as they both share the proline- and arginine-rich LR2 region. However, PDE4A4B 
has a much higher affinity for LYN because it contains the additional proline- and 
arginine-rich sequence within its unique N-terminal (as already discussed). The 
differences in the unique N-tenninals of PDE4A4B and PDE4A10 also causes their 
catalytic sites to adopt distinct conformations as detected by the greater sensitivity of 
PDE4A10 to rolipram [Rena et al., 2001].
1.4.1.2 Regulation of PDE4As
Challenge of U937 cells with lipopolysacharide (EPS) or interferon-y (IFN-y) leads
to activation of PDE4A4B [MacKenzie and Houslay, 2000] and the stimulation of 3T3-
F442A pre-adipocytes with growth hormone causes the phosphorylation and activation of
PDE4A5 (rat homologue of PDE4A4) [MacKenzie et al., 1998]. The activation of both
these enzymes can be prevented by ti eatment of these cells with the phosphatidylinositol-3
kinase (PÏ3-kinase) inhibitor wortmanin or the inununosuppressant rapamycin.
Stimulation of PDE4A4B and PDE4A5 activity is mediated tlirough a pathway involving
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the PI3-kinase mediated activation of p70S6 kinase [MacKenzie et al., 1998; MacKenzie 
and Houslay, 2000]. The activation of PDE4A5 in 3T3-F442A cells sei*ves to block their 
differentiation into adipocytes.
Phosphatidic acid (PA) and phosphatidylserine (PS) can also activate PDE4A long 
isoforms by interacting with a region in the UCRl domain [Nemoz et al., 1997]. These 
phospholipids have no effect on the activity of the PDE4A short isoforms because they 
lack the UCRl domain. The lack of selectivity between different acidic phospholipids 
probably indicates a charge-charge interaction. This is in marked contrast to the selective 
interaction of PDE4A1 with PA, which occurs thiough binding to the TAPAS 1 domain.
PDE4As are not susceptible to the inhibitory phosphorylation by ERK2 because 
they cannot be recognised as substrates. This is because the first proline of the P-x-S/T-P 
ERK2 consensus motif is replaced by an arginine [Alvarez et a l, 1991].
1.4.2 PDE4B subfamily
There are currently four isoforms encoded by the PDE4B gene, including the three 
long isoforms of PDB4B1, PDE4B3, PDE4B4 and the short PDE4B2 isofonn [Huston et 
a l, 1997]. All of the transcripts generated from the human PDE4B gene are shown 
schematically in figure 1.3. All these enzymes have been found distributed between the 
particulate and soluble fractions of the cell. The particulate isoforms must interact with 
different binding partners as they are released differently with the use of different 
detergents. cAMP and phospholipids can impose different regulatory effects on the 
multiple PDE4B splice variants. For example, phosphorylation of PDE4B1 on Ser^^  ^by 
ERK2 imposes an inliibitory effect, whereas phosphorylation of PDE4B2 on its cognate 
serine residue (Ser"^ ^^ ) serves to activate this isoform [Baillie et a l, 2000]. Also, 
phosphatidic acid (PA) activates the long PDE4B1 isoform yet has no effect on the activity 
of the PDE4B2 short isoform [Nemoz et a l, 1997], indicating again a need for UCRl in 
mediating activation by PA.
Interestingly, PDE4B2 accounts for 95-100% of total cellular PDE4 mRNA in 
neutrophils and monocytes stimulated with EPS [Wang et a l, 1999; Jin and Conti, 2002]. 
This suggests that PDE4Bs may have an important role in mediating the immune response 
and in the future may serve as targets for anti-inflammatory dmgs [Jin and Conti, 2002].
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1.4.3 PDE4C subfamily
The human PDE4C gene is located on clnomosome 19pl3.1 and encodes for the 
three long fonns: PDE4C1, PDE4C2 and PDE4C3 [Owens et al., 1997; Sullivan et al., 
1999]. The transcripts generated from the human PDE4C gene are shown schematically in 
figure 1.3. As yet no short PDE4C isoforms have been identified and their occun'ence has 
been postulated to be very unlikely due to the extremely short introns at the position of 
predicted splice junctions [Sullivan et ah, 1999]. That PDE4C demonstrates a very 
specific tissue distribution, suggests that they have a particular fimctional role. Long 
PDE4C isofonns like all the other long form PDE4s are susceptible to the inhibitory 
phosphoiylation of ERK2 on Ser^^  ^within the catalytic unit [Baillie et al., 2000]
1.4.4 PDE4D subfamily
The PDE4D gene encodes for the short and super-short isoforms of PDE4D1 and 
PDE4D2, respectively and the three long isofonns of PDE4D3, PDE4D4 and PDE4D5. 
These differ by virtue of their extreme N-terminals, generated as a result of alternative 
5’mRNA splicing [Bolger et al., 1997]. All the transcripts generated from the human 
PDE4D gene are shown in figure 1.3. These isoforms differ in their tissue distributions, 
intracellular distribution and regulation by phosphorylation.
1.4.4.1 PDE4D localisation and targeting
Generally, PDE4D1 and PDE4D2 exist as soluble species [Erdogan and Houslay,
1997], whereas the long PDE4D isoforms are distributed between the particulate and 
soluble fractions of cells [Jin et al., 1998]. The particulate association of these enzymes is 
mediated by their ability to interact with other proteins via their N-tenninal domains, as 
discussed below.
PDE4D3 has been found localised to the centrosomal region in Sertoli cells (testis), 
where it has been found in a complex with PKA and the centrosomal PKA anchor protein 
AKAP450 [Tasken et al., 2001]. In heart tissues, PDE4D3 is localised to the perinuclear 
region by virtue of 15 residues of sequence located within its unique N-terminal, which 
mediates the interaction with the muscle selective A-Kinase Anchoring Protein (mAKAP) 
[Dodge et al., 2001]. Recently, it has been reported that PDE4D3 can be targeted to the 
golgi and centrosomes in certain cells by associating with the protein myomegalin [Verde 
et al., 2001]. This targeting of PDE4D3 to specific sub-compartments in the cell may serve
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to bring PDE4D3 to the sites of PKA action and allow the control of local cAMP levels 
and levels of PICA activity.
PDE4D4 interacts with the SRC homology 3 (SH3) domains of the proteins LYN, 
FYN, SRC and the cytoskeletal protein fodrin, an interaction that is mediated by the unique 
proline- and arginine-rich 136 amino acid N-terminal region [Beard et a l, 1999]. Unlike 
PDE4A4B, PDE4D4 demonstrates no preference for any particular SH3 domain- 
containing proteins [Beard et al,. 1999].
The 88 amino acid N-terminal of PDE4D5 allows it to interact with the WD-repeat 
protein RACKl (receptor for activated C-kinase) [Yarwood et a l, 1999]. Amino acids 12- 
29 of the PDE4D5 N-tenninal are found to be absolutely necessary for the binding of 
RACKl [Yarwood et a l, 1999]. Additionally native RACKl and PDB4D5 have been 
found to interact constitutively in numerous other cell types including HEK-293, SK-N-SH 
cells and 3T3-F442A fibroblasts. As yet the functional significance of this interaction 
remains to be elucidated.
1.4.4.2 Regulation of PDE4Ds
PDE enzymes can also be regulated by the post-translational modification of 
phosphorylation. Contained within the N-terminal of PDE4D3 are two PKA 
phosphorylation sites positioned at Ser^  ^ and Ser^ "^  [Hoffinan et a l, 1998; Sette and Conti,
1996]. Phosphorylation of Ser^ "^  is responsible for activating PDE4D3 activity, suggesting 
that other long forms could be substrates for PKA as this Ser^ "^  site is located within the 
highly conserved UCRl domain. Once phosphorylated, PDE4D3 demonstrates a 
heightened sensitivity to inhibition by rolipram, indicating that it has undergone a 
confonnational change.
PDE4D3 also harbours an ERK2 phosphorylation site within its C-terminal 
catalytic region, positioned at Ser^^ .^ ERK2 phosphorylation inhibits PDE4D3 activity 
[Hoffhian et a l, 1999], an effect that has also been reported for all other long PDE4 
iso forms with the exception of the PDE4As [Baillie et a l, 2000]. PDE4As are not 
recognised by ERK2 because the first pro line of the P-x-S/T-P ERK2 consensus motif is 
replaced by an arginine [Alvarez et a l, 1991]. Encompassing this ERK2 phosphorylation 
site in PDE4s are a KIM domain and FQF domain that seem to mediate the docking of 
ERK2. This was shown when mutation of these domains ablated the ability of ERK2 to 
bind to and phosphorylate PDE4D3 [MacKenzie et a l, 2000]. The short isoform of 
PDE4D1 also possesses the ERK2 consensus motif but, in contrast to PDE4D3, PDE4D1 
is activated by ERK2 phosphorylation [Baillie et a l, 2000].
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EOF stimulation of COS-1 cells over-expressing PDE4D3, induces inhibitory 
phosphorylation of this enzyme by ERK2, an effect that has also been demonstrated in 
cells where PDE4D3 is expressed natively [MacKenzie et al., 2000]. The resultant increase 
in cAMP causes activation of PKA, which then phosphorylates and re-activates PDE4D3. 
Therefore, PKA is able to reverse the ERK2 inhibitory effect [MacKenzie et al., 2000]. 
This provided evidence of cross-talk between ERK2 and cAMP signalling.
Both PDE4D3 and PDE4D5 are phosphorylated and activated by PKA in vascular 
smooth muscle cells (VSCM) in response to forskolin treatment [Liu and Maurice., 1999]. 
In addition, PDE4D3 was also foimd to be phosphorylated and activated by the PKC- 
mediated activation of the Raf-MEK-ERK cascade in these cells rather than inhibited, in 
response to Angiotensin II (Angll) [Liu and Maurice, 1999]. hiterestingly, stimulation of 
these VSCMs with both forskolin and Angll appeared to result in the activation and 
ti anslocation of a small fraction o f particulate PDE4D3 into the cytosolic fraction [Liu and 
Maurice, 1999].
PA has been shown to interact directly with sequence present within the N-terminal 
region of PDE4D3, which overlaps into the UCRl domain [Grange et al., 2000]. This 
interaction causes the same increase in activity in this enzyme that would result from 
phosphorylation by PKA. The PDE4D short fonns are unaffected by PA, possibly because 
they lack the required UCRl region [Grange et al., 2000].
PDE4D5 is activated in human aortic smooth muscle (HASM) cells in response to 
phorbol 12-myristate 13-acetate (PMA), which is smprising as ERK2 phosphorylation 
nonnally results in the inhibition of this enzyme. In this case however, ERK2 does inliibit 
PDE4D5 but it also promotes the generation of prostaglandin E2 (PGE2), which stimulates 
adenylyl cyclase to produce cAMP. This leads to the activation of PKA, which 
phosphorylates PDE4D5, ablates the inhibitory effect imposed by ERK2 phosphorylation 
and results in the activation of PDE4D5 [Baillie et al., 2001].
1.5 Transcriptional regulation of PDE4s
The expression patterns of PDE4s in cells can be regulated in response to chronic
hormonal stimulation [reviewed in Conti and Jin, 1999]. For example, the induction of
PDE4D1 and PDE4D2 has been noted in a number of cell types. This was first
demonstrated in Sertoli cells where treatment with follicle stimulating hoiTnone (FSH),
caused an increase in the levels of PDE4D1 and PDB4D2 mRNA after 1 hour and reached
maximum levels between 3 and 12 hours. This effect could be mirrored by treatment of
these cells with cAMP analogs [Swinnen et al., 1991]. An increase in PDE4D1 and
25
PDE4D2 luRNA levels in response to cAMP analogs, have been reported in a number of 
other cell types including Mono-Mac-6 cells [Verghese et al., 1995], L6 myoblasts [Naro 
et a l, 1999], FRTL-thyroid cells [Jin et a l, 1998] and Jurkat cells [Erdogan and Houslay,
1997]. FSH and thyroid stimulating hormone (TSH) stimulation of Sertoli cells and 
FRTL-5 thyroid cells respectively, induce the expression of only PDE4D1 and PDE4D2 
with no effect on the regulation of the other PDE4Ds. This led to the discovery that the 
expression of PDE4D1 and PDE4D2 were controlled by a distinct promoter from that of 
the other long form PDE4Ds [Vicini and Conti, 1997].
The levels of PDE4A and PDE4B mRNA transcripts are also found regulated in 
response to chronic activation of adenylyl cyclase. For example, PDE4A and PDE4B 
transcripts increase with the elevation of cAMP levels in Mono-Mac-6 cells [Verghese et 
a l, 1995] and U937 cells [Torphy et a l, 1992]. In one report elevated cAMP levels in 
Jurkat cells led to reduced levels of PDE4A mRNA [Erdogan and Houslay, 1997].
1.6 Importance of PDE4s
The importance of PDEs in mediating cAMP signalling was first demonstrated in 
very early studies whereby fruit flies containing mutations in the Drosophila dunce PDE 
gene demonstrated impairments in their learning behaviour and caused female sterility 
[Davis and Dauwalder, 1991]. PDE4D (mammalian homologue Drosophila dunce) is 
important for growth and fertility in mice. This was demonstrated by recent studies 
whereby mice containing targeted disruption of the PDE4D gene were of reduced body 
weight, viability and the female mice were notably less fertile [Jin et a l, 1999].
cAMP has been found to inhibit the function of cells involved in generating an
inflammatory response. That PDE4 activity plays a major role in mediating the cAMP
levels in inflammatory cells such as neutrophils, eosinophils, mast cells and basophils, it
was not surprising to find that PDE4 inhibitors can suppress the inflammatory response by
elevating cAMP levels. Clinical trials are being performed on PDE4 inhibitors for the
treatment of diseases such as asthma [Torphy, 1998] chronic obstmctive pulmonary
disease (COPD) [Torphy et a l, 1999], atopic dermatitis [Hanifin et a l, 1996] and multiple
sclerosis [Dinter, 2000]. Unfortunately, nausea and emesis are side-effects still associated
with general PDE4 inhibitors because these enzymes are also expressed highly in many
other tissues including the brain. Development of PDE4 isoform specific inhibitors may
help to overcome these pitfalls. For example, a PDE4 isofonn receiving much interest is
that of PDB4B2. This enzyme is the most predominant isofonn expressed in neutrophils,
monocytes and leukocytes, therefore, provides an ideal anti-inflammatory target [Wang et
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al., 1999]. Because the expression of PDE4B2 is low in the brain, development of 
PDE4B2 specific inhibitors would provide a means of treating inflammatory diseases in 
which monocytes and neutrophils were the mediators, without the side-effect of emesis.
My interest in PDE4A7 developed following the discovery that this PDE4A 
isofoim was devoid of any cAMP-specific catalytic activity. I decided to investigate its 
intracellular localisation using the methods of subcellular fractionation and Laser Scanning 
Confocal Microscopy (LSCM). This work uncovered the interesting finding that PDE4A7 
was localised exclusively within the nucleus. Using a series of chimeras I then made 
attempts to gain insight into the basis of the intracellular targeting of this protein. In 
Chapter 4 I used the yeast two-hybrid screening method in an attempt to identify possible 
binding partners of PDE4A7, with the hope that this would give insight into its functional 
role. The methods of gene microan'ay and RT-PCR analysis were used in Chapter 5 to 
address whether the functional role of PDE4A7 within the nucleus was to control the 
expression levels of other genes involved in cAMP signalling. In addition, I also 
performed some characterisation studies on the novel PDE4A long isoform called 
PDE4A11 (TM3).
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Chapter 2 
Materials and Methods
In the following section, the names of companies from where reagents were purchased are 
given in the parentheses. Where no company name is mentioned, the reagent was 
purchased from either Sigma or Fisons and were of analytical grade.
2.1 Mammalian cell culture
2.1.1 Cell culture techniques
2.1.1.1 COS-1 and COS-7 cell lines
COS-1 and COS-7 cells (ATCC CRL-1650 and CRL-1651 respectively) are both 
African green monlcey kidney fibroblast-like cell lines, which were derived from the CV-1 
cell line by transfonnation by an origin-defective mutant of SV40 (Gluzman, 1981).
2.1.1.2 HEK-293 ceii line
HEK-293 cells are a human embryonic kidney cell line (ATCC CRL-1573), which 
have an epithelial cell moiphology (Harrison, Graham et al. 1977).
2.1.1.3 Maintenance of cell lines
COS-1, COS-7 and HEK-293 cells were all maintained in the cell culture medium 
of Dulbecco’s Modified Eagle’s Medium (DMEM) that had been supplemented with 2mM 
L-glutamine, 10% (v/v) foetal bovine calf serum (FBCS) and lOOunits/ml of penicillin/ 
streptomycin at 37°C in a 5% CO2  atmosphere. Cells were passaged upon reaching -90% 
confiuency, which involved rinsing the cells with pre-warmed phosphate buffered saline 
(PBS) followed by incubation with 2-4mls of 0.25% trypsin/0.03% EDTA solution until 
the cells detached. The detached cells were resuspended in 8mls of fi'esh culture medium, 
transferred to a sterile 50ml centrifuge tube and pelleted by centrifuging at 3000 rpm for 
3mins in the MSE Mistral 1000 swinging bucket centrifuge. Medium was removed from 
the pelleted cells, which were then resuspended in lOmls of fresh culture medium. The
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cells were then diluted 1:5 into new culture flasks containing pre-warmed fresh culture 
medium.
2.1.2 Transfection of COS-1 cells with plasmid DNA
Cells at -70%  confluency were passaged 24hrs before transfection and seeded onto 
new 100mm plates at -  50% confluency. lOpg of DNA was diluted in 250pl of Tris- 
EDTA (TE) buffer (ImM Ethylenediaminetetra-acetic acid (EDTA), lOmM Tris/HCl, pH 
7.5) in a sterile tube, to which 200pl of DEAE dextran solution (lOmg/ml in PBS) was 
added. This mixture was incubated for 15mins at room temperature to allow DNA-DEAE 
dextran complexes to which 5mls of transfection medium and 5pi o f lOOmM chloroquine 
were added. This mixture was added to a 100mm dish o f monolayer cells and incubated at 
37°C in an atmosphere of 5% CO2  for 3-4 hr s. After incubation the cells were shocked 
with 10% DMSO (dissolved in sterile PBS) for 2mins and then rinsed twice with lOmls of 
PBS. After washing, lOmls of growth medium was added to each plate of cells, which 
were then incubated at 37°C for ~48-72hrs in an atmosphere of 5% CO2 .
2.1.3 Transfection of HEK-293 cells with plasmid DNA
Cells at -70%  confluency were passaged 24hrs prior to transfection and seeded 
onto 100mm dishes at -40-50% confluency. 5pg of DNA was diluted in 50pl sterile 
HEPES-buffered saline (HBS) buffer (20mM HEPES, 150mM NaCl (pH 7.4)) in a sterile 
tube. In a separate sterile tube 30pi of DOTAP (Roche) was mixed with 70pl of HBS. 
This DOTAP solution was added the nucleic acid solution, mixed by pipetting and 
incubated at room temperatui'e for 15mins. 14mls of growth medium (DMEM containing 
10% (v/v) new born foetal calf serum (NCBS)) was added to the DOTAP/nucleic acid 
solution, mixed and added to cells, which were then incubated overnight at 37°C in an 
atmosphere of 5% CO2 . The next day this culture medium was removed from the cells and 
replaced with fresh growth medium (DMEM containing 10% (v/v) foetal calf serum). 
Cells were incubated for a further 48hrs at 37°C in an atmosphere of 5% CO2 .
2.2 Biochemical Techniques
During cell lysis procedures, cells were maintained on ice and buffers were also 
pre-chilled to minimise the effect of protein degradation.
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2.2.1 General subcellular fractionation of cells
Approximately 481irs after transfection cell plates were transferred from the 37°C 
incubator onto ice. After removing the growth medium, cells were rinsed once with ice- 
cold PBS (5mls/100mm dish) and drained before the addition of ice-cold complete KHEM 
buffer (50mM HEPES-KOH (pH 7.4), 50mM KCl, lOmM EGTA, 1.92mM MgCh 
supplemented with ImM diothiotrietol (DTT) and protease inhibitors) (2mls/100mm dish), 
which was incubated with the cells for 5mins at 4°C and then drained. The cells from 
100mm dishes were scraped into a 1.5ml eppendorf and were disrupted by passing the cell 
lysate 30 times through a 26i/2 gauge needle attached to a disposable 1ml syiinge.
Cell lysates were centrifuged at 2000ipm for lOmins at 4°C to produce the low 
speed pellet fraction (PI) that is enriched in nuclear and cytoskeletal components. The 
resultant supernatant was then centrifuged at 75000g for 30mins at 4°C (Beckman TL-100 
ultracentrifuge), which produced a high speed supernatant fraction enriched in cytosolic 
proteins and a high speed pellet fraction (P2) enriched in plasma membranes, endoplasmic 
reticulum, lysosomes, endosomes and golgi vesicles. Both the PI and P2 pellets were 
washed twice in 500pl of ice-cold complete KHEM and then resuspended in the same 
volume of complete KHEM as the S fraction. Each of the cell fractions were aliquoted, 
snap frozen and stored at -80^0 until required.
2.2.2 Immunoprécipitation
Growth medium was removed and the cells were washed with 5mls ice-cold PBS, 
drained and then scraped into SOOpl of ice-cold 3T3-lysis buffer (20mM N-2- 
Hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), pH 7.4, 50mM NaCl, 50mM 
NaF, 10% glycerol, 1% triton X-100, lOmM Ethyleneglycol-bis(P-aminoethylether)- 
N,N,N’,N’-Tetra-acetic acid (EGTA), 30mM sodium pyrophosphate and protease inhibitor 
cocktail was added). Cells were homogensied with 20 strokes of a 261 /2 gauge needle 
attached to a disposable 1ml syringe. Cell lysates were clarified by low speed 
centrifugation (3000rpm at 4°C for lOmins). 50pl of protein A beads were washed in 
500jul of complete 3T3-lysis buffer and pelleted by centrifuging at 3000rpm for 2mins at 
4^C in a refrigerated bench top centrifuge. These beads were used to pre-dear the 
supernatant (cell lysate) for 30mins at 4°C with end-over-end rotation. The protein A 
beads were recovered by centrifugation (3000ipm at 4*^ C for 3mins) the supernatant was 
transferred to a clean 1.5ml eppendorf. The antibody for detection of the target protein 
was added to the supernatant (cell lysate) at the optimal concentration (0.2~2\xg) and
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incubated for 2hrs at 4°C with end-over-end mixing. This mixture was then added to a 
fresh eppendorf containing 50jal of protein A beads (that had been washed with 3T3 lysis 
buffer) and incubated at 4°C for a further hour. The immune complexes were recovered by 
low speed centrifugation at 3000rpm at 4°C for 3mins. To remove any non-specific 
protein, beads were washed three times with SOOpl of chilled 3T3-lysis buffer followed by 
another wash with 500pl of ice-cold PBS. All the supernatant was removed and the beads 
were resuspended in 60jli1 of 2X SDS sample buffer and boiled for analysis by SDS-PAGE 
electrophoresis. With every immunoprécipitation an additional lysate was prepared and 
used as a control to run in parallel with the experimental immunoprécipitation. Instead, 
this control lysate was incubated with control IgG rather than the primary antibody of 
interest.
2.2.3 Quantification of protein
To quantify the protein concentration of sample cell lysates, protein assays were 
performed in 96 well microtitre plates. A spectrophotomeric standard curve of protein 
concentration was produced using 0-5pg bovine serum albumin (BSA) dissolved in 
distilled water. Quantifying the amount of protein in cell lysates involved adding 2pi of 
sample to a well in the 96 microtitre plate followed by 200pl of Bio-Rad reagent diluted 
1:5 with distilled water. Each sample was analysed in triplicate. The plate was analysed 
using a MRX microtitre plate reader (Dynex Technologies), which read sample 
absorbances at 590nm. The Revelation software package was used to construct a standard 
curve of absorbances from the BSA standards. Least squared regression analysis was used 
to determine the line of best fit and the equation of this line was used to calculate the 
protein concentration of each sample.
2.2.4 SDS-polyacryiamide gel electrophoresis
2.2.4.1 Preparation of samples
Cell lysates were assayed for protein concentration and diluted 1:5 with 5X 
Laemmli sample buffer (260mM Tris/HCl (pH 6.7), 55.5% glycerol, 8.8% SDS, 0.007% 
bromophenol blue, 11.1% p-mercaptoethanol (Laemmli, Beguin et al. 1970)) to give a 
final protein concentration of 20pg. Samples were then boiled for 5mins to denature the 
protein.
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2.2.4.2 Molecular weight protein standards
The prestained molecular markers contained the following proteins as standards: 
myosin (250kDa); p-galactosidase (150kDa); phosphorylase b (lOOkDa) bovine seiiun 
albumin (BSA) (75kDa); ovalbumin (50kDa); carbonic anhydrase (37kDa); soybean 
trypsin inhibitor (25kDa); lysozyme (15kDa) and aprotinen (lOkDa).
2.2A.3 Casting and running tris-glycine gels
The Protean II xi Cell (BIO-RAD) gel apparatus was assembled in accordance with 
the manufacturer’s instructions. A resolving gel containing the appropriate percentage of 
acrylamide for the size of the proteins to be separated, which was usually 10% (10% 
acrylamide:N,N’-methylenebisacrylamide mix, 375mM Tris/HCl (pH 8.8), 0.1% SDS, 
0.1% Ammonium persulphate, 0.06% N,N,N’,N’,-tetramethylethylenediamine (TEMED)) 
was poured between the gel plates and overlaid with water to produce an even surface. 
After allowing the gel to set for llir the water was removed and a comb was inserted 
between the plates before pouring a 5% stacking gel (5% 29:1 acrylamide:N,N’- 
methylenebisacrylamide mix, 125mM Tris/HCl (pH 6.8), 0.1% SDS, 0.1% Ammonium 
persulphate, 0.1% TEMED). When the stacking gel had set, the comb was removed and 
the wells were washed with tank buffer (192mM Glycine, 25mM Tris, 0.15% SDS), to 
remove any excess acrylamide solution. The gels were then placed in a rmining tank 
where both the upper and lower reservoir were filled with tank buffer. Protein samples 
already mixed and boiled with the appropriate amount of 5X laemmli’s were loaded into 
the wells. The gels were then run at the appropriate current (8 milliamps overnight) until 
the dye front reached the bottom of the gel.
2.2.4.4 Transfer of proteins onto nitrocellulose
Following electrophoresis the gels were placed into a transfer cassette. In 
summary, a piece of sponge (from cassette apparatus) was soaked in transfer buffer 
(192mM Glycine, 25mM Tris, 20% Methanol) and placed into the cassette. Two pieces of 
Whatman filter paper and a piece of Protran nitrocellulose (Schleicher & Schuell) were cut 
to fit the gel slice and were also soaked in transfer buffer. The Whatmann filter paper was 
placed on top of the sponge followed by the gel slice, Protran nitrocellulose, another piece 
of Whatmann filter paper and finally another piece of sponge. During assembly of this 
sandwich care was taken to ensure all air bubbles were excluded from each of the layers.
3 2
The cassette was closed and placed into the tank with the nitrocellulose side of cassette 
towards the positive electrode. The tank was filled with transfer buffer and the proteins 
transferred for 0.05 amps overnight or 0.8 amps for Ihr.
2.2.4.5 Immunoblotting
After transfer, the nitrocellulose was rinsed with distilled water and then incubated 
at room temperature with Ponceau S stain (0.1% Ponceau, 3% Trichloroacetic acid) until 
protein bands appeared. The nitrocellulose was then rinsed several times with TBS-Tween 
20 (137mM NaCl, 20mM Tris/HCl (pH 7.6), 0.1% Tween 20) before proceeding with 
immunological detection. To block any unoccupied protein binding sites, the 
nitrocellulose membrane was incubated with 5% skimmed milk in TBS-Tween 20 for Ihr 
with gentle shaking at room temperature, followed by tlu'ee 5min washes with TBS-Tween 
20. The antibody specific to the protein of interest was diluted to the appropriate 
concentration in lOmls of TBS-Tween 20 (containing 1% skimmed milk powder) and 
incubated with the nitrocellulose for 21u's at room temperature with vigorous shaking. The 
nitrocellululose was then washed several times with TBS-Tween 20. The secondary 
antibody, which was a horse-radish peroxidase conjugated antibody directed against the 
primary antibody, was diluted to the appropriate concentration in lOmls TBS-Tween 20 
(containing 1% skimmed milk powder) and incubated with the nitrocellulose membrane at 
room temperature for Ihr with vigorous shaking. After tliree 5min washes with TBS- 
Tween 20, the membrane was incubated with reagents from the enhanced 
chemiluminescence (ECL) kit (Amersham) according to the manufacturers instructions and 
exposed to Kodak X-ray film for different lengths of time, Film was developed in the 
Kodak X-omat.
2.2.5 Laser Scanning Confocai Microscopy (LSCM)
COS-1 cells were plated out onto coverslips (18mm X 18mm) at -40%  confluency 
24hi's prior to transfection. Cells were then transfected with the required plasmid DNA. 
481u'S after transfection, cells were fixed for lOmins in 4% parafonnaldehyde (dissolved in 
Tris buffered saline (TBS) (150mM NaCl, 20mM Tris, pH 7.4) followed by three 5min 
washes with 5mis of TBS. COS-1 cells were then permeabilised by performing three 5min 
incubations with 200pl of 0.2% triton in TBS, followed by a blocking step consisting of 
thiee 5min incubations with blocking buffer (either 20% goat serum and 4% BSA or 20% 
donkey serum and 4% BSA dissolved in TBS). The primary antibody was diluted to the
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required concentration in dilutant buffer (10% blocking buffer diluted with TBS) and 
200 |l i 1 of this mix was added to the slide and left to incubate at room temperature for 2hrs. 
Slides were then washed with thiee changes of blocking buffer and incubated with 200pi 
of 1:200 diluted Alexa 594-conjugated anti-rabbit IgG (Molecular Probes) or Alexa 594- 
conjugated anti-donkey IgG (Molecular Probes) for Ihi'. Cells were then washed five 
times with TBS before mounting the coverslips on microscope slides with Immunomount 
(Sandon).
Cells were visualised using the Zeiss Axiovert 100 laser scanning confocai 
microscope (Zeiss, Oberkochken, Geimany) using a Zeiss Plan-Apo 63 X 1.4 NA oil 
immersion objective. The Alexa 594-conjugated secondary antibodies were both excited at 
543mn and detected at 590mn.
2.2.6 Phosphodiesterase assay
Phosphodiesterase activity was measured using a modification of the two step 
procedure of Thompson and Appleman [Thompson and Appleman., 1971], as described 
previously by Marchmont and Houslay [Marchmont and Houslay., 1980]. The first step is 
the hydrolysis of the ^H-cyclic nucleotide (8 position of the adenine or guanine ring) by the 
phosphodiesterases, which generates labelled nucleotide monophosphate, hi the second 
step, incubation with snake venom, (which has 5’-nucleotidase activity) converts the 
mono-phosphate ring to the corresponding labelled nucleoside. The unliydrolysed cyclic 
nucleotide was separated from the nucleoside by batch binding of the mixture to Dowex 
1X8-400 anion exchange resin. This binds only the charged nucleotides and leaves behind 
the uncharged nucleosides
2.2.6.1 Activation of Dowex 1X8-400 anion exchange resin
To activate the Dowex 1X8-400 resin, 4L o f IM NaOPI was added to 400g of the 
resin and gently mixed for 15mins at room temperature. After allowing the resin to settle 
by gravity the supernatant was removed and the resin was washed 30 times with 4L of 
distilled water. After the final wash the resin was resuspended in 4L of IM HCl and gently 
mixed for 15mins at room temperature before being allowed to settle. The resin was then 
washed 3 times with 4L of distilled water until the supernatant had a pH of 3. The 
activated resin was stored as a 1:1 slurry with distilled water at 4°C until required.
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2.2.6.2 Preparation o f assay tubes
The appropriate volume of cell lysate was added to each 1.5ml eppendorf tube and 
made up to a volume of 50pl by adding 20mM Tris, pH 7.4. All assay tubes were 
incubated on ice and each sample was performed in duplicate. 50pl of 2pM cAMP 
containing 3pCi [^HJcAMP in 20mM Tris/HCl/lOmM MgCh (pH 7.4) was added to all 
tubes and mixed by voitexing. These tubes were incubated at 30°C for lOmins and boiled 
for 2mins. After cooling the assay tubes on ice for 15mins, 25 pi of 1 mg/ml snake venom 
(diluted in 20mM Tris, pH 7.4) was added to each tube. These samples were then 
incubated for lOmins at 30°C. The tubes were transferred back to ice and 400pl of a 1:1:1 
Dowex/ethanol/water mix was added to all the tubes and mixed by vortexing. The tubes 
were then incubated on ice for 20min before vortexing the samples again. The dowex resin 
was pelleted by centrifuging at 13000rpm and 150pl of the resultant supernatant was added 
to 1ml of Opti-scint scintillation fluid and counted on a Wallac 1409 liquid scintillation 
counter.
2.3 Molecular techniques
To prevent any contamination all glasswai'e, tubes, tips, buffers and media used for 
molecular biology were sterilised.
2.3.1 Small scale production of DNA
A sterile universal containing 5mls of L-broth (170mM NaCl, 0.5% (w/v) 
BactoYeast Extract, 1% (w/v) Bacto-Tryptone, pH 7.5) supplemented with 50pg/pl of 
ampicillin was inuoculated from a glycerol stock of bacteria (transformed with the plasmid 
of interest) using a sterile pipette tip. The culture was incubated at 37°C overnight with 
agitation. Cells were then pelleted by centrifuging at 3000rpm for 15mins. The DNA was 
extracted using the QIAprep Spin Miniprep Kiit (Qiagen) according to the manufacturer’s 
instructions, hi brief, the pelleted cells were resuspended in 250pl of buffer PI 
(resuspension buffer) and transfeiTed to a microfuge tube. 250pl of buffer P2 (lysis buffer) 
was added and the tubes were mixed and then incubated at room temperature for 4mins. 
350pl of buffer N3 (neutralisation buffer) was added and the solutions were mixed again 
before centrifuging at 13000ipm for lOmins. The supernatant was added to a QIAprep 
column by decanting and centrifuged for 60secs. The flow-thi'ough was discarded and the 
column was washed with 750pl of buffer PE. The column was centrifuged for Imin prior
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to the elution of the bound DNA. To elute the DNA from the column, 50pi of buffer EB 
was applied to the centre of the column and incubated at room temperature for Imin before 
centrifuging at ISOOOrpm for Imin to collect the DNA.
2.3.2 Large scale production of DNA
500mls of sterile L-broth supplemented with 50pg/pl o f ampicillin was innoculated 
from a glycerol stock of bacteria (transformed with the plasmid of interest) using a sterile 
pipette tip. The culture was incubated overnight at 37°C with vigorous agitation. The cells 
were pelleted by centrifugation at 6000g for 15mins at 4°C. The bacterial pellet was 
resuspended in lOmls of buffer PI (resuspension buffer), followed by the addition of lOmls 
of buffer P2 (lysis buffer), which was mixed by inverting 4-6 times. Cells were then 
incubated at room temperature for 5mins. After incubation, lOmls of chilled buffer P3 
(neutralisation buffer) was added and mixed with the lysed cells, followed by a 15min 
incubation on ice. The sample was centrifuged at lOOOOg for 30mins at 4°C. Meanwhile a 
QIAGEN-tip 500 was equilibriated by adding I Omis of buffer QBT and allowed to empty 
by gravity flow. The supernatant from the previous spin was added, and allowed to flow 
through the column before washing twice with 1 Omis of buffer QC. The DNA was eluted 
from the column using 15mls of buffer QF. To precipitate the DNA 0.7 volumes of room- 
temperature isopropanol was added to the eluate, mixed and centrifuged at 15000g for 
30mins at 4°C. The supernatant from this spin was removed and the remaining DNA pellet 
was washed with 5mls of room-temperature 70% ethanol and centrifuged at 15000g for 
lOmins. The remaining DNA pellet was allowed to air-dry for 5-lOmins, before it was 
resuspended in SOOpl of TE buffer pH 8.0.
2.3.3 DNA and RNA quantification
Both DNA and RNA concentrations were quantified spectrophotometrically using a 
WPA lightwave UV spectrophotometer blanked with distilled water. 5 pi of DNA or RNA 
were diluted to 1ml with distilled water and absorbance measurements were taken at 
260nM and 280nM. The concentration of DNA or RNA was calculated using the 
following spectrophotometric conversions:
An absorbance of 1 at 260nM corresponds to 50pg/ml of double stranded DNA
33pg/ml of single stranded DNA 
40pg/ml of single stranded RNA
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The ratio between the absorbance measurements at 260nM and 280nM indicates the purity 
of the nucleic acid. DNA or RNA, in solution, typically have A2 6 o:A2 8 o ratios of 1.8 and 2 
respectively. Ratio values lower than these indicate that the nucleic acid may be 
contaminated.
2.3.4 Glycerol stock production
600pl from an overnight culture of transformed cells containing the DNA of 
interest was transferred aseptically into a sterile screw top cryovial and mixed with 400pl 
of sterile 80% glycerol. This glycerol stock was stored at -80°C.
2.3.5 Agarose gel electrophoresis
DNA was separated and visualised using ethidium bromide agarose gels, the 
concentration of agarose used was dependent on the size of DNA fragment to be separated 
(see table below). The 1% agarose mix was dissolved in 1 X TAB buffer (40mM Tris/HCl, 
pH 8.0, ImM EDTA, 0.114% glacial acetic acid) and heated until the agarose dissolved. 
The agarose was allowed to cool slightly before the addition of Ipl ethidium bromide. The 
agarose/ethidium bromide mix was then added to the pre-assembled casting tray minigel 
apparatus and allowed to set. The combs and stoppers were removed and the tank was 
filled with IX TAE buffer. Samples were diluted 6:1 in 6X loading dye (0.25% 
Bromophenol Blue, 0.25% xylene cyanol blue, 30% glycerol in water) and loaded into the 
sample wells. In order to size the DNA fragments, the molecular size markers of either 
Marker X (Promega) or the Ikb ladder marker (Promega) were loaded alongside the 
samples. The gel was run at 50 volts until the dye front moved through the gel. Due to the 
presence of intercalating ethidium bromide dye the resultant DNA bands could be 
visualised with UV transillumination.
Percentage Gel Size of Fragment (kb)
0,9 0.5-7
1.2 0.4-6
1.5 0.2-3
2 0.1-2
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2.3.6 Gel extraction of DNA
DNA of interest was isolated from an agarose gel using the QIAquick Gel 
Extraction Kit (Qiagen) according to the manufacturer’s instructions. Briefly, DNA was 
excised from the agarose gel and weighed in an eppendorf to which three volumes of 
Buffer QG to one volume of gel was added. This was incubated at 50°C for lOmins until 
the gel had dissolved and then one gel volume of isopropanol was added to the sample and 
mixed. The DNA sample was added to a QIAquick column and centrifuged at 13000ipm 
for Imin. The column was washed with 750pl of Buffer PE and centrifuged at 13000rpm 
for Imin twice to remove any residual buffer. The DNA was eluted from the column by 
adding 30pl of buffer EB to the centre of the membrane, which was allowed to stand for 
Imin before centrifuging at 13000rpm for Imin.
2.3.7 Restriction digestion of DNA
The restriction enzyme and the appropriate restriction buffer used depended on the 
site(s) of digestion. The enzymes used for digestion were supplied by Promega. DNA was 
digested with the appropriate enzyme(s) by incubating the digestion mixture at 37°C for 1- 
21irs.
2.3.8 DNA ligation
DNA and vector DNA were ligated using the Rapid DNA Ligation Kit (Roche). 
Briefly, lOOng of restriction digested DNA, at 1:2 and 1:5 ratios (v/v) of vector:insert DNA 
were added to a sterile 0.5ml eppendorf and made up to a final volume of lOpl by the 
addition of IX DNA dilution buffer. To the DNA mix lOpl of 2X T4 DNA ligation buffer 
and Ipl of T4 DNA-ligase were added and mixed. The tube contents were mixed and 
incubated at room temperature for 5mins.
2.3.9 Reverse transcription polymerase chain reaction (RT- PCR)
2.3.9.1 RNA isolation
Briefly, total RNA was extracted from cells by firstly aspirating off the growth 
medium and then adding 600pl of RLT lysis buffer to each plate. The cells were then 
scraped into eppendorfs and mixed by pipetting to remove any cell clumps. Samples were
3 8
homogenised by passing the lysates five times through a 20-gauge needle fitted to a 
syiinge, 600pl of 70% ethanol was added to the lysates and mixed by pipetting. The 
lysate was then added to an RNAeasy spin column and centrifuged for 15secs at SOOOrpm. 
700jLil of buffer RW l was added to the column and allowed to incubate at room 
temperature for 5mins before centrifuging for 15secs at SOOOrpm. The columns were 
washed twice with 500pl of buffer RPE followed by centrifuging for 15secs at SOOOrpm 
each time. To ensure that ethanol was completely removed, the columns were centrifuged 
at full speed for Imin. Columns were transferred to a clean collection tube where RNA 
was eluted from the column by adding 30pl of RNase-ffee water directly to the column and 
centrifuging for Imin at SOOOrpm.
2.3.9.2 First strand cDNA synthesis
First strand cDNA was synthesised using in accordance with the instruction manual 
from Promega. Briefly, 2pg of RNA was mixed with 2pi of Ipg oligo (dT) primer and 
made up to a total volume of lOpl by adding water in a sterile microfuge tube. This 
mixture was mixed, centrifuged briefly to collect sample in the bottom of the tube and then 
heated to 70°C for 5mins before incubation on ice for 5mins. This mix was again 
centrifuged briefly to collect the solution at the bottom of the microfuge tube. To this mix 
5pi of AMV Reverse Transcriptase 5X Reaction Buffer, 40 units of RNasin Ribonuclease 
inhibitor, 30 units of AMV Reverse Transriptase, 2.5pl of dNTP mix, and 40mM sodium 
pyrophosphate (which had already been prewarmed to 42°C) were added and made up to a
total volume of 25pi using RNase-fi'ee water. The sample was mixed again and
centrifuged briefly to collect contents. Samples were then incubated at 42°C for 60mins, 
followed by heating to 95°C for 5mins. cDNA was then stored at -20°C until it was 
required.
2.3.9.3 PCR reaction
PCR was perfonned using Platinum Pfx DNA Polymerase (Life Technologies) in 
accordance with the manufacturer’s instructions. Briefly, Ipg cDNA (generated in 2.2.9.2) 
was added to 5 pi of lOX Pfx amplification buffer, 1.5pi of lOmM dNTPs, Ipl 50mM 
MgS0 4 , Ipl (50pmol/pl)) of each of sense and antisense primers for detection of the 
transcript of interest, Ipl (50pmol/pl) of sense and antisense primers for cyclophylin, Ipl of 
Platinum Pfx DNA Polymerase and made up to a total volume of 50pl with RNase- free 
water. The PCR conditions used were as follows:
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94°C 2mins
94°C 15secs
55^C (variable depending on Tin of primer) 30secs 35 cycles
68“C 60secs
2.3.10 Cloning and PCR
2.3.10.1 PCR conditions used for generating PDE4A7 cDNA containing the 
nuclear export signal (NES) of PKIa and for incorporating EcoRI and BamHI sites 
onto PDE4A7
The amplification of PDE4A7 DNA either containing the nuclear export signal of 
PKIa or EcoRI and BamHI restriction sites was performed using the Expand High Fidelity 
PCR System (Roche). Briefly in one sterile vial 400ng of PDE4A7 DNA was added to a 
tube containing master mix 1 buffer (Ipl of each of the sense and antisense primers 
(50pmol/pl), 2pi of each dNTP (lOmM) and made up to a final volume of 50pl with sterile 
water). In a separate vial, master mix 2 buffer was prepared (lOpl of lOX Expand High 
Fidelity buffer containing 15mM MgCH was mixed with 0.75pl of the Expand High 
Fidelity PCR System enzyme mix and made up to a total volume of 50pl with sterile 
water). Then 25pi of mastermix 1 was mixed with 25pi of mastermix 2 in a separate sterile 
PCR tube. The PCR conditions used were as follows:
94°C 2mins
94°C ISsecs
55°C (variable depending on Tin of primer) 30secs 30 cycles
72"C Imin
72"C 7mins
2.3.10.2 Transformation of Ecoli with plasmid DNA
lOpl of the DNA extracted from the yeast cells or Ipl o f plasmid DNA in all other 
cases was added into a vial of chemically competent Ecoli, mixed gently and incubated on 
ice for 30mins. Cells were heat-shocked for 30secs at 42°C and immediately transfeiTed to 
ice. 250pl of room temperature SOC medium was added to the cells, which were then 
incubated at 3TC  for llir with gentle shaking (200 ipm). Cells were pelleted by
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centrifuging at 2000rpm for 5mins at room temperature and plated out onto either 
kanamycin or ampicillin (50pg/pl). Plates were incubated overnight at 37°C.
2.3.10.3 TOPO cloning
The TOPO cloning and transformation were carried out using the pcDNA3.1/V5~ 
His TOPO TA Expression Kit (Invitrogen) according to the manufacturer’s instructions. 
Briefly, 0.5pi of fresh PCR product, Ipl of salt solution, Ipl of TOPO vector and 2.5pl of 
sterile water were added to a sterile microfuge tube, mixed by pipetting and incubated for 
30mins at room temperature. 2pi of this reaction was added to into vial of One Shot 
TOP 10 chemically competent E.coli (Invitrogen), mixed gently and incubated on ice for 
30mins. Cells were heat shocked for 30secs at 42°C and the tubes were inunediately 
transferred to ice followed by the addition of 250pl of SOC medium. The cells were then 
incubated at 37°C for Ihr with agitation. lOOpl and 200pl of the cells were spread on a 
prewarmed ampicillin plate (50pg/pl). Colonies were then screened using PCR to check 
for desired product (conditions shown below), DNA was isolated from the positive 
colonies using QIAprep kits and sequenced.
2.3.10.4 PCR screening of colonies
A small portion of a colony was scraped fr om the ampicillin plate using a sterile 
yellow tip and transfeiTed to a sterile PCR tube containing 25pi of PCR buffer. As a large 
number of PCR screens were performed at any one time a 500pl stock of this buffer was 
prepared in a separate vial. This buffer contained; 50pl o f 25mM MgCk, 50pl of lOX 
Thermophilic DNA Buffer, lOpl of lOmM dNTPs, 5pi of sense and antisense primers 
(lOOpmol/pl), Ipl of Taq DNA Polymerase, which was made up to a total volume of 500pi 
with distilled sterile water. Each portion of colony was resuspended in 25pi of this PCR 
buffer in a sterile PCR tube. The PCR conditions used to amplify the insert were as 
follows;
94'^ C
94°C
47°C (variable depending on Tm of primer)
72°C
72°C
2mins
30secs
30secs
Imin
7mins
35 cycles
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2.3.11 DNA sequencing
Inserts from the yeast two hybrid screen or PCR products were sequenced using the 
BigDye termination kit. The plasmid DNA (500ng) was mixed 3.2 pmol of primer and 8 pi 
of Big Dye Sequencing mix and made up to a final volume o f 20pl with sterile distilled 
water. The PCR conditions used were as follows:
96®C 30secs
50°C (variable depending on Tm of primer) 15 secs
60°C 4mins
25 cycles
The resultant DNA was precipitated by adding 2pi of 3M NaOAc, pH 4.8 and 50pl of 
EtOH. After mixing, this solution was incubated on ice for lOmins. The precipitated DNA 
was pelleted by centrifuging at 13000rpm for 30mins at 4°C. The pellet was washed once 
with 70% ethanol and dried by heating in the PCR machine for 3mins at 80^C.
2.3.11.1 Sequence analysis
All DNA sequence analysis was performed using the Gene Jockey II program.
2.4 Yeast two hybrid analysis
2.4.1 Testing the bait plasmid for toxicity effects, transcriptional activation and 
effect on yeast mating efficiency
The details of this procedure are outlined in on pages 25 and 26 of the Clontech 
Pretransfonned MATCHMAKER Libraries User Manual.
2.4.2 Preparation of SD/-Ade/-His/-Leu/-Trp plates
A  combination of Minimal SD Agar base (for preparation of plates) or Minimal SD
base (for liquid medium), both from Clontech were combined with the appropriate DO
Supplement (Clontech) to produce a synthetic, defined minimal medium lacking one or
more specific nutrients (details are listed in the Yeast Protocols Handbook from Clontech)..
For example, to prepare sterile synthetic dropout (SD) agar plates lacking adenine (Ade),
histidine (His), leucine (Leu) and tryptophan (Trp) (SD/-Leu/-Tip/-Ade/~His) then to each
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litre of YPD Agar medium (70g YPD Agar medium per litre of distilled water) 0.6g of -  
Ade and 0.62g of -Leu, -Trp, -His DO supplement (Clontech) was added. Once medium 
was prepared it was heated until the agarose dissolved. Medimn was allowed to cool 
slightly before pouring into the 150mm plates. The SD Agar plates were dried at room 
temperature for 3 days before use. To prepare YPD liquid medium the protocol is similai 
except YPD medium (50g per litre o f distilled water) is used in place of the YPDA agar.
2 .4.3 Preparation of competent yeast cells
AH109 cells were streaked from a glycerol stock on a YPD agar plate (70g of YPD 
Agar Medium powder (Clontech) dissolved in 1 litie of distilled water, autoclaved and 
cooled slightly before pouring into plates). Cells were grown agar side up at 30°C for -3  
days. One colony of these cells were picked using a sterile yellow tip and used to inoculate 
5Omis of sterile YPD medium (50g of YPD powder supplied by Clontech dissolved in 1 
litre of distilled water and autoclaved to sterilise). Cells were grown overnight at 30^C 
with shaking. The next day this culture was transferred to a sterile falcon tube and the cells 
were pelleted by centrifugation at 3000g for 3mins at room temperature and the YPD 
medium was removed. Cells were rinsed with 5Omis of sterile water and then pelleted by 
centrifugation at 3000 for a fuither 3mins. The water was removed and the cells were 
washed with ~12.5mls of filter sterilized LiSorb (lOOmM lithium acetate, lOmM Tris-HCl, 
pH 8.0, ImM EDTA, IM sorbitol) and centrifuged at 3000rpm for 5mins. The LiSorb was 
removed and cells were centrifuged for a further 5mins at 3000rpm at room temperature to 
remove any remaining LiSorb. Cells were then resuspended in 300pl of LiSorb. Canier 
DNA (sonicated hemng testes carrier DNA) was heat denatuied for 5mins at 99°C and 
~35pl was added to the yeast cells/LiSorb solution and mixed. Cells were aliquoted and 
stored at -80°C until required.
2.4.4 Transformation of DNA into AH109 yeast cells
The competent AH109 cells were thawed at room temperature and Ipl of plasmid 
DNA was added to 15pi o f AH109s and mixed. 100pi of LiPEG (40% PEG 
(polyethylethe glycol), O.IM TE buffer (O.IM Tris-HCl, lOmM EDTA, pH 7.5), IM LiAc 
(lithium acetate, pH 7.5) were then added to the cells and mixed by vortexing. Cells were 
then incubated at room temperatm'e for 20mins. lOpl of DMSO was added to the cells and 
mixed. Cells were then heat-shocked for 15mins in a 42°C water bath and then chilled on 
ice for 2mins. The cells were pelleted by centrifuging at 4000g for 3min and the resultant
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supernatant was removed. The pelleted cells were resuspended in 200pl of PBS and plated 
onto SD/-Trp plates, which were incubated at 30°C agar side up for ~3 days.
2.4.5 Protein extraction from yeast
Yeast cells from which protein was to be extracted were scraped from plates using 
a sterile blue tip and resuspended in 1ml of ice-cold water. 15Opt of 1.85M NaOH and 
1 1  pi of p-mercaptoethanol were added to the yeast cell suspension, mixed by vortexing 
and incubated on ice for lOmins. After this incubation, 150pl of 55% TCA was added to 
the yeast cell suspension, mixed by vortexing and incubated on ice for a fmther lOmins. 
Cells were then centrifuged at 14000rpm for 5mins at 4°C. The supernatant was removed 
and cells were centrifuged again briefly and any remaining TCA was removed. The cell 
pellet was resuspended in 150pl of 2X Laemmli buffer and boiled for 5mins to denature 
the protein.
2.4.6 Small scale yeast mating
One colony of each type (i.e., AH109[pGBKT7-PDE4A7] and Y187[pACT- 
RanBPM9] or AH109[pGBKT7-PDE4A7] and Y187[pACT-CBP] ) was used to inoculate 
0.5ml of 2X YPDA medium (lOOg of YPD powder per litre of distilled water, to which 
3Omis of adenine hemisulphate solution was added). Cells were resuspended by vortexing 
for Imin and then incubated at 30^C overnight with gentle shaking (200rpm). The 
appropriate controls included in the small scale yeast mating procedure were 
AH109[pGBKT7~53] mated with Y187[pTDl-l] as the positive control and 
AH109[empty-pGBKT7] mated with Y187[empty-pACT2], AH109[pGBKT7-PDE4A7] 
mated with Y187[empty-pACT2] as negative controls. The diploid yeast cells were plated 
out on SD/-Leu/-Trp/-Ade/-His plates and incubated at 31°C agar side up for 3-5 days, A 
small amount of each of the mated yeast cells were picked using a sterile yellow tip and 
resuspended in 5pi of sterile PBS. Each was gently pipetted onto an SD/-Leu/-Trp plate 
and grown for 1 day, so that each yeast mating grew as separate circles. This was in 
preparation for the p-galactosidase assay.
2.4.7 Large scale yeast mating
A  large fresh colony of bait strain (AH109[pGBKT7~PDE4A7]) was used to 
inoculate a flask of 5Omis of SDZ-Tip medium. This flask was incubated overnight at 30°C
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with shaking at 250-270 ipm. Once the ODeoo of this culture had reached >0 . 8  the cells 
were centrifuged at lOOOg for 5mins and the supernatant was removed. The cell pellet was 
resuspended in the residual liquid by vortexing. The library culture was thawed in a room 
temperature water bath and mixed by gentle vortexing. The bait culture 
(AH109[pGBKT7-PDE4A7]) and the library were combined in a sterile 2-L flask, 
containing 45mls of 2X YPD A/Kan (YPDA containing 50pg/pl of kanamycin). Two 1ml 
aliquots of 2X YPDA/Kan were used to rinse the cells from the library tube. The flask was 
incubated at 30°C overnight with gentle swirling (30-50 rpm) to allow mating. The next 
day, this mating culture was transferred to a sterile centrifuge bottle and cells were pelleted 
by centrifuging at lOOOg for lOmins. The mating flask was rinsed twice with 5Omis of 2X 
YPDA/Kan. These rinses were combined and used to resuspend the first pellet. The cells 
were centrifuged for a further lOmins at lOOOg and the resultant cell pellet was 
resuspended in lOmls of 0.5X YPDA/Kan. 750pl of this mating mixture was spread onto 
150mm plates containing SD/-Ade/-His/-Leu/-Trp agar also referred to as quadruple 
dropout out (QDO) medium. These plates were incubated, colony side down, at 30°C until 
the appearance of colonies (typically between 8-21 days). Resultant colonies were 
streaked out a further twice onto SD/-Ade/-His/-Leu/-Trp agar to check they were 
‘authentic’ two-hybrid positives.
2.4.8 Assay for j3-galactosidase activity
p-galactosidase activity was determined by overlaying the diploid cells with a top 
agar containing the substrate of 5-bromo-4-chloro-3-indolyl-p-D-galactoside (X-Gal). 
Briefly, 289mM Na2 HP0 4 , 21 ImM NaH2P 0 4  (pH 7.0), 20mM KCl, 2mM MgClz, and 1% 
(w/v) SDS were dissolved in 5Omis of distilled water. Separately, 0.5g of low melting 
point agarose (Gibco) was made up to 45mls with distilled water and heated in a 
microwave until the agarose was dissolved. The agarose solution was allowed to cool to 
~50°C before mixing with the previous solution. 1ml of 40mg/ml X-Gal was added to this 
agarose solution under mixing before slowly pouring over the plate of diploid yeast cells.
2.4.9 Plasmid isolation from yeast cells
To extract the library plasmid containing the insert of interest, a portion of the
diploid yeast cells were scraped from the plate using a sterile blue tip and resuspended in
600|ul of plasmid isolation buffer (IM  sorbitol, lOOmM EDTA and 14mM p-
mercaptoethanol), followed by the addition of 8.5pl of lyticase. The yeast cell suspension
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was heated at 30°C for 30-60mins and centiifliged at 7500rpm for lOmins. The resultant 
pellet was resuspended in 30pl of EB buffer (from the QIAprep Spin Miniprep Kit 
(Qiagen).
2.5 Gene microarray anaiysis
Both the control and experimental samples were labelled with different fluors 
(Cyanine 3 or Cyanine 5) by mixing the following in a sterile PCR tube: 8 pi of 5X First 
Strand reaction buffer (Superscript II, Life Technologies), 1.5 pi of AncT mRNA primer 
(lOOpmol/pl), 3pl of 20mM ddNTP (-dCTP) (6.67mM each ofdATP, dGTP, dTTP), ip l of 
2mM dCTP, Ipl of ImM Cyanine 3 or Cyanine 5, 4pl of O.IM DTT, 5pg of RNA (total 
RNA) and made up to a total volume of 40pl with RNase-free water. This labelling
:reaction was incubated at 65°C for 5mins, followed by a 5niin incubation at 42°C. 2 pi of ' 
reverse transcriptase (Superscript II, Life Technologies) was added to this mixture and was 
then incubated at 42°C for -3hrs. This mix was briefly centrifuged and placed on ice. 4pl 
of 50mM EDTA (pH 8.0) and 2pi of lOM NaOH was added to the reaction. RNA was 
hydrolysed by incubating at 65°C for 20mins and then adding 4pl of 5M acetic acid. The 
control and test mixtures were then mixed together. DNA was precipitated by adding 
lOOpl of isopropanol and incubated on ice for 30mins. Samples were centrifuged for 
lOmins at 4°C and the isopropanol was removed. The remaining pellet was rinsed with 
ice-cold 70% ethanol. Samples were pulse centrifuged and any remaining alcohol was 
removed by pipetting. Pellets were then resuspended in 5pi of RNase-ffee water. In a 
separate sterile PCR tube, lOOpl of DIG Easy Hyb solution (Roche), 5pi of yeast tRNA 
were mixed and then incubated at 65°C for 2mins and cooled to room temperature. 3Opt of 
this hyb solution was then added to each pooled pair of Cyanine 3 and Cyanine 5 labelled 
cDNA, mixed and then incubated at 65°C for a further 2mins and cooled back to room 
temperature. The hyb mixture was then pipetted onto the coverslip which was placed on a 
solid flat reliable surface. The slide was inverted and placed carefully onto the coverslip.
Slides were then placed into a hybridization chamber (black microscope boxes) containing 
a small amount of DIG Easy Hyb solution and placed into a 37°C incubator for -18 hrs.
After this incubation coverslips were removed ftom the array slides by quickly dipping the 
array into IX SSC (3M NaCl, 0.3M Na3 Citrate, IM HCl). Array slides were then placed 
into a staining rack and washed three times for lOmins in a clean slide staining box 
containing ftesh IX SSC buffer containing 0 .1 % SDS with gentle agitation. After the 
washes slides were rinsed in IX SSC by plunging 4-6 times. Slides were dried at room 
temperature and stored in the dark until scanning.
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Chapter 3 
intracellular Targeting of PDE4As
3.1 Introduction
The human PDE4A gene encodes four splice variants of which PDE4A4B (PDE46) 
[Sullivan et ah, 1998], PDE4A10 [Rena et ah, 2001] and PDE4A11 [TM3; unpublished] 
are long form isoenzymes that share an identical catalytic and C-terminal sequence but 
diverge at their N-terminal regions as a result of alternative 5’ mRNA splicing. The fourth 
PDE4A splice variant, PDE4A7 (2EL) [Horton et ah, 1995] is the only PDE4A found to 
undergo both 5’ and 3’ mRNA splicing, generating a PDE that contains both unique N- and 
C-terminal domains. PDE4A7 contains a 34bp insert, which results in premature 
tennination of the open reading frame (ORE), producing an enzyme devoid of any catalytic 
PDE activity [Horton et ah, 1995]. Transcripts of PDE4A7 have been detected in a 
number of tissues (Houslay Lab, unpublished), but the functional role of this protein 
remains to be elucidated.
PDEs are not randomly distributed throughout the cell, but are targeted to specific 
intracellular compartments. The idea that the unique N-terminal region of PDE4s may 
contain the information required for their subcellular targeting came originally from 
studies perfoimed on the rat PDE4A isofonn, PDE4A1 (RDI) [Scotland et ah, 1995; 
Shakur et ah, 1993]. PDE4A1 is found to be membrane-associated, both natively and 
when over-expressed. However, it becomes a fully soluble enzyme when its unique N- 
temiinal region is removed, implying that the signal required for its membrane targeting is 
contained within its unique 25 amino acid residue N-teiminal region [Shakur et ah, 1993]. 
Following this discovery, the N-teiminal regions of various other PDE4s were shown to 
mediate their intracellular targeting and interaction with other proteins. For example, the 
unique N-terminal domains of both PDE4A4B and PDE4D4 contain multiple PxxP motifs 
that allow these enzymes to interact with SH3 domain-containing proteins [M^Phee et ah, 
1999],'and the N-terminal region of PDE4D5 mediates its interaction with the RACKl 
scaffold protein [Yarwood et ah, 1999]. However, although removing the unique N- 
terminal region of PDE4A4B corresponds to a loss in its membrane localisation, the 
truncated species is still able to associate with the perinuclear region of the cell, implying 
that signals other than those located in the extreme N-terminal region are responsible for 
conferring targeting on PDE4A4B [Huston et ah, 2000].
In this chapter attempts were made to identify targeting signals in PDE4A outwith 
the unique N-tenninal region that characterises individual PDE4 isoforms. hi this study, 
distribution analysis was performed on recombinant PDE4A4B. This is because it is 
impossible, as yet, to analyse endogenously expressed PDE4A4B. Despite the enonnous 
efforts made by the MDH research group, no cell line we know of expresses PDE4A4B at 
the levels, which have allowed us to detect it unequivocally. This is because it is expressed 
at such low levels. Also, there is the potential to confuse PDE4A4B with PDE4A10 as 
both of these proteins co-migrate on SDS-PAGB. In addition the PDE4A4-specific 
antisera we have from Novartis is ten to one hundred fold less sensitive than that of the 
existing PDE4A C-terminal antisera. Thus, our group continue to examine PDE4A4B only 
in recombinant systems.
3.2 Results
3.2.1 Subcellular distribution of PDE4A4B (PDE46) and PDE4A4C (h6.1) in
COS-1 ceils
Before proceeding with this study it was essential to have an ‘internal control’. I 
based this upon results obtained from previous PDE4A targeting analyses performed, in 
particular comparing the targeting of PDE4A4B (PDE46) to that of its truncate, PDE4A4C 
(h6.1). PDE4A4C (h6.1) was originally believed to be an authentic PDE4A long isofonn. 
It was actually constmcted fr'om two over-lapping cDNA clones that we now know 
encompass amino acids 210 through to the extreme C-tenninus of PDE4A4B [Bolger, 
Michael! et ai., 1993]. However, h6.1 also contains a unique N-terminal domain of 9 
amino acids. The nucleotide sequences of PDE4A4B and h6.1 aie aligned (figure 3.1), 
with the coloured residues representing the coloured domains shown in the subsequent 
schematic diagrams.
Lysates from COS-1 cells were transfected to express either PDE4A4B (figure 3.2,
panel A) or h6.1 (figure 3.3, panel A). These transfected cell lysates were subjected to a
basic subcellular fractionation in order to generate low speed (PI) and high speed (P2)
pellet fractions as well as a high speed supernatant fraction (S2) (Materials and Methods
2.2.1). These fractions were then immunoprobed with the general PDE4A antiserum,
which recognises the C-temiinal domain located in all PDE4As. This is apail from the
catalytically inactive PDE4A7 splice variant, as it is C-terminally truncated. PDE4A4B
(121±3kDa) was found in the S2 soluble fraction and also with both the PI and P2
particulate fractions (figure 3.2, panel B and see Table 3.1). In contrast h6.1 (98±2kDa)
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whilst located both in the PI and S2 fractions was absent from the P2 fraction (figure 3.3, 
panel B and see Table 3.1). These biochemical data correlate well with results of previous 
researchers [Huston et ah, 1996] indicating that the basic subcellular fractionation protocol 
used here was suitable for the comparative membrane/particulate targeting analyses.
3.2.2 Analysis of transfected COS-1 cells using Laser Scanning Confocai
Microscopy (LSCM)
Laser scanning confocai microscopy (LSCM) was utilised to investigate further the 
intracellular localisation of these various PDE4A proteins. COS-1 cells were transfected to 
express either PDE4A4B or h6 .1. The cells were then fixed, permeabilised and incubated 
with the PDE4A general antiserum followed by the Alexa293-labelled anti-donkey 
antiserum for the specific fluorescent detection of the PDE4A proteins (Materials and 
Methods 2.2.5). Transfected cells were easy to identify as their fluorescence was more 
intense and defined than that of the surrounding cells, which were presumed to be 
untransfected. The fluorescence signal for PDE4A4B was found distributed throughout the 
cytosol with concentrated staining found in the area around the nucleus and the margins of 
the cell (figure 3.2 panel C). The fluorescent signal for I1 6 .I was found distributed 
throughout the cytosol with increased staining visualised around the nucleus (figure 3.3 
panel C). However, this differed from PDE4A4B in that it was not found localised to the 
cell margins. Therefore, PDE4A4B does not become frilly soluble upon removal of its 
unique N-terminal and instead can still associate with the perinuclear region of COS-1 
cells. This suggested that motifs other than those found within the unique N-terminal 
region are responsible for confemng targeting on PDE4A4B. Again, these data are 
identical to those data previously published [Huston et ah, 1996]. Such experiments 
support the idea that it is the N-teiminal region of PDE4A4B leads to a loss in the fidelity 
of its intracellular targeting (compare figure 3.2, panel C with figure 3.3, panel C).
As I was able to reproduce the results from previous studies I concluded that both 
the subcellular fractionation and LSCM methods were suitable for use in the subsequent 
targeting analyses.
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PD E46 MEPPTVPSERSLSLSLPGPREGQATLKPPPQHLWRQPRTPIRIQQRGYSDSAERAERERQ 60h6.1 -----------------------------------------------------------------hybl -----------------------------------------------------------------hyb2 -----------------------------------------------------------------
2 E L  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
PDE 4 6 PHRPIERADAMDTSDRPGLRTTPI4SWPSSFHGTGTGSGGAGGGSSRRFEAENGPTPSPGR 120h6.1 -----------------------------------------------------------------hybl -----------------------------------------------------------------hyb2 -----------------------------------------------------------------
2 E L  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
PDE 4 6 SPLDSQASPGLVLHAGAATSQRRESFLYRSDSDYDMSPKTMSRNSSVTSEAHAEDLIVTP 180h6.1 -----------------------------------------------------------------hybl -----------------------------------------------------------------hyb2 -----------------------------------------------------------------
2 E L  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
PD E4 6 FAQVLASLRSVRSNFSLLTNVPVPSNKRSPLGGPTPVCKATLSEETCQQLARETLEELDW 24 0h6.1   PLGGPTPVCKATLSEETCQQLARETLEELDW 4 0hybl -----------------------------------------------------------------
hyb2 ---------------------  PLGGPTPVCKATLSEETCQQLARETLEELDW 4 0
2 E L  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
P D E 4 6  CLEQLETMQTYRSVSEMASHKFKRMLNRELTHLSEMSRSGNQVSEYISTTFLDKQNEVEI 300h6.l CLEQLETMQTYRSVSEMASHKFKRMLNRELTHLSEMSRSGNQVSEYISTTFLDKQNEVEI 100hybl -----------------------------------------------------------------
hyb2 CLEQLETMQTYRSVSEMASHKFKRMLNRELTHLSEMSRSGNQVSEYISTTFLDKQNEVEI 100
2 E L  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
P D E 4 6  PSPTMKEREKQ<2APRPRPSQPPPPPVPHLQPMSQITGLKKLMHSNSLNNSNIPRFGVKTD 360h6.1 PSPTMKEREKQQAPRPRPSQPPPPPVPHLQPMSQITGLKKLMHSNSLNNSNIPRFGVKTD 160hybl  MVLPSDQGFKLLGNVLQGPEPYRLLT 26
hyb2 PSPTMKEREKQQAPRPRPSQPPPPPVPHLQPMSQITGLKKLMHSNSLNNSNIPRFGVKTD 160
2 E L   MVLPSDQGFKLLGNVLQGPEPYRLLT 26
P D E 4 6  QEELLAQELENLNKWGLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYML 42 0h6.1 QEELLAQELENLNKWGLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYML 220hybl SGLRLHQELENLNKWGLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYML 86
hyb2 QEELLAQELENLNKWGLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYML 220
2 E L  SGLRLHQELENLNKWGLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYML 8 6
PD E46 TLEDHYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGV 480h6.l TLEDHYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGV 280hybl TLEDHYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGV 14 6hyb2 TLEDHYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGV 280
2 E L  TLEDHYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGV 14 6
P D E 4 6  SNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDM 54 0
h6.1 SNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDM 34 0hybl SNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDM 206hyb2 SNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDM 34 0
2 E L  SNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDM 206
PD E4 6  VLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLE 600h6.1 VLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLE 400hybl VLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLE 266hyb2 VLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLE 400
2 E L  VLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLE 2 66
PDE4 6 LYRQWTDRIMAE FFQQGDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADL 660
h6.1 LYRQWTDRIMAEFFQQGDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADL 4 60hybl LYRQWTDRIMAEFFQQGDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADL 32 6hyb2 LYRQWTDRIMAE FFQQGDRERERGMEIS PMCDKHTASVEKSQVQARGIDGRAQGGFY 457
2 E L  LYRQWTDRIMAEFFQQGDRERERGMEISPMCDKHTASVEKSQVQARGIDGRAQGGFY 323
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PDE46 v h p d a q e i l d t l e d n r d w y y s a i r q s p s p p p b : e f ,s r g p g h p p l p d k f q f e l t l e e e e e e e  7 2 0
h 6 .1  VHPDAQEILDTLEDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEE 5 2 0
hyb l  VHPDAQEILDTLEDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEF.e e  3 8  6
hyb2 ------------------------------------------------------------------------------------------------------------------------------------
2 E L  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
P D E 4 6  ISMAQIPCTAQEALTAQGLSGVEEALDATIAWEASPAQESLE'/MAQEASLF,AF,LF,AVYLT 7 80
h6.1 ISMAQIPCTAQEALTAQGLSGVEEALDATTAWEASPAQESLEYT4A0EASLEAELEAVYLT 58 0hybl ISMAQT PCTAQEALTEQGLSGVEEALDAT1 AWE AS PAQESLE'\/MAQEAS LEAF LEAVYLT 4 4 6hyb2 -----------------------------------------------------------------
2 E L  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
P D E 4 6  QQAQSTGSAPVAPDEFSSREEFWAVSHSSPSALALQSPLLPAWRTLSVSEHAPGLPGLP 840h6.1 QQAQSTGSAPVAPDEFSSREEFWAVSHSSPSALALQSPLF.PAWRTLSVSEHAPGLPGLF 64 0hybl QOAQSTGSAPVAPDEFSSREEF'WAVSHSSPSALALQSPLLPAWRTLSVSEHAPGLPGLP 506hyb2 -----------------------------------------------------------------
2 E L  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
P D E 4 6 STAAEVEAQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT 8  8  6h6.1 STAAEVEAQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT 68 6
hybl STAAEVEAQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT 552hyb2 -------------------------------------------------
2 E L  -----------------------------------------------------------------------------------------------------------------------------------------
Figure 3.1. Alignment of PDE4A4B (PDE46), PDE4A4C (h6.1), PDE4A7 (2EL), 
hybl and hyb2. Alignment of sequences was performed using the clustalw software 
(http://www2.ebi.ac.uk/clustalw/). The N-terminal of PDE4A4B is shown in black, 
the 9 residue unique N-terminal of h6 .1 is shown in yellow, the regions of sequence 
common to all PDE4As is shown in dark blue, the N-terminal of the catalyic region 
found in all active PDE4As is shown in purple, the unique N-terminal of PDE4A7 is 
highlighted in green, the central core shared by all PDE4As is shown in blue, the C- 
terminal of PDE4A7 is shown in red and the C-terminal tail of all active PDE4As is 
shown in grey. The colour of these sequences corresponds to the coloured domains
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Figure 3.2 Distribution of PDE4A4B (PDE46) in COS-1 cells. A, shows 
a schematic representation of the PDE4A4B protein with its unique 112 
residue N-terminal shown in black, the UCRl, LRl, UCR2 and LR2 regions 
are shown in blue, the N-terminal of the catalytic unit (common to all active 
PDE4As) in purple, the central core in blue, the C-terminal of the catalytic 
unit (shared by all active PDE4As) is shown in aqua and the PDE4A C- 
terminal in grey. The first and last six amino acids of the protein are also 
indicated. B, COS-1 cells were either mock transfected or transfected with 
PDE4A4B construct and allowed to express for 48 hours. Cell lysates were 
lysed, dirupted and subjected to subcellular fractionation. 20pg o f the S 
fraction and equal volumes of both the particulate fractions (PI and P2) 
were separated by 10% SDS-PAGE before immimoprobing with the general 
PDE4A antisera. The migration o f PDE4A4B is indicated, with the 
positions of standard protein molecular mass markers (in kDa) shown on the 
left. This immunoblot is representative of data from three separate 
experiments. C, COS-1 cells transfected with PDE4A4B were fixed, 
permeabilised and incubated with the general PDE4A antisera followed by 
Alexa-labelled anti-donkey antiserum used for the fluorescent detection of 
the enzyme. LSCM was used to image a section through the centre of the 
cell. The left hand panel shows the fluorescent image and the right hand 
panel shows the brightfleld image of the transfected cell. The horizontal 
white bar shown in the panels is the 25pm scale marker.
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3.2.3 Subcellular localisation of PDE4A7 (2EL)
The PDE4A gene encodes the highly truncated, catalytically inactive PDE4A7 
(2EL) enzyme. However, no studies have been done to analyse its intracellular 
distribution. Therefore the methods of general subcellular fractionation and LSCM were 
used to determine the intracellular location of this curious protein. That PDE4A7 is 
truncated at the C-terminal end means its expression cannot be detected using the general 
PDE4A antiserum. Therefore, to overcome this problem PDE4A7 was engineered to 
contain the VSV-epitope tag (YTDIEMNRLGK) at its C-terminal. The nucleotide 
sequence of PDE4A7 has been aligned with both PDE4A4B and h6.1 (figure 3.1). The 
coloured residues represent the coloured domains shown in the subsequent schematic 
diagrams.
Subcellular analysis of COS-1 cells transfected with VSV-epitope tagged 
PDE4A7 (figure 3.4, panel A) were immunoprobed with the polyclonal anti-VS V antibody, 
which identified PDE4A7 as a 31±5kDa immunoreactive band associated exclusively with 
the PI fraction (figure 3.4, panel B). As the PI fraction contains both nuclear and 
cytoskeletal components, LSCM was used to determine the precise intracellular location of 
this protein. Once again, COS-1 cells were transfected to express PDE4A7, fixed, 
peiineabilised and incubated with the polyclonal anti-VSV antibody followed by the 
Alexa293-labelled anti-goat antiserum for the fluorescent detection of this enzyme 
(Materials and Methods 2.2.5). hiterestingly, the fluorescent signal for PDE4A7 was 
detected exclusively within the nuclear compartment (figure 3.4, panel C). One possibility 
then is that, as with previous studies done on PDE4 enzymes, the distribution of PDE4A7 
is dependent on its unique N-tenninal sequence. However, it is also possible that targeting 
of PDE4A7 could be achieved by its unique C-teiminal region.
On the basis of previous studies perfonned whereby the unique N-terminal regions 
of PDE4s have been found to target them to specific intracellular locations, I expected that 
the extensively truncated PDE4A7 would be cytosolic. This was clearly not the case. So I 
set out to determine the basis for the nuclear localisation of PDE4A7 and why in contrast, 
PDE4A4B was found to be extranuclear. Initially, my strategy was to evaluate whether the 
N- or C- tenninal regions of h6.1 allowed it to be targeted to the S2 fraction.
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Figure 3.4 Distribution of PDE4A7 (2EL) in COS-1 cells. A, shows a 
schematic representation o f PDE4A7 protein with its unique N-terminal 
highlighted in green, the central core in blue and the unique 14 residue C- 
terminal in red The first and last six amino acids of the protein are also 
indicated. B, COS-1 cells were either mock transfected or transfected with 
the PDE4A7 construct and allowed to express for 48 hours. Cells were 
lysed, disrupted and subjected to subcellular fi-actionation. 20pg of the S 
fraction and equal volumes of both the particulate fractions (PI and P2) 
were separated by 10% SDS-PAGE and immunoprobed with the 
polyclonal anti-VSV antibody. The migration of PDE4A7 is indicated, 
with the position of the standard protein molecular mass markers (in kDa) 
shown on the left. This immunoblot is representative of data from three 
separate experiments. C, COS-1 cells transfected with PDE4A7 were 
fixed, permeabilised and incubated with the VSV-polyclonal antibody 
followed by Alexa-labelled anti-goat antiserum used for the fluorescent 
detection of the enzyme. LSCM was used to image a section through the 
centre of the cell. The left hand panel shows the fluorescent image and the 
right hand panel shows the brightfield image of the transfected cell. The 
horizontal white bar shown in the panels is the 25pm scale marker.
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3.2.4 Subcellular distribution of the PDE4A7 chimeras, hyb1 and hybl in 
COS-1 ceils
Targeting studies were performed on the PDE4A7 chimeras of hybl and hyb2 to 
evaluate whether hising the N- or C-terminal regions of I1 6 .I to PDE4A7 could target it 
into the cytosol. Hybl and hyb2 were originally engineered to determine whether 
PDE4A7 was inactive by virtue o f its C- or N-tenninal truncation, respectively [Erdogan 
and Houslay, unpublished]. Hybl is a fusion between the unique N-terminal 32 amino 
acids of PDE4A7 and the last 520 amino acids of h6.1 (also shared by all other active 
PDE4As) (figure 3.5, panel A), whereas hyb2 is a fusion between the Erst 443 amino acids 
of h6.1 and the unique 14 amino acid C-terminal region of PDE4A7 (figure 3.6, panel A). 
Hybl and hyb2 sequences have been aligned with the other PDE4As (figure 3.1) with 
coloured residues coiTesponding to the coloui'cd domains on the subsequent schematic 
diagrams.
Hybl was used here to determine whether replacing the C-teiminal region of 
PDE4A7 with the C-teiminal of h 6 .1 would cause PDE4A7 to target to the S2 fraction. 
Subcellular fractions of hybl-transfected COS-1 cells were immunoprobed with the 
general PDE4A antisera, which identified hybl as a 76+2kDa species located not only in 
the cytosol but also showing both PI and P2 association (figure 3.5, panel B, Table 3.1 
shows densitometry data). As the N-teiminal region of PDE4A4B was found responsible 
for its association with the P2 fraction previously, it was surprising to find that hybl, 
which contains the N-terminal of h6.1, was still capable of associating with this fraction. 
One possible explanation for the aberrant targeting of hybl to the P2 fraction might be that 
extensive truncation has caused it to adopt a different conformation to that of h6 ,l, 
possibly resulting in the exposure of an othemise masked targeting motif. If time had 
permitted, LSCM would have proved useful in identifying the precise intracellular location 
of hybl. This is because association with P2 fraction does not necessarily suggest plasma 
membrane localisation, as the P2 fr action also contains endosomes, lysosomes, golgi stacks 
and cytoskeletal components.
Subcellular fractionation analyses of hyb2 were performed to determine whether
replacing the N-teiminal region of PDE4A7 with the N-teiminal of I1 6 .I would alter the
targeting of the central core of PDE4A7. As it is C-teiminally tnmctated, hyb2 was also
engineered to contain the VSV-epitope tag at its C-teiminus. Subcellular fractionation of
hyb2-transfected COS-1 cells was done and fractions were immunoprobed with the
polyclonal anti-VSV antibody. This identified hyb2 as a 49±2kDa species associated
mainly with the PI fraction (figure 3.6, panel B, Table 3.1 shows densitometry data) as
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with PDE4A7. From these data I concluded that sequence within the C-temiinal region of 
I1 6 .I was responsible for its S2 distribution. This might explain why PDE4A7, which is 
truncated at the C-terminus and therefore lacks this domain, cannot associate with the S2 
fraction. These data also prove that the targeting information of PDEs is not strictly 
located within their unique N-terminal regions.
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Table 3,1 Distribution of I16.I, hybl and hyb2 in COS-1 cells
These data are given as means ± S.D. for three separate experiments.
Subcellular Fraction
Construct PI (%) s (%) P2 (%)
PDE4A4B 33+6 60+4 17+6
h6 . 1 20+4 80+4 -
hybl 44+4 36+6 20+3
hyb2 92+5 8+4 -
5 8
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Figure 3.5 Subcellular localisation of hybl. A, shows a schematic 
representation of the hybl protein indicating the unique 32 residue N- 
terminal of PDE4A7 in green, the central core in blue, the C-terminal of the 
catalytic subunit shared by all active PDE4As shown in aqua and the 
PDE4A C-terminal tail in grey. The first and last six amino acids of the 
protein are also indicated. B, COS-1 cells were either mock transfected or 
transfected with the hybl construct and allowed to express for 48 hours. 
Cell lysates were subjected to subcellular fractionation and 20pg of the S 
fraction and equal volumes of both the particulate fractions (PI and P2) 
were separated by 10% SDS-PAGE. Fractions were immunoprobed with 
general PDE4A anti serum.. This immunoblot is representative of data 
obtained from three separate experiments. The migration of hybl is 
indicated, with the positions o f the standard molecular weight markers on 
the left. The mock lysate lane was taken from the same gel as the sample 
lanes.
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Figure 3.6 Subcellular localisation of hybl. A, shows a schematic 
representation of the hybl protein indicating the unique 9 residue N- 
terminal in yellow, the sequence common to all PDE4As in blue, the N- 
terminal of catalytic subunit shared by all active PDE4As is shown in purple 
and the 14 residue C-terminal of PDE4A7 in red. The first and last six 
amino acids of the protein are also indicated. B, COS-1 cells were either 
mock transfected or transfected with the hybl construct and left to express 
for 48 hours. Cell lysates were subjected to subcellular fractionation. lOpg 
of the S fraction and equal volumes of both the particulate fractions (PI and 
PI) were separated by 10% SDS-PAGE. Fractions were immunoprobed 
with the polyclonal anti-VSV antibody. This immunoblot is representative 
of data obtained from three separate experiments. The migration of hybl is 
indicated,with the positions of the standard protein molecular weight 
markers (in kDa) shown on the left. The mock lysate lane was taken from 
the same gel as the sample lanes.
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3.2.5 Expression of hyb1 truncates in COS-1 ceiis
My next aim was to gain insight into the basis for nuclear targeting of PDE4A7. 
Firstly I set out to determine whether the unique N-or C-terminal regions present in 
PDE4A7 were responsible for its PI association. This was addressed by engineering two 
constructs. In the first construct (delta N-C), both the N- and C-teiminal regions of 
PDE4A7 were deleted to leave the PDE4A core region. In the second construct only the 
C-terminal region of PDE4A7 was deleted (delta 309) to address whether the N-terminal of 
PDE4A7 harboured the targeting signal. As both of these constructs are C-terminally 
truncated, protein expression could not be detected using the general PDE4A antisera. To 
obviate this problem each truncate was engineered to contain a FLAG epitope tag 
(DYKDDDDK) at the C-terminal, which meant their expression could be detected by 
using the anti-FLAG antibody. COS-1 cells were transfected with each of the constructs, 
harvested and cell lysates were subjected to general subcellular fractionation before 
immunoblotting with the polyclonal FLAG antibody. The nucleotide sequences of the 
PDE4A7 truncates have been aligned with hybl and PDE4A7. The coloured residues 
con'espond to the coloured domains in the subsequent schematics {figure 3.7).
I expected that the extensively tmncated delta N-C construct would be a fully 
soluble species and that association with the PI would only occur when the PDE4A7 N- 
tenninal was present. However, subcellular fractionation studies (Materials and Methods
2.2.1) identified the delta N-C construct {figure 3.8, panel A), as a 29±3kDa species 
associated exclusively with the low speed PI fraction {figure 3.8, panel B). This result 
demonstrated that even in the absence of both the N- and C-terminals, the core of PDE4A7 
(and of all PDE4As) was still targeted to the low speed PI fraction. The next step was to 
determine whether the addition o f the PDE4A7 unique N-terminal to the central core 
would alter this subcellular distribution. The delta 309 constmct, which encodes amino 
acids 1-309 of the hybl protein {figure 3.10, panel A) was associated with the PI fraction 
only (31 ±3kDa) {figure 3.10, panel B). From these analyses I concluded that the sequence 
motif responsible for the PI targeting of PDE4A7 was located within its central core and 
that the S2 targeting demonstrated by hybl was due a motif located within its C-terminus. 
Determining the sequence motif in the hybl C-terminus responsible for S2 distribution is 
of great interest as this C-terminal sequence is shared by all active long form PDE4s, and 
may therefore participate in their targeting.
In summary, residues within the C-teiminal of hybl appear to be involved in
targeting it to the S2 fraction. In an attempt to identify the approximate location of this
signal, C-terminal truncations of the hybl construct were engineered (constructs were
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made by Dr Ian McPhee). Again, each of these constructs were C-terminally truncated and 
were also engineered to contain the FLAG-epitope tag at their C-termini to allow detection 
of their expression by immunoblotting. The sequences of these hybl truncates have been 
aligned with hybl and PDE4A7, with coloured residues corresponding to the coloured 
domains in the subsequent schematics (figure 3.7).
The delta 328 construct, encoding amino acids 1-328 of hybl (figure 3.10, panel A) 
was constructed to detemiine whether replacing the C-teiminal of PDE4A7 with 19 amino 
acids from the C-teiininal of hybl would cause it to localise within the S2 fraction. 
Subcellular analyses identified delta 328 (32±4kDa) mainly within the PI fraction, with 
some S2 distribution (figure 3.10, panel B and see Table 3.2). This demonstrated that the 
minimal common PDE4A C-tenninal sequence required to confer S2 distribution on the 
PDE4A7 central core was located between amino acids 309 to 328 of the hybl C-tenninal 
region (conesponding to amino acids 643 to 662 of PDE4A4B). The most significant 
change in distribution was observed with the delta 410 constmct, encoding amino acids 1- 
410 of hybl (figure 3.11, panel A and see Table 3.2). This protein was identified as a 
50±4kDa band in both the S2 and low speed PI fractions, with some P2 association (figure 
3.10, panel B). This data demonstrated that replacing the C-tenninal o f PDE4A7 with 101 
amino acids from the PDE4A C-terminal caused the greatest shift of the PDE4A7 central 
core to the S2 fraction. To identify the motif responsible for allowing extranuclear 
targeting, then further tmncations upstream of residue 328 in hybl would have to be 
engineered and evaluated.
LSCM was perfonned on these constructs to determine their precise intracellular 
localisation, however, many problems were encountered with high backgroimd staining 
generated from the FLAG antibody, which made distinguishing between transfected and 
untransfected cells difficult. If time had permitted these constmcts would have been 
engineered to contain the VSV-epitope tag instead because the anti-VSV antibody has been 
found in these studies to be more specific than the anti-FLAG antibody. Therefore, in the 
friture it will be interesting to determine the precise intracellular distribution of hybl, hyb2 
and the hybl chimeras by using LSCM.
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Table 3.2 Distribution of delta 328 and delta 410 in COS-1 cells
These data are given as means ± S.D. for tlmee separate experiments.
Subcellular Fraction
Construct FI (%) S (%) P2 (%)
delta 328 71+9 29+9 -
delta 410 55+4 37+5 8±4
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hybl MVLPSDQGFKLLGNVLQGPEPYRLLTSGLRLHQELENLNKWGLNIFCVSDYAGGRSLTCI 60
NCterm ---------------------------------- QELENLNKWGLNIFCVSDYAGGRSLTCI 28
3 0 9  MVLPSDQGFKLLGNVLQGPEPYRLLTSGLRLHQELENLNKWGLNIFCVSDYAGGRSLTCI 60
3 2 8  MVLPSDQGFKLLGNVLQGPEPYRLLTSGLRLHQELENLNKWGLNIFCVSDYAGGRSLTCI 60
4 1 0  MVLPSDQGFKLLGNVLQGPEPYRLLTSGLRLHQELENLNKWGLNIFCVSDYAGGRSLTCI 60
2 E L  MVLPSDQGFKLLGNVLQGPEPYRLLTSGLRLHQELENLNKWGLNIFCVSDYAGGRSLTCI 60
hybl MYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVLLATPAL 12 0
N C t e r m  MYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVLLATPAL 8 8
3 0 9  MYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVLLATPAL 120
3 2 8  MYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVLLATPAL 120
4 1 0  MYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVLLATPAL 120
2 E L  MYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVLLATPAL 120
hybl DAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLL 180
N C t e r m  DAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLL 148
3 0 9  DAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLL 180
3 2 8  DAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLL 180
4 1 0  DAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLL 180
2 E L  DAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLL 180
hybl QEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLD 24 0
N C t e r m  QEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLD 208
3 0 9  QEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLD 24 0
3 2 8  QEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLD 24 0
4 1 0  QEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLD 240
2 E L  QEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLD 240
hybl NYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKH 300
N C t e r m  NYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKH 2 68
3 0 9  NYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKH 300
3 2 8  NYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKH 300
4 1 0  NYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKH 300
2 E L  NYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKH 300
hybl TASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTLEDNRDWYYSAIRQSPSPPFEEF 360
N C t e r m  TASVEKSQV-------------------------------------------------------- 277
3 0 9  TASVEKSQV--------------------------------------------------------- 309
3 2 8  TASVEKSQVGFIDYIVHPLWETWADLVH----------------------------------- 328
4 1 0  TASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTLEDNRDWYYSAIRQSPSPPPEEE 360
2 E L  TAS VE KS QVQARGIDGRAQGG FY-----------------------------------------323
hybl SRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPCTAQEALTEQGLSGVEEALDATIAWEA 420
N C t e r m  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
3 0 9  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
3 2 8  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
4 1 0  SRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPCTAQEALTEQGLSGVEE----------- 410
2 E L  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
hybl SPAQESLEVMAQEASLEAELEAVYLTQQAQSTGSAPVAPDEFSSREEFVVAVSHSSPSAL 4 80
N C t e r m  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
3 0 9  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
3 2 8  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
4 1 0  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
2 E L  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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hyb l ALQSPLLPAWRTLSVSEIiAPGLPGLPSTAAEVEAQREHQAAKRACSACAGTFGEDTSALP 5 4 0
N C t e r m  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
3 0 9  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
3 2 8  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
4 1 0  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
2 E L  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
h yb l  APGGGGSGGDPT 5 5 2
N C t e r m  -----------------------------------
3 0 9  -----------------------------------
3 2 8  -----------------------------------
4 1 0  -----------------------------------
2 E L  -----------------------------------
Figure 3.7. Alignment of hybl and PDE4A7 (2EL) with the engineered hybl 
chimeras. Alignment of these sequences were performed using the clustalw software 
(http://www2.ebi.ac.uk/clustalw/). The unique N-terminal of 2EL is highlighted in 
green, the central catalytic core shared by all PDE4As are shown in blue, the C- 
terminal of the catalytic domain found in all active PDE4As are shown in aqua, the C- 
tenninal of 2EL is shown in red and the C-terminal tail shared by all active PDE4As is 
shown in grey. The colour of these sequences corresponds to the coloured domains of 
the schematics.
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Figure 3.8 Subcellular localisation of delta N-C terminal. A, shows a 
schematic representation of the delta N-C terminal that encodes the central 
core (blue). The first and last six amino acids of the protein are also 
indicated. B, COS-1 cells were either mock transfected or transfected with 
the delta N-C terminal construct and allowed to express for 48 hours. Cells 
were lysed, disrupted and subjected to subcellular fractionation. 20pg of the 
S fraction and equal volumes of both the particulate fractions (PI and P2) 
were separated by 10% SDS-PAGE. Fractions were immunoblotted with 
the polyclonal anti-flag antibody.. This immunoblot is representative of data 
obtained from three separate experiments. The migration of delta N-C 
terminal is indicated, with the positions of the standard protein molecular 
mass standards (in kDa) shown on the left.
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Figure 3.9 Subcellular localisation of delta 309. A, shows a schematic 
representation of the delta 309 protein, with the unique 32 residue N- 
terminal of PDE4A7 shown in green and the central core domain in blue. 
The first and last six amino acids of the protein are also indicated. B, COS- 
1 cells were mock transfected or transfected with the delta 309 construct 
and allowed to express for 48 hours. Cells were lysed, disrupted and 
subjected to subcellular fractionation. 20pg of the S fraction and equal 
volumes of both the particulate fractions (PI and P2) were separated by 
10% SDS-PAGE. Fractions were immunoblotted with the polyclonal anti­
flag antibody. This immunoblot is representative data from three separate 
experiments. The migration of delta 309 is indicated, with the position of 
the standard protein markers (in kDa) shown on the left. The mock lysate 
lane was taken from the same gel as the sample lanes.
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Figure 3.10 Subcellular localisation of delta 328. A, shows a schematic 
representation of the delta 328 protein indicating the unique 32 residue N- 
terminal of PDE4A7 in green, central core in blue, the C-terminal of the 
PDE4A catalytic unit (shared by all active PDE4As) in aqua and the 
truncated C-terminal tail of hybl in grey. The first and last six amino acids 
of the protein are also indicated. B, COS-1 cells were either mock 
transfected or transfected with the delta 328 construct and allowed to 
express for 48 hours. Cells were lysed, disrupted and subjected to 
subcellular fractionation. 20pg of the S fraction and equal volumes of both 
the particulate fractions (PI and P2) were separated by 10% SDS-PAGE. 
Fractions were immunoblotted with the polyclonal anti-flag antibody. This 
immunoblot is representative data from three separate experiments. The 
migration of delta 328 is indicated, with the positions of the standard protein 
molecular weight standards (in kDa) shown on the left. Both the mock 
lysate lane and sample lanes were taken from the same gel.
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Figure 3.11 Subcellular localisation of delta 410. A, shows a schematic 
representation of the delta 410 protein indicating the unique 32 residue N- 
terminal of PDE4A7 in green, central core in blue, the C-terminal of the 
PDE4A catalytic unit (shared by all active PDE4As) in aqua and the 
truncated C-terminal tail of hybl shown in grey. The first and last six amino 
acids of the protein are also indicated. B, COS-1 cells were either mock 
transfected or transfected with the delta N-C terminal construct and allowed 
to express for 48 hours. Cells were lysed, disrupted and subjected to 
subcellular fractionation. 20pg of the S fraction and equal volumes of both 
the particulate fractions (PI and P2) were separated by 10% SDS-PAGE. 
Fractions were immunoblotted with the polyclonal anti-flag antibody. This 
immunoblot is representative of three separate experiments. The migration 
of delta 410 is indicated, with the positions of the standard molecular weight 
markers (in kDa) shown on the left.
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3.2.6 Conclusions from targeting anaiysis of PDE4As
hi smnmary, targeting studies performed on the hybl and hyb2 chimeras (section 
3.2.4) demonstrated that replacing the C-terminal of PDE4A7 with the C-tenninal region 
of hybl was enough to cause some redistribution to the S2 fraction of COS-1 cells. Data 
fi'om subcellular analyses perfonned on the hybl truncates revealed that the minimum 
sequence required for S2 targeting was contained within amino acids 309 to 328 of the 
hybl sequence. At this stage, the exact sequence motif responsible for this targeting was 
unknown.
3.2.7 Attempt to identify nuclear import and export signais on PDE4A7 and 
PDE4A4B,respectively.
The next aim was to gain more insight into the basis of nuclear entry for PDE4A7, 
as the nuclear import of proteins is a very tightly regulated process. Nuclear import is 
mediated by pores in the nuclear membrane called nuclear pore complexes (NPCs). The 
central chaimel of these pores allows the passive diffrision of smaller molecules (<40Kda) 
whereas the larger molecules (>40kDa) can only enter the nucleus by an energy-driven 
active transport process [Gorlich et ah, 1999; Kaffinan et al., 1999]. As PDE4A7 is only 
32±3kDa in size it should, theoretically, be able to enter the nucleus by passive diffusion, 
however, this is unlikely as most of the proteins localised to the nuclear compartment are 
actively transported. Even proteins smaller (20-3 OkDa) than PDE4A7, such as histones 
[Kurz et ah, 1997] depend on signal-mediated import. Proteins requiring active transport 
usually contain import signals that commonly fall into two categories, either consisting of 
3-5 basic amino acid residues (monopartite) as first identified in the simian virus 40 
(SV40) large T-antigen (PKKKRKV) [Kalderon et ah, 1984], or of two basic stretches of 
amino acids separated by 10 amino acids (bipartite) as found in nucleoplasmin [Robbins et 
ah, 1991].
Analysis of the PDE4A7 sequence for putative NLSs in PDE4As revealed two 
separate putative monopai-tite signals. KKFR is positioned between amino acids 72 and 75 
and KKVT between amino acids 229 and 232 of PDE4A7. These NTS motifs are much 
shorter than the monopartite signal identified in the SV40 large T-antigen. However, a 
small basic motif of KRK has been shown to be sufficient to direct the nuclear import of 
the Src homology 2 domain-containing protein tyrosine phosphatase SHP-1 [Graggs et ah, 
2001]. If either KKFR or KKVT were NLSs in PDE4A7 then one might expect that all 
PDE4As would be capable of entering the nuclear compartment as these motifs are located
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within the PDE4A central core domain that is shared by all PDE4As, However, 
PDE4A4B, which also harbours this sequence, is found outside the nucleus. Thus, it may 
be the large size of PDE4A4B that keeps it excluded from the nucleus, or, that only in the 
drastically tmncated PDE4A7 do these putative NLSs become exposed. Alternatively, all 
PDE4A isoforms might have the ability to cycle tlirough the nucleus, but that strong 
interactions with proteins outside the nucleus keep them excluded from this compartment.
Nucleolin was the first protein found to undergo nucleocytoplasmic shuttling [Borer 
et ah, 1989], but ever since its discovery, a huge number of other proteins including steroid 
hormone receptors [Hache et ah, 1999], transcription factors [Cartwright et ah, 2000], cell 
cycle regulators [Pines et ah, 1999] and transport receptors [Gorlich et ah, 1999] have been 
found to cycle between the nucleus and cytoplasm. Shuttling proteins typically contain 
both an NLS and an NES [Mattaj et ah, 1998] although some proteins contain 
nucleocytoplasmic shuttling signals (NS) that are neither an NLS or an NES but can 
mediate both import and export [Michael., 2000]. The most common and researched type 
of NES contains a stretch of hydrophobic, leucine-rich residues and resemble the ‘LX(i. 
3 )LX(2 -3 )LXL’ NES consensus [Kaffinan et ah, 1999; Wen et ah, 1995]. Mutations of the 
crucial leucine residues in proteins containing well-characterised NESs were found to 
ablate their nuclear export [Henderson et al 2000].
Therefore, in order to cycle through the nucleus, PDE4As in addition to possessing an 
NLS, would also have to contain an NES. Analysis of the hybl C-terminal sequence (also 
shared by all active PDE4As) for any putative NES was initially focussed to the sequence 
between amino acids 309 and 328 as this region was previously found to confer the 
cytosolic (S2) distribution on the central core of PDE4A7. However, no putative NESs 
were found in this region, but further downstream between amino acids 436 and 445 of 
hybl (or amino acids 770 to 779 of PDE4A4B) the ‘LEAELEAVYL’ motif was identified, 
which resembled the common consensus NES motif. Therefore, the extranuclear targeting 
signal located within amino acids 309 and 328 may actually serve in mediating the 
interactions of the long forms with other proteins. I next hypothesised that both the active 
PDE4As and the inactive PDE4A7 were capable of entering the nucleus and that only the 
active PDE4A isoforms could exit from this compartment as they contained the C-terminal 
region that harbours the putative NES. To address these questions, the putative NLSs of 
PDE4A7 were removed by mutation and the putative NES was removed from hybl by 
mutation.
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3.2.8 Mutational analysis of the putative nuclear import signai of PDE4A7
Firstly, to establish whether KKFR or KKVT were responsible for the nuclear 
import of PDE4A7, each domain was removed in the PDE4A7 protein by mutating the 
basic residues to aspartates {figure 3.12, panel A and figure 3.13, panel A) (engineered by 
Irene Gall). The subcellular fractions of COS-1 cells over-expressing either the KKFR or 
KKVT mutant were immunoblotted with the polyclonal VSV antibody which identified the 
34±2kDa immunoreactive band of PDE4A7 only in the PI fraction in both cases {figure 
3.12, panel B and figure 3.13, panel B). If either of these motifs had been functional NLSs 
then an accumulation of these proteins within the S2 fraction would have been expected. 
This result suggested that neither the KKFR or KKVT motifs were responsible for import 
of PDE4A7 into the nucleus, hr the future it would be interesting to analyse the targeting 
of these constructs using LSCM.
3.2.9 Mutational analysis of the putative export signal in PDE4A4B
Secondly to determine whether the putative NES found in the C-terminal of 
PDE4As was responsible for exporting them from the nuclear compartment, the leucine 
residues in this domain of hybl were removed by mutation to aspartate (engineered by 
Irene Gall). As before, subcellular fractions of COS-1 cells over-expressing the hybl NES 
mutant were immunoblotted with PDE4A antisera, but unfortunately this construct did not 
express. Therefore, the question of whether the ' LE AELE AV YL ' motif of PDE4As 
functions as an NES remains to be resolved, as time constraints did not allow me to pursue 
this study any further.
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Figure 3.12 Subcellular localisation of PDE4A7 containing import 
mutation 1. A, shows a schematic representation of the PDE4A7 import 
mutant protein indicating the unique N-terminal of PDE4A7 in green, the 
central core in blue and the unique 14 residue C-terminal of PDE4A7 in red. 
The position of the amino acids that were mutated are also shown. B, COS-1 
cells were either mock transfected or transfected with the KKFR PDE4A7 
import mutant and allowed to express for 48 hours. Cells were lysed, 
disrupted and subjected to subcellular fractionation. 20pg of the S fraction 
and equal volumes of both the particulate fractions (PI and P2) were 
separated by 10% SDS-PAGE. Fractions were immunoblotted with the 
polyclonal anti-VSV antibody. This immunoblot is representative of data 
from three separate experiments. The migration of the PDE4A7 import 
mutant is indicated, with the standard protein molecular weight standards (in 
kDa) shown on the left.
73
A Central core
KK V
V VVNP A A V A
B Cell fraction(kDa) Mock PI P2
•s~ f* 7
PDE4A7 import 
^  mutant 2
Figure 3.13 Subcellular localisation of PDE4A7 containing import 
mutation 2. A, shows a schematic representation of PDE4A7 import 
mutant 2 protein, with the unique N-terminal of PDE4A7 in green, the 
cennal core in blue and the unique 14 residue C-terminal of PDE4A7 in 
red. The position of the amino acids that were mutated are also indicated. 
B, COS-1 cells were either mock transfected or transfected with the KKVT 
PDE4A7 import mutant and allowed to express for 48 hours. Cells were 
lysed, disrupted and subjected to subcellular fractionation. 20pg of the S 
fraction and equal volumes of both the particulate fractions (PI and P2) 
were separated by 10% SDS-PAGE. Fractions were immunoblotted with 
the polyclonal anti-VSV antibody. This immunoblot is representative of 
data from three separate experiments. The migration of the PDE4A7 
import mutant is indicated with the positions of the standard molecular 
weight standards (in kDa) shown on the left.
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3.2.10 Engineering an NES to the C-terminai of PDE4A7
My previous hypothesis was that PDE4A7 was restricted to the nuclear compartment 
because it lacked the PDE4A C-terminal containing the NES. However, it was yet to be 
proven whether an NES was capable of causing PDE4A7 to relocate to the cytosol. To 
address this question PCR was used to fuse the ‘LQLPPLERLTLYT’ NES of PKIa onto 
the C-tenninal of PDE4A7 cDNA. The sequence of the primers used are given below with 
the PCR conditions used for amplification described in Materials and Methods 2.3.10.1.
Primer
S= Sense A= Antisense
s GATAATGGTGCTTCCTTCAGACCAAGGC
A GTTACTTTCCCAGCCTGTTCATCTCTATATCGGTGTACAACGTTAGACGCTC
CAACGGCGGCAGCTGCAGATAAAACCCAC
Table 3.3 Table showing the sense and antisense primers used to incorporate the NES of 
PKIa onto the C-terminal of PDE4A7
The sizes of the resultant PCR products were checked by 1% agarose gel electrophoresis,
in which the clear band of PDE4A7 was detected as a 1 OOObp band in all cases (figure
3.14, panel A). The TOPO cloning kit fimn Invitrogen was used to insert the PDE4A7
NES-containing cDNA into the pcDNA3.1/V5-His-TOPO vector (Materials and Methods
2.3.10.3). These PCR products were used to transfoim Ecoli that were streaked out onto
ampicillin plates and left to gi'ow overnight at 30°C (colonies will only grow if they
contain the TOPO vector carrying the ampicillin resistance gene) (Materials and Methods
2.3.10.2). Resultant colonies were PCR screened (Materials and Methods 2.3.10.3) to
check that plasmids contained the PDE4A7 insert, only three of the six colonies screened
were found to contain the PDE4A7 insert (figure 3.14, panel B, lanes 1, 2 and 6),
therefore, a further six colonies were screened, of which another four were found to
contain PDE4A7 (data not shown). These plasmids were then sequenced to confinn that
PDE4A7 had been inserted into the TOPO vector in the correct orientation (Materials and
Methods 2.3.11). Unfortunately all constructs contained numerous mutations in the
attached NES. The only construct that was suitable for evaluation was one where a key
leucine residue had been replaced with valine. As valine is also hydrophobic, it should not,
theoretically, upset the 3:2:1 distribution of key hydrophobic residues. RanBP-1, which
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undergoes nuclear export also contains a valine residue at this key position, therefore, there 
was the possiblity that this mutated NES sequence of PKIa may still be recognised by its 
export receptor.
The NES of PETa was chosen as export assays have shown that this is one of the 
most active export signals [Henderson et ah, 2000]. Subcellular fractions of COS-1 cells 
over-expressing the PDE4A7 NES-containing protein were immunoblotted with the 
polyclonal VSV-antibody, which identified a 40±3kDa band of PDE4A7 only in the PI 
fraction. This result indicated that PDE4A7 could not exit the nucleus by virtue of an 
exogenously added NES. A number of reasons may explain this finding. Firstly, the 
mutation of one of the important leucine residues to valine may have been enough to 
prevent this NES fi'om being recognised by its cognate export receptor. It is possible that 
PDE4A7 is tightly associated with another protein in the nuclear compartment and that the 
export signal of PKIa was not strong enough to over-come this binding affinity. Also, 
PDE4A7 may adopt a conformation that masks the NES and prevents it from being 
recognised by the nuclear export machinery. Indeed, the NES of PKIa remains buried in 
this protein until PKIa interacts with its substrate of cAMP dependent kinase [Wen et ah, 
1995] indicating that presentation of this NES is crucial to its functioning.
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Figure 3.14 Engineering the NES of PKIa to the C-terminal of
PDE4A7. A, PCR was used to fuse the NES of PKIa to the 3’ end of 
PDE4A7 cDNA. PCR products were analysed by 1% agarose gel 
electrophoresis. B, PDE4A7 NES-containing cDNA was inserted into the 
TOPO cloning vector (see materials and methods). This TOPO vector was 
transformed into Ecoli that were plated out onto ampicillin plates and 
grown overnight at 30°C. Resultant colonies were PCR screened using the 
T7 and PDE4A7 reverse NES primer to identify tose vectors containing the 
PDE4A7 insert. Product sizes were analysed by 1% agarose gel 
electrophoresis. The migration of size markers (in bp) are indicated on the 
left.
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Figure 3.15 Subcellular localisation of PDE4A7 containing a NES. A,
shows a schematic representation of the PDE4A7 NES-containing protein, 
with the unique 32 residue N-terminal of PDE4A7 shown in green, central 
core in blue, unique 14 residue C-terminal in red and the engineered NES in 
black. The position of the putative NES that was mutated is also shown. B, 
COS-1 cells were either mock transfected or transfected with the PDE4A7 
export construct and allowed to express for 48 hours. Cells were lysed, 
disrupted and subjected to subcellular fractionation. 20pg of the S fraction 
and equal volumes of both the particulate fractions (PI and P2) were 
separated by 10% SDS-PAGE. Fractions were immunoblotted with the 
polyclonal anti-VSV antibody. The migration of the PDE4A7 export protein 
is indicated, with position of the standard molecular mass protein standards 
(in kDa) shown on the left. This immunoblot is representative of data from 
three separate experiments.
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3.3 Discussion
As the role of PDEs within cells is to regulate the levels of cyclic nucleotides, it 
was surprising to find that the PDE4A gene encoded a splice variant, PDE4A7, that is 
devoid of any catalytic activity. My study of this protein began by focussing on its 
intracellular targeting. I made the novel discovery that PDE4A7 was located exclusively to 
the nuclear compartment of COS-1 cells when over-expressed. This was interesting as 
previous work had demonstrated that a core complex formed from the catalytic unit and C- 
terminal were fully soluble, with targeting to membrane sites only achieved in the presence 
of isoform-specifrc N-terminals, thus I had expected that the highly truncated PDE4A7 
would also be fully soluble [Scotland et ah, 1995].
I next investigated whether replacing the unique N- or C-terminal regions of 
PDE4A7 with the N-and C-terminal regions common to all other PDE4As would alter its 
targeting. To address this the PDE4A7 chimeras of hybl and hyb2 were used. Hybl, in 
which the unique C-terminal of PDE4A7 is fused to the C-terminal common to all active 
PDE4A isoforms was found in not only the particulate fractions (PI and P2), but also in 
the S2 fraction. Hyb2, in which the uirique C-terminal of PDE4A7 is fused to the N- 
terminal of h6.1, was found essentially in the PI fr'action. These studies demonstrated that 
the core of PDE4A7 could be targeted to the cytosol by replacing its unique C-terminal 
with 19 amino acids of the C-terminal region common to all PDE4As. I concluded that the 
signal that allowing for the extranuclear localisation of active PDE4As was contained 
within their C-terminals.
My next aim was to determine whether it was the unique N-terminal of PDE4A7 
that was responsible for its targeting. To investigate this I used two constructs, hi one 
constmct, both the unique N- and C-tenninal regions of PDE4A7 were deleted to leave 
only the central core that is common to all PDE4As (delta N-C). The second construct 
only contained the core region and C-terminal of PDE4A7 (delta 309). Both these 
constructs were found to associate exclusively with the PI fraction of COS-1 cells. This 
was very surprising as I had expected that the central core alone would be fully soluble and 
that PI distribution would only be restored when the N-terminal of PDE4A7 was present. I 
concluded from these analyses that the PI association of PDE4A7 was mediated by 
sequence present in the central core and not the unique N- or C-temiinal regions. This also 
proved that the S2 targeting of hybl must be mediated by sequence in its C-terminal 
region.
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In an attempt to identify the approximate location of this S2 signal in the PDE4A 
C-terminal, truncation analysis of the hybl C-terminal region was performed. In one 
construct (delta 328), the C-terminal of PDE4A7 was replaced with 19 amino acids from 
the C-terminal sequence of hybl. In the second construct (delta 410), the C-terminal of 
PDE4A7 was replaced with 101 amino acids from the hybl C-terminal sequence. 
Subcellular analyses revealed that the minimal sequence required for to target the PDE4A7 
core to the cytosol was contained within amino acids 309-328 of the hybl C-teiminal 
(amino acids 644 to 662 of PDE4A4B).
I next set out to identify the basis of PDE4A7 nuclear entry. On the basis that 
nuclear import is a highly regulated process and usually requires the presence of an NLS, I 
identified two putative NLSs namely KKFR and KKVT, located within the PDE4A7 
central core. However, PDE4A4B, which also shares this core region is found located 
outside the nucleus. I hypothesised that the active PDE4A isoforms might cycle through 
the nucleus, but that stronger interactions outwith this compartment keep them excluded. 
The residues responsible for this interaction may reside within residues 309-328 of the 
hybl C-terminus. Proteins that cycle between the nucleus and the cytosol typically contain 
both an NLS and NES. A putative NES was identified within the C-terminal of hybl that 
is common to all PDE4As. This ' LE AELE A V YL ' motif was positioned between residues 
436-445 in the hybl sequence (between residues 770-779 of the PDE4A4B sequence). 
Therefore, I postulated that both active PDE4A long forms and PDE4A7 were capable of 
entering the nucleus, but that only the active forms could exit as they contained this NES. 
To address these questions both the NLSs and the NES were mutated. Subcellular analysis 
of the NLSs mutants demonstrated that neither KKVT nor KKFR were responsible for the 
nuclear import of PDE4A7. It would be interesting to mutate both sites together, in case 
just one of these signals alone can function to import the protein, even if the other one is no 
longer functional. Of course it is possible that PDE4A7 is transported to the nucleus by an 
unconventional NLS that bears no resemblance to the classical NLS motifs, such as the 
PPXXR motif found to mediate the import of Sam68 [Ishidate et ah, 1997]. Alternatively, 
PDE4A7 may not contain any NLS itself but may gain entry into the nuclear compartment 
by piggybacking on a protein that does contain a classical NLS. Thus, as yet the transport 
mechanism for PDE4A7 remains to be elucidated.
The NES mutant of hybl failed to express and whether the ' LE AELE A V YL ' 
motif can act as an NES for the PDE4As remains to be investigated. Cycling of PDE4As 
could also be addressed in the future by treating cells over-expressing PDE4A4B (or other 
PDE4As) with the export inhibitor of Leptomycin B. Leptomycin B inhibits the nuclear
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export receptor of CRM-1, which would be expected to cause PDE4A4B to accumulate in 
the nucleus. There is the possibility that PDE4As do not shuttle through the nucleus, and 
that after translation they simply reside in the cytosol. Even if an NLS was located in 
sequence common to both PDE4A7 and the other active PDE4As, this signal may be 
masked by the folding of PDE4A4B.
Finally, attempts were made to shift PDE4A7 from the nuclear compartment into 
the cytosol by fusing the NES of PKIa to the C-terminal region. In this study I expected to 
see PDE4A7 within the S2 fraction. However PDE4A7 was still associated exclusively 
with the PI fraction. This suggested that such an NES may not suffice to ‘pull’ PDE4A7 
out of the nucleus possibly because PDE4A7 may be tightly bound to another nuclear 
protein.
Here I have made a novel discovery that the highly truncated PDE4A7 is targeted 
to the nuclear compartment. This would suggest that PDE4A7 must have an important 
functional role within this compartment. The mechanism of nuclear localisation is 
unknown but I have demonstrated that a small portion from the C-terminal region found in 
all catalytically active PDE4A species is responsible for their S2 targeting.
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Chapter 4
An attempt to identify PDE4A7 (2EL) interacting
proteins
4.1 Introduction
As yet, the only PDE4A splice variant found to be exclusively localised within the 
nuclear compartment is the catalytically inactive PDE4A7 (2EL) splice variant. The 
mechanism used by PDE4A7 to gain entry to the nucleus remains to be elucidated. 
Originally, I postulated that PDE4A7 might be actively transported by virtue of sequences 
that resembled common nuclear localisation signals (NLSs). However, mutational analysis 
of the two putative NLSs found in PDE4A7 did not cause it to accumulate within the 
cytosol, as might be expected if they were functional NLSs. This suggests that PDE4A7 is 
transported into the nucleus by either an unconvential NLS or by a completely different 
process altogether. Although PDE4A7 is small enough to diffuse passively into the 
nucleus, literature has suggested that it is unlikely that even small proteins fi*eely diffuse 
into this compartment and rather that their entry is strictly controlled [Gorlich et al., 1999]. 
It is possible that PDE4A7 contains no NLSs itself and that its nuclear entry is mediated by 
interacting with a protein that does contain an NLS. This process is called the ‘piggy-back 
mechanism’ and has been demonstrated by the (50kDa) glucokinase protein (GK), which 
enters into the nucleus by piggy-backing on the GK regulatory protein (GKRP) [Shiota et 
al., 1999].
In this chapter the yeast two-hybrid screening procedure was used to tiy and 
identify binding partners of PDE4A7. Identification of proteins interacting with PDE4A7 
could give insight into the functional role of this curious protein within the cell and/or the 
mechanism used by PDE4A7 to gain entry into the nucleus (this project was performed 
with advice from Magda Magiera).
4.1.1 The yeast two hybrid principal
The yeast two-hybrid (Y2H) method uses the different functional domains of a 
transcription factor to study protein-protein interactions and was an idea first proposed 
over twenty years ago [Fields and Song., 1989]. The Matchmaker GAL4 Two-hybrid
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System purchased from Clontech was used to identify putative binding partners for 
PDE4A7. This system is based on the principal that GAL4 cannot activate transcription 
unless its DNA binding domain (DNA-BD) and activation domain (AD) are physically 
associated. Usually, the DNA-BD and the AD are both part of the native GAL4 protein, 
but in the Matclimaker system these domains have been physically separated. The DNA- 
BD is derived from amino acids 1-147 of the yeast GAL4 protein and the activation 
domain from amino acids 768-881. Fusions of these domains to genes encoding proteins 
that may interact are generated using two different cloning vectors. Therefore the DNA- 
BD and AD domains will only interact if  there is an association between the bait protein 
(in this case PDE4A7 which is fused to the DNA-BD) and the library protein (in this case 
human brain library fused to the AD) (figure 4.1). Interaction leads to the activation of 
reporter genes possessing promoters with GAL4-responsive elements. The expression of 
reporter genes allows yeast in which the protein-protein interaction has occurred to be 
detected by gi'owing them on defined medium.
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Figure 4.1 The yeast two-hybrid principle. GAL4 protein is a yeast 
transcription factor which activates genes involved in galactose 
metabolism. GAL4 binds to an Upstream Activating Sequence (UAS) 
which is located in GAL4-responsive genes. The GAL4 DNA binding 
(DNA-BD) and activation domains (AD) which are expressed as 
fusions are brought together as a result of protein-protein interaction 
causing expression of metabolic genes (in this case ADE2, HIS3, and 
lacZ) (diagram taken from the CLONTECH manual).
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4.2 Results
4.2.1 Constructing the bait piasmid
The first step in the yeast two-hybrid procedure was construction of the bait 
plasmid. The bait plasmid contains a fusion between the gene of interest (PDE4A7) and 
the DNA-BD vector (pGBKT7). Before PDE4A7 could be inserted into the multiple 
cloning site of pGBKT7, it had to engineered to contain appropriate compatible restriction 
sites. PCR was used to incoiporate an EcoRI site at the 5’ end and a BamHf site at the 3’ 
end of PDE4A7 cDNA. The sequences of the oligonucleotide primer pairs used in this 
PCR reaction are shown below and the PCR conditions used for amplification are 
described in Materials and Methods (section 2.3.10).
Primer sequence for incorporation of an EcoRI site into PDE4A7 (PDE4A7 EcoRI) 
EcoRI site
C C G G A A TTC pT G C T T C C T T C A G A C C A A G G C T T C  |
Sequence from PDE4A7 
Primer sequence for incorporation of a BamHI site into PDE4A7 (PDE4A7 BamHI)
BamHI site
I|CG G G CACAG G G TG G G TTTTATTG A|GGATCCGCG
Sequence from PDE4A7
To determine whether the amplification of the full open reading PDE4A7 (from 
methionine (1) to tyrosine (323) and also containing EcoRI and BamHI restriction sites) 
was successful, the size of the resultant PCR products were checked by 1% agarose gel 
electrophoresis (Materials and Methods 2.3.5). A DNA fragment o f -1000 base pairs was 
detected for each of the three PCR reactions performed, which was the correct size for the 
PDE4A7 product {figure 4,2, lanes 1-3). This demonstrated that the PCR conditions used 
were suitable for amplification of the PDE4A7 product. At this stage it was still unclear 
whether the EcoRI and BamHI restriction sites had been correctly incorporated into the
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PDE4A7 cDNA. These PCR products were gel purified (Materials and Methods 2.3.6) and 
used in the subsequent digestions.
4.2.2 Digestion of pGBKT7 vector and PDE4A7 insert
Both the pGBKT7 vector and gel purified PDE4A7 cDNA (containing the 
appropriate restriction sites) were digested with the EcoRI and BamHI restriction enzymes 
(Material and Methods 2.3.7) and the product sizes were checked by 1% agarose gel 
electrophoresis. The digestion products were of the correct size as the PDE4A7 cDNA 
was detected as a band of lOOObp and the pGBKT7 vector as a ~7300bp band (figure 4.3). 
These products were gel purified (Materials and Methods 2.3.6) and used for ligation 
reactions (Materials and Methods 2.3.8).
Ecoli were transformed with the ligation products (Materials and Methods
2.3.10.2), plated onto kanamycin plates, to select for those bacteria containing the 
pGBKT7 vector (pGBKT7 contains the kanamycin resistance gene), and giown overnight 
at 30°C. Two checks were performed on plasmids from the resultant colonies to ensure 
they all contained the PDE4A7 insert. Firstly, colonies were PCR screened and product 
sizes were analysed by 1% agarose gel electrophoresis as before. The resultant PCR 
product from each colony was detected as a -lOOObp product, which is the correct size for 
the PDE4A7 (figure 4.4). Secondly, these plasmids were re-digested with EcoRI and 
BamHI enzymes to check that the PDE4A7 insert could be detected. The digested DNA 
was separated by agarose gel electrophoresis, which produced a band of -7300bp 
representing the pGKBT7 vector and a lOOObp fragment corresponding to the PDE4A7 
insert (data not shown).
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Figure 4.2 Incorporation of EcoRI and BamHI restriction 
sites into PDE4A7 cDNA. PCR was used to insert an EcoRI 
and a BamHI restriction sites at the 5’ and 3’ ends 
(respectively) of PDE4A7 cDNA. The PCR products were 
analysed by 1% agarose gel electrophoresis. The size 
markers (in bp) are shown on the left.
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pGBKT7 vector 
PDE4A7 cDNA
Figure 4.3 Digestion of the pGBKT7 vector and 
PDE4A7 cDNA. The pGBKT7 vector and PDE4A7 
cDNA (containing the EcoRI and BamHI sites) were 
digested with the EcoRI and BamHI enzymes and 
product sizes were analysed by 1% agarose gel 
electrophoresis. The size markers (in bp) are shown on 
the left.
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Figure 4.4 Identification of pGBKTT vectors containing the 
PDE4A7 insert. The pGBKT7 vector and PDE4A7 cDNA 
were ligated, transformed into Ecoli, plated onto ampicillin 
plates and grown overnight at 30°C. Resultant colonies were 
PCR-screened using the T7 and PDE4A7 BamHI primers to 
identify those PDE4A7 insert-containing pGBKT7 plasmids. 
Product sizes were analysed by 1 % agarose gel electrophoresis. 
The migration size markers (in bp)are shown on the left.
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4.2.3 Restriction analysis of pGBKT7-PDE4A 7
To verify that the PDE4A7 cDNA had been inserted into pGBKT7 in the correct 
orientation, restriction analysis using the Ncol enzyme was performed (Materials and 
Methods 2.3.7). As well as a Ncol site present in multiple cloning region of the pGBKT7 
vector, there is also a Ncol site at position 667 in the PDE4A7 sequence. Therefore, if 
PDE4A7 were inserted into the pGBKT7 vector correctly, a restriction digest should 
produce a DNA fragment of approximately 667bp. However, if PDE4A7 were inserted in 
the reverse orientation, restriction digestion with Ncol would produce a smaller fragment 
of333bp.
The products of Ncol digestions performed on tluee o f the putative pGBKT7- 
PDE4A7 plasmids were analysed by 1% agarose gel electrophoresis as before. All three 
plasmids were found to contain PDE4A7 in the coiTect orientation as only bands of ~667bp 
were detected from each digestion {figure 4.4, lanes 1-3). The DNA sequence of each of 
these plasmids were checked using automated sequencing (Materials and Methods 2.3.11), 
which also confirmed that the PDE4A7 insert was in the comect orientation.
4.2.4 Verification of PDE4A7 protein expression in the AH109 yeast reporter 
strain
To determine whether the PDE4A7 protein could be expressed successfully in the 
yeast reporter strain, the engineered pGBKT7-PDE4A7 construct was transformed into 
AH 109 yeast cells (Materials and Methods 2.4.4). The pGBKT7 vector also encodes a c- 
Myc epitope tag (EQKLISEEDL) in frame with the GAL4 DNA-BD and bait protein. 
Thus, PDE4A7 expression could be detected using the anti c-Myc antibody. Protein was 
extracted from the AH109[empty-pGBKT7] or AH 109[pGBKT7-PDE4A7] (Materials and 
Methods 2.4.5) and the resultant cell lysates were subjected to 10% SDS-PAGE 
electrophoresis and immunoblotted using the anti c-Myc antibody, which identified a 
50kDa irnmimoreactive band representing PDE4A7, which was only detected in those 
AH 109s that were transformed with pGBKT7-PDE4A7 {figure 4.6). PDE4A7 migrates at 
a higher molecular weight than normal because it is fused to the GAL4 activation domain. 
The previous result demonstrated that PDE4A7 could be expressed in AH 109 cells and that 
any three of the engineered pGBKT7-PDE4A7 constructs would be suitable for use in the 
Y2H screen.
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4.2.5 Testing for PDE4A7 bait protein toxicity effects
Preliminary tests were perfoi*med on the pGBKT7-PDE4A7 construct before 
proceeding with mating (these checks were earned out by Magda Magiera) see Materials 
and Methods 2.4.1). Firstly, the growth rates of AH109[empty-pGBKT7] and 
AH109[pGBKT7“PDE4A7] were compared to check the pGBKT7-PDE4A7 constmct was 
non-toxic to the yeast. As growth rates were approximately the same it was concluded that 
this construct did not interfere with the growth of AH109s. Secondly, to check that 
PDE4A7 alone was incapable of inducing reporter gene activity, AH 109s were co­
transformed with pGBKT7-PDE4A7 and empty library vector pACT2 and compared with 
AH 109s co-transfoimed with pGBKT7-p53 and pTDl-1, which are two proteins known to 
interact and therefore provided a positive control. These AH 109s were then plated onto 
SD-Leu/-Trp and tested for (3-galactosidase activity (Materials and Methods 2.4.8). Only 
colonies from those AH109s co-transfonned with pGBKT7-p53 and pTDl-1 turned blue in 
colour as expected. Thus demonstrating that PDE4A7 alone was incapable of auto­
activation. The final test was to check that the pGBKT7-PDE4A7 did not effect the mating 
efficiency of the yeast cells. In brief, the AH109[pGBKT7-PDE4A7] were mated with the 
Y187[pTDl-l] control strain and compared to the growth of Y187[pTDl-l] with 
AH109[pGBKT7-53] and subsequently plated on SD-Tip/-Leu. There were no major 
differences found in the mating efficiency (data not shown) indicating that the pGBKT7- 
PDE4A7 constmct was suitable for use as bait in the Y2H screen.
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Figure 4.5 Restriction analysis of putative 
pGBKT7/PDE4A7 DNA. Putative pGBKT7/PDE4A7 
DNA clones were digested using the Ncol enzyme and 
analysed by 1% agarose gel electrophoresis. The 
migration of the size markers are shown on the left.
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Figure 4.6 Verification of expression of PDE4A7 in 
AH 109 yeast cells. AH 109 yeast cells were transformed 
with the each of the three engineered pGBKT7/PDE4A7 
constructs. Protein was extracted from pGBKT7/PDE4A7- 
transformed and untransformed AH 109s (negative control) 
by TCA extraction and 20pg of each cell lysate was 
separated by 10% SDS-PAGE before immunoblotting with 
the anti-cMyc antibody. The migration of PDE4A7 
containing the 16kDa GAL4D DNA-BD is indicated, with 
the positions of the standard protein molecular weight 
markers (in kDa) shown on the left.
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4.2.6 Yeast mating
The previous tests showed that the pGBKT7-PDE4A7 bait was suitable for use in 
the Y2H screen. Therefore, AH109s containing the pGBKT7 bait were mated with Y187s 
containing the pACT2 library plasmid and plated onto selective quadruple dropout (QDO) 
medium (SD-Ade/“His/-Leu/-Tip) (Materials and Methods 2.4.2, 2.4.7). This, QDO 
medium allows for the selection of yeast cells that have been transformed with plasmids 
carrying the appropriate nutritional mai'ker. In this case the growth on -Leu/-Trp selects 
for only those diploids containing the pACT2 and pGBKT7 plasmids, which introduce 
functional leucine and tryptophan genes (respectively). Secondly, the reason for omitting 
adenine and histidine from the medium, was that activation of the reporter genes encoding 
adenine and histidine would only occur in those diploids where the PDE4A7 bait interacts 
with a library insert. A total of seventy colonies were produced from this Y2H screen, 
however, to test if these colonies were true positives further analysis was required (see 
below).
4.2.7 Testing forp-gaiactosidase activity
Colonies produced from the yeast two-hybrid screen were plated out a further twice 
to increase the chance of selecting for true positives. Also, to confiiin further that these 
resultant colonies were tme positives, each were assayed for |3-galactosidase activity 
(figure 4.7) (Materials and Methods 2.4.8). In colonies where an interaction between the 
bait and the library plasmid occuned the lacZ reporter gene was activated to produce the p- 
galactosidase enzyme, which catalysed X-gal to produce a blue coloured product. 
However, in those colonies where no interaction occured the lacZ gene remained inactive 
and these cells were incapable of producing p-galactosidase for the degradation of X-gal, 
therefore these colonies remained white in colour. Out of the seventy colonies analysed 
only 20 turned blue. The library plasmid was rescued from each of these 20 colonies.
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Figure 4.7 Testing positive colonies for B-galaetosidase activity.
AH 109s containing the pGBKT7/PDE4A7 hait plasmid were mated 
with Y187s containing the pACT2 library-containing plasmid. 
Diploids were plated onto SD-Ade/-His/-Leu/-Trp and grown for 4-6 
days at 30°C. Resultant positive colonies were re-streaked a further 
twice onto SD-Ade/-His/-Trp/-Leu. A sterile toothpick was used to 
streak surviving colonies out in a grid-like manner and grown for 2-4 
days at 30®C, before assaying for B-galactosidase activity.
95
4.2.8 Rescue of the library plasmid
At this stage the yeast colonies contain a mixture of both the bait plasmid and the 
library plasmid, therefore, to identify the binding partner of PDE4A7 we had to enrich for 
the plasmid containing the library insert (Materials and Methods 2.4.9). In brief, both 
plasmids were isolated from the yeast colonies and the DNA was transfoimed into Ecoli 
unable to grow in the presence of ampicillin (Materials and Methods 2.3.10.2). The Ecoli 
were plated out on medium containing ampicillin so that only those Ecoli expressing the 
pACT2 plasmid (providing bacteria with the ampicillin resistance gene) would be rescued.
4.2.9 Proteins found to interact with PDE4A7 in the yeast two hybrid screen
All of the rescued activation plasmids were sequenced and the inserts were 
identified using the nucleotide blast search database located in the National Centre for 
Biotechnology Infoimation (NCBI) website (http://www.ncbi.nlm.nih.gov/BLAST/1. 
From a total of 20 colonies only 7 of the library plasmids generated quality sequence. Six 
binding partners were identified for PDE4A7, which included Ran binding protein 9 
(RanBPM9), with five hits, CREB binding protein (CBP) with only one hit and mRNA 
h'om the human KIAA0160 gene with one hit. CBP is a nuclear protein that can bind to 
the phosphorylated form of the cAMP-responsive transcription factor CREB [Chirvia et 
al,, 1993]. CBP participates in the activation of hundreds of different transcription. This 
suggested that PDE4A7 might also have an important role in the tianscriptional regulation 
of various genes possibly of those involved in cAMP signalling. RanBPM9 is a 90kDa 
protein that is also found in the nucleus and in the cytoplasmic region surrounding the 
centrosome. It exists in a large complex of more than 670kDa. As yet the biological 
function of this complex remains to be elucidated [Nishitani et ah, 2001], therefore it was 
hard to speculate the role for PDE4A7 within this protein complex. KÏAA0160 is a 
relatively new gene for which the exact function remains to be elucidated [Nagase et al., 
1995]. The nucleotide sequence of each of the inserts are shown in Table 4.1, with the 
areas of homology highlighted in grey. The nucleotide sequence of CBP, RanBPM and 
KIAA0160 have been aligned with those inserts that show sequence homology to them 
(figure 4.8, figure 4.9 and figure 4.10, respectively)
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Table 4.1 Nucleotide sequences of inserts identified from the Y2H study
Insert
identified
NCBi
number
Nucleotide sequence of insert
CREB
binding
protein
(Insert 1)
NM 004380
TCCCCACCAA
TCCAGATTAC
TCCGAATTCG
ACCCAAAAAA AGAGATCTCT  
GCTAGCTTGG GTGGTCATAT  
CGGCCGCGTC GAjS P f l S I Ë f r
f f lS S ü C G G Â C  CGCCCAACCC CAAAAGAGCC  
GACAGCACAG ATTTTGGATC  
TGAGCTGATA CCCAATGGAG 
TTGTTCCAG A TGCTGCTTCC  
GGAGGCAGCG GCTCTAGTAT  
CAGCCCCGTG CAGCAGGGCC
flBf -----------
etC G G C G A A T  
jkTCTTCCTGA  
RGTGGGAACC  
IM ST C T A C G A  
ËGAGCGCCAG  
ICKPCCGAACA
ATGGCTTACC
GGCCATGGAG
TGAAÀATGGC
AAACTCAGCT
ATTGTTTG AC
GAGAATTAGG
AAACATAAAC
CAACCCAGGA
TGGGTGGCCA
CATACGATGT
GCCCCGGGGA
TGAGAACrfÜ
CGCCCGG TT*
TTG G AA A AT^
CCTTTTaMMi
A A C TG TC G G »
A T A G G A A A tB
GGCTCAAGGfll
RanBPM 9
(Insert 2)
NM 005493
AAAGAGATCT
GGTGGTCATA
CTATGGCTAC
TGGCCATGGA
CCATACGATG
GGCCCCGGGG
TTCCAGATTA
ATCCGAATTC
C G ^ C C G C C T
(SBSc c c c g g g
pAG CTCTGG T
{fCGGCCCTGA
CTACCCGGCC
OttMfcQGACAA
NCCCCTGCCT  
CCTTGCAGCG  
GGCGGGCAGC 
ACGAGCAGGA  
GTGGACGAAC 
GTTCAjj
CAGCGGCTGC
GGCCCCGGCC
AGCGCCGCGG
GAAGGAGTTG
AAGAGACGCC
CCCCGCCAGC
GGCTGGAGGA
CCCCCTTCCC
CAGCGGCGGC
GCTGCCTCGG
CGCTAGCTTG  
GCGGCCGCGT 
GGGCCGCCC 
GCCCCGACC 
TCACGGGC 
TGAAGCGTC 
TCCTGGAGOC
RanBPM 9
(Insert 3)
NM 005493 CACCAAACCC
GATTACGCTA
AATTCGCGGC
CCAGCGGGCC
jlGGAGCCCCG
kcC C T C A C G G
PQOCTGAAGC
tC G G TC C TG G
AAAAAAAGAG
GCTTGGGTGG
CGCGTCGAjÿC
ATCTCTATGG
TCATATGGCC
CTTACCCATA
ATGGAGGCCC
GC C GfCCCCC
ACCCCAGCTC
GGACTCGGCC
GTCTCTACCC
AGCCCGAAGG
CGCCTCCCCC
GGGCCTTGCA
TGGTGGCGGG
CTGAACGAGC
GGCCGTGGAC
ACAAGTTCAG
TGCCTCAGCG
GCGGGCCCCG
CAGCAGGGCC
AGGAGAAGGA
GAACAAGAGA
c t a c T
CGANGTTCCA
CGGGGATCCG
GCTGCOeCCi
g c c c g g c t O b
GCGGCCCCOB
g t t g c a o o m I
CGCCGCTGC g
RanBPM 9
(Insert 4)
NM 005493
CCACCAACCC 
CTAGCTTGGG 
CCGCGTCGAC 
SCGTCCCCC" jenecccAGCT 
jaOBGACTCGG 
0CGTCTCTAC 
iGAGCCCGAA
AAAAAGAATC
TGGTCATATG
CCGjB fB B & C fr
GGGCCTTGCA
CTGGTGGCGG
CCCTGAACGA
CCGGCCGTGG
GGACAAGTTC
TCTTGGCTAC
GCATGGAGGC
CCATCGATGT
CCGGGGATCC
TGCCTCAGCG
AGCGGGCCCC
GCAAGCAGCG
GCAGGAGAAG
ACGAACAAGA
É
GCTGCCCCCG
GGCCCGGCTG
CCGCGGCCCC
GAGTTGCAGC
GACGCCGCTG
TCCAGATTCG  
GAATTCGCGG 
CAGCGGGCCÏ 
GAGGAGCCC< 
CTTCC C TC; 
GGCGGCTC 
CCTCGGTC
RanBPM 9
(Insert 5)
NM 005493
AGAGATCTCT
GGTCATATGG
CCCGjÈÈÏCCCC'
SëeGGGCCTT
tCTG G TG G C G
TGGCTNCCCA
GCATGGAGGC
CTGCCTCAGC
GCAGCGGGCC
GGCAGCAGCG
TACGATGTTC
CCCGGGGATC
CAGATTACGC
CGAATTCGCG
GGCTGCCCCC
CCGGCCGGCT
CCGCGGCCCC
GCCAGCGGGC
GGAGGAGCCC
CTTCCCTNAC
TAGCTTGGGT
GNCGCGTCGA
CGACCCCAG 
GGGGACT
RanBPM 9
(Insert 6)
NM 005493
AAGAGATCTC
GTGGNCATAT
ACCCGCCTCC
CCCCCGGGCC
GCTCTGGTGG
M C C C T G A A C
ifcCCCGGCCGT
M g g a c a a g t
TATGGCTTAC CCATACNATG  
GGCCATGGAG GCCCCGGTTT 
CCCTGCCTCA GCGGCTGCCC 
TTGCAGCGGG CCCCGGCCGG  
CGGGCAGCAG p GCCGCGGCC
TTNCANATTC
CCGAATTCGC
CCGCCAGCGG
CTGGAGGAGC
GCTNGCTNGG
GGCCGCGTCG
GCCGCCCGCT
CCCGACCCCA
GAGCAGGAGA AGGAGTTGCA  
GGACGAACAA GAGACGCCGC TCASd —
CCCTTCCCTC
GCGGCGGCTG
TGCCTCGGTC
ACGGGGACTCj
AAGCGTCTCS^
CTGGAGCCC8
KIAA0160
gene
(Insert 7)
D63881
A GATCTCTAT
GGTCATATGG
C A A A A A A A U 'rnmiGCA5GT
fT C C C G T C C C
CÜTGGTGAAG
(HkGAGTTTAA
0ÏG A A G A G C T
ÂCATTTGTTG
AACÂAGCGAG
A ATA TA ATTA
GGCTTACCCA
GCATGGAGGC
ÀAGGATGTAT
GCCTTTGAAT
TTGCAGTTTC
TC TTACTTG T
TGGAATGATT
TCCAGCCAGA
CACAAATGAC
g c t c c c a c a a "
TACGATGTTC
CCCGGGGATC
GTTGTCCÀAT
CCTGACCTCA
CAGTAATGAA
TGCTATTTAG
AATGGAGAAA
AGAAAATGAA
AGTATTTGAT
T G fT C T G G A A
CAGATTACGC
CGAATTCGCG
a a g g c a a g t Y
ATCAAACAAA
TTTGA A CC TA
AGTGACTCGT
CCATGAAAAT
A T C G T G A G G ^
AAAAACAQ ^
ATG TTTTC A T
TAGCTTGGGT
GCCGCGTCGA
C C C A C A G #T *
A C C TG G A A A t
G T A A C A G C #
CCAAGAAG M i
A T T G A T G T d^
TGGGGAAAA#
AATGTTGATG
TCTGAAGCAG
97
CBP
CBP
CBP
CBP
I n s e r t
TGAGGAATCA
CGCGATCTAC
GCTCCTCTCC
GCCGGCCCGG
ACAGCCGCCA
TCGGCCCCGC
CTCGCAGCCG
CCGCCCGTGC
TCTTGTCGCG
CGGTCCCGGG
GCAGGGCCCC
CCGGGGCTGT
GACCCGACCG
CCCCACAACC
CGACCCCCGT
TTTCGCGAGC
CGAGC
GGGCTTCGAG
GCCCGCGCTC
CCGGGCCCTC
AGGTGAAAAT
AGGTGAAAAT
50
1 0 0
1 5 0
2 0 0
CBP GGCTGAGAAC TTGCTGGACG GACCGCCCAA CCCCAAAAGA GCCAAACTCA 2 5 0
I n s e r t 1 GGCTGAGAAC TTGCTGGACG GACCGCCCAA CCCCAAAAGA GCCAAACTCA
CBP GCTCGCCCGG TTTCTCGGCG AATGACAGCA CAGATTTTGG ATCATTGTTT 3 0 0
I n s e r t 1 GCTCGCCCGG TTTCTCGGCG AATGACAGCA CAGATTTTGG ATCATTGTTT
CBP GACTTGGAAA ATGATCTTCC TGATGAGCTG ATACCCAATG GAGGAGAATT 3 5 0
I n s e r t 1 GACTTGGAAA ATGATCTTCC TGATGAGCTG ATACCCAATG GAGGAGAATT
CBP AGGCCTTTTA AACAGTGGGA ACCTTGTTCC AGATGCTGCT TCCAAACATA 4 0 0
I n s e r t 1 AGGCCTTTTA AACAGTGGGA ACCTTGTTCC AGATGCTGCT TCCAAACATA
CBP AACAACTGTC GGAGCTTCTA CGAGGAGGCA GCGGCTCTAG TATCAACCCA 4 5 0
I n s e r t 1 AACAACTGTC GGAGCTTCTA CGAGGAGGCA GCGGCTCTAG TATCAACCCA
CBP GGAATAGGAA ATGTGAGCGC CAGCAGCCCC GTGCAGCAGG GCCTGGGTGG 5 0 0
I n s e r t 1 GGAATAGGAA ATGTGAGCGC CAGCAGCCCC GTGCAGCAGG GCCTGGGTGG
CBP CCAGGCTCAA GGGCAGCCGA ACAGTGCTAA CATGGCCAGC CTCAGTGCCA 5 5 0
I n s e r t 1 CCAGGCTCAA GGGCAGCCGA ACAGTG---------
CBP TGGGCAAGAG CCCTCTGAGC CAGGGAGATT CTTCAGCCCC CAGCCTGCCT 6 0 0
7 6 0 1 TTTTTATTCC
GATGTTTAAA
TGATTTAAAT
GGGGGGGTTC
TTGTTTGGAT
ACGGGAAAAA
ACTTTAAACA
GATTCCTGAA
TTTCGGGAAG
TACCCTGGAT
CACACATCTA
TAGAAATTGT
AGGGATGATC
TTTTCTTTCT
AAATCATGCA
AATCACTGTA
TTAAATAAAC
TGTACATGGT
TGTTTTCAAC
ATAAAGTACC
TTCTGTTCTT
ATATATATTT
TAGATGGAAC
GAAACAATAC
ATCTGGTCTC
TTTTTTTTCC
TCTTTTTGTC
CAAGTTCATT
TTTATGTTTA
ATAATGCAAG
ATTTTTTTCT
GATAGGAATT
TCTATACATA
TGCTTTGTTT
ACTCTTAGAC
TCTATGTGAA
AGCGCTCTAA
TAGAATGGTA
TGTGTGCAAC
ATTAACACTT
ATTGTATTTG
GCTTAAAATT
TAAGATCCCC
TTTGGTCTGT
TGCGACTTCC
AAAGAATATA
TCTCTTTGGT
GTTTTGTTTT
GTCATTGCTG
ATATTCATAT
AAAGTAAGAA
CTTATAATGT
ATAGTGAACT
GACTCCGGCG
ATGGCTGAAG
CTCTGATAAA
CATGCTAATG
ACTTGAAATG
TTCCTATAAA
AAATACCAAC
AGACAAAAAG
AGTGTTCGGG
GACTATGCAT
GATATAAATT
TGTAAGAATG
TCTTTGTAAA
GAGCCATGGA
TTTTTTTGTT
TTTTTTTTGG
TGTTTGGGGG
GTGACTCATG
TTTTTATTTG
GAAAAATAAT
ATCCCGATAA
CTGTGGGCGT
TGCACACACG
CCAAACTTGT
ACTGGTTTTA
TTACTAGAGA
AGGAAAAGCA
TACGAAACTC
TCATTTCTTA
GGTGGTCCTT
GTTTTTTGTT
GTGTTTTTTC
ACTGAGGTTT
TTTAAGGTTT
AAAAAAAAAA
AGGGTGGATT
AAAAACCAGT
CGGGGGGGTG
GAGGGGGGTT
CCTTTTTTTA
TATTTTCAAG
ATTCAGAACT
CTTTGTGATG
CTCCCAGTAT
TACACACCCA
CTTGCAGATG
GACAAAAAAT
AGAAGCCTTC
ATTCTAGTGT
GAGAAGATTC
TATCATATTG
CTTGAATTCA
ATGAAAATGC
CCCATTGTAT
TTAACATGTA
TTATTTATTT
AAAA
7 6 5 0
7 7 0 0
7 7 5 0
7 8 0 0
7 8 5 0
7 9 0 0
7 9 5 0
8 0 0 0
8 0 5 0
8 1 0 0
8 1 5 0
8 2 0 0
8 2 5 0
8 3 0 0
8 3 5 0
8 4 0 0
8 4 5 0
8 5 0 0
8 5 5 0
8 6 0 0
8 6 5 0
8 6 5 0
Figure 4.8 Sequence alignment of the insert demonstrating 
homology to CREB binding protein (CBP). The nucleotide 
sequence o f the insert demonstrating homology with the CBP 
protein has been aligned with the CBP protein nucleotide sequence. 
The CBP sequence is shown in black and the insert is shown in blue, 
with * marking the regions of insert sequence that do not align with 
CBP sequence. 98
RanBPM 9 CCGCCGTCGC CCCCGCCTCC CCCTGCCTCA GCGGCTGCCC CCGCCAGCGG 50
I n s e r t  2  CCCGCCTCC CCCTGCCTCA GCGGCTGCCC CCGCCAGCGG
I n s e r t  3  CCCGCCTCC CCCTGCCTCA GCGGCTGCCC CCGCCAGCGG
I n s e r t  4  CTCC CCCTGCCTCA GCGGCTGCCC CCGCCAGCGG
I n s e r t  5  CTCC CCCTGCCTCA GCGGCTGCCC CCGCCAGCGG
I n s e r t  6 ------------------------------------------------------------------------------------------------------------------------------
RanBPM
I n s e r t
I n s e r t
I n s e r t
I n s e r t
I n s e r t
GCCGCCCGCT CCCCCGGGCC TTGCAGCGGG CCCCGGCCCG GCTGGAGGGG 1 0 0  
GCCGCCCGCT CCCCCGGGCC TTGCAGCGGG CCCCGGCCCG GCTGGAGGGG 
GCCGCC***T CCCCCGGGCC TTGCAGCGGG CCCCGGCCCG GCTGGAGGGG 
GCC**CCG*T CCCCCGGGCC TTGCA*CGGG CCCCGGCCCG GCTGGAGGGG 
GCCGCCCGCT CCCCCGGGCC TTGCAGCGGG CCCCGGgcCG GCTGGAGGgq
RanBPM
I n s e r t
I n s e r t
I n s e r t
I n s e r t
I n s e r t
CCCCGACCCC
CCCCGACCCC
CCCCGACCCC
CCCCGACCCC
CCCCGACCCC
AGCTCTGGTG
AGCTCTGGTG
AGCTCTGGTG
AGCTCTGGTG
AGCTCTGGTG
GCGGGCAGCA
GCGGGCAGCA
GCGGGCAGCA
GCGGGCAGCA
GCGGGCAGCA
GCGCCGCGGC
GCGCCGCGGC
GCGCCGCGGC
GCGCCGCGGC
*CGCCGCGGC
--CGCCGCGGC
CCCCTTCCCT 1 5 0
CCCCTTCCCT
CCCCTTCCCT
CCCCTTCCCT
CCCCTTCCCT
CCCCTTCCCT
RanBPM 9 CACGGGGACT CGGCCCTGAA CGAGCAGGAG AAGGAGTTGC AGCGGCGGCT 2 0 0
I n s e r t  2 CACGGGGACT CGGCCCTGAA CGAGCAGGAG AAGGAGTTGC AGCGGCGGCT
I n s e r t  3 CACGGGGACT CGGCCCTGAA CGAGCAGGAG AAGGAGTTGC AGCGGCGGCT
I n s e r t  4 CACGGGGACT CGGCCCTGAA CGAGCAGGAG AAGGAGTTGC AGCGGCGGCT
I n s e r t  5 *ACGGGGACT CGG--------------------------------------------------------------------------------------
I n s e r t  6 CACGGGGACT CGGCCCTGAA CGAGCAGGAG AAGGAGTTGC AGCGGCGGCT
RanBPM 9 GAAGCGTCTC TACCCGGCCG TGGACGAACA AGAGACGCCG CTGCCTCGGT 2 50
I n s e r t  2 GAAGCGTCTC TACCCGGCCG TGGACGAACA AGAGACGCCG CTGCCTCGGT
I n s e r t  3 GAAGCGTCTC TACCCGGCCG TGGACGAACA AGAGACGCCG CTGCCTCGGT
I n s e r t  4 GAAGCGTCTC TACCCGGCCG TGGACGAACA AGAGACGCCG CTGCCTCGGT
I n s e r t  5 ---------------------------------------------------------------------------------------------------------------------
I n s e r t  6 GAAGCGTCTC TACCCGGCCG TGGACGAACA AGAGACGCCG CTGCCTCGGT
RanBPM 9 CCTGGAGCCC GAAGGACAAG TTCAGCTACA TCGGCCTCTC TCAGAACAAC 3 0 0
I n s e r t  2 CCTGGAGCCC GAAGGACAAG TTCAG----------------------------------------------------------
I n s e r t  3 CCTGGAGCCC GAAGGACAAG TTCAGCTAC-------------------------------------------------
I n s e r t  4 CCTGGAGCCC GAAGGACAAG TTCA------------------------------------------------------------
I n s e r t  5 ---------------------------------------------------------------------------------------------------------------------
I n s e r t  6 CCTGGAGCCC GAAGGACAAG TTCAGC-------------------------------------------------------
RanBPM 9 CTGCGGGTGC
AGTTCGAGCC
AAGTAAAAAT
TCTGCTCAAG
ATATGGTTAC
GACAACCTTA
GTTAATCTTA
AGGTATTGCT
TTCAAACACC
GTGTTTGATA
ACAGATAGAT
TGATACAAAA
ACAGCAGAGG
AGCTTCCATT
GAATGGGAGA
GAAAGAAATC
AATGGTGAAT
CAAAGTCTCA
AGTATGAGCC
AGGAAGCACC
ACTACAAAGG
ACGCATCCAA
TGTCAGTAAG
GTGTGAACAT
CATGGGGATG
TGGACCAACT
TCAACAATAC
TTCACTGACC
AGGAGAAGTG
TAGAAGACTA
CGATTTCCTA
AATGGTTTCA
CCTTTGCCAG
AAGAATAGAC
AGCCATTGAA
CTAATCTCCT
GGTACAGATA
AGACAGTTAT
CCAGCCATGG
GCACATTTTT
TCATGGCAAA
TACCAGCAGC
GGAAGAGATG
GAATAGACTA
ATGGACATTC
TTCACTACTG
CTGCTTTTAC
TACCGCCAAA
GTCGATGCCA
TATGCGGGAG
TCGGAGATCG
TCTTATTTAG
ATCTACAGAC
AAAGAATTCA
ACAACACAAC
TTTCACATTA
GTGAAGTACG
CCTGTTAGTC
AATGAATATC
CAGGTTTTGA
ACCCCAAAAG
CTGTGGGATT
GTTACATGGG
CCAGGTTGGG
GTTTTGTTCT
GTGATGTCAT
ACCAAGAATG
TTTGTATCCT
ATTTTGGGCA
TGGAGAACCA
AGAAGGAGAA
TCCACCATGG
CAGACCGTTC
GAAATTGGTA
AGTTATACCC
AAAGTGCGTC
ATGTTTGGGA
CTCGACCTTT
CACAATTTAG
AAGTTGTAGT
ATGCCGCGTC
TATTATTTTG
AATTGGTCTT
ATAAGCATTC
TCTGGAACTG
TGGCTGTTGT
GACATAGTTT
ACTGTGGGGC
ACATCCTTTC
AAATCCAGGC
TGGCAGACCA
GTACTGTGCC
TAGAAGAATT
TTAGCAGGAA
AAGTTTACTT
AGTTTATAGA
GGCCGAAGTC
TAGTAGTCCA
CATCAGGCAA
AATGGTGTAA
3 5 0
4 0 0
4 5 0
5 0 0
5 5 0
6 0 0
6 5 0
7 0 0
7 5 0
8 0 0
8 5 0
9 0 0
9 5 0
1000
1 0 5 0
1 1 0 0
1 1 5 0
1200
1 2 5 0
1 3 0 0
99
RanBPM 9 CCGCCGTCGC CCCCGCCTCC CCCTGCCTCA GCGGCTGCCC CCGCCAGCGG 50
I n s e r t  2  CCCGCCTCC CCCTGCCTCA GCGGCTGCCC CCGCCAGCGG
I n s e r t  3  CCCGCCTCC CCCTGCCTCA GCGGCTGCCC CCGCCAGCGG
I n s e r t  4  CTCC CCCTGCCTCA GCGGCTGCCC CCGCCAGCGG
I n s e r t  5  CTCC CCCTGCCTCA GCGGCTGCCC CCGCCAGCGG
I n s e r t  6 ------------------------------------------------------------------------------------------------------------------------------
RanBPM
I n s e r t
I n s e r t
I n s e r t
I n s e r t
I n s e r t
GCCGCCCGCT CCCCCGGGCC TTGCAGCGGG CCCCGGCCCG GCTGGAGGGG 1 0 0  
GCCGCCCGCT CCCCCGGGCC TTGCAGCGGG CCCCGGCCCG GCTGGAGGGG 
GCCGCC***T CCCCCGGGCC TTGCAGCGGG CCCCGGCCCG GCTGGAGGGG 
GCC**CCG*T CCCCCGGGCC TTGCA*CGGG CCCCGGCCCG GCTGGAGGGG 
GCCGCCCGCT CCCCCGGGCC TTGCAGCGGG CCCCGGGCCG GCTGGAGGgq
RanBPM
I n s e r t
I n s e r t
I n s e r t
I n s e r t
I n s e r t
CCCCGACCCC
CCCCGACCCC
CCCCGACCCC
CCCCGACCCC
CCCCGACCCC
AGCTCTGGTG
AGCTCTGGTG
AGCTCTGGTG
AGCTCTGGTG
AGCTCTGGTG
GCGGGCAGCA
GCGGGCAGCA
GCGGGCAGCA
GCGGGCAGCA
GCGGGCAGCA
GCGCCGCGGC
GCGCCGCGGC
GCGCCGCGGC
GCGCCGCGGC
*CGCCGCGGC
--CGCCGCGGC
CCCCTTCCCT 1 5 0
CCCCTTCCCT
CCCCTTCCCT
CCCCTTCCCT
CCCCTTCCCT
CCCCTTCCCT
RanBPM 9 CACGGGGACT CGGCCCTGAA CGAGCAGGAG AAGGAGTTGC AGCGGCGGCT 2 0 0
I n s e r t  2 CACGGGGACT CGGCCCTGAA CGAGCAGGAG AAGGAGTTGC AGCGGCGGCT
I n s e r t  3 CACGGGGACT CGGCCCTGAA CGAGCAGGAG AAGGAGTTGC AGCGGCGGCT
I n s e r t  4 CACGGGGACT CGGCCCTGAA CGAGCAGGAG AAGGAGTTGC AGCGGCGGCT
I n s e r t  5 *ACGGGGACT CGG--------------------------------------------------------------------------------------
I n s e r t  6 CACGGGGACT CGGCCCTGAA CGAGCAGGAG AAGGAGTTGC AGCGGCGGCT
RanBPM 9 GAAGCGTCTC TACCCGGCCG TGGACGAACA AGAGACGCCG CTGCCTCGGT 2 50
I n s e r t  2 GAAGCGTCTC TACCCGGCCG TGGACGAACA AGAGACGCCG CTGCCTCGGT
I n s e r t  3 GAAGCGTCTC TACCCGGCCG TGGACGAACA AGAGACGCCG CTGCCTCGGT
I n s e r t  4 GAAGCGTCTC TACCCGGCCG TGGACGAACA AGAGACGCCG CTGCCTCGGT
I n s e r t  5 ---------------------------------------------------------------------------------------------------------------------
I n s e r t  6 GAAGCGTCTC TACCCGGCCG TGGACGAACA AGAGACGCCG CTGCCTCGGT
RanBPM 9 CCTGGAGCCC GAAGGACAAG TTCAGCTACA TCGGCCTCTC TCAGAACAAC 3 0 0
I n s e r t  2 CCTGGAGCCC GAAGGACAAG TTCAG----------------------------------------------------------
I n s e r t  3 CCTGGAGCCC GAAGGACAAG TTCAGCTAC-------------------------------------------------
I n s e r t  4 CCTGGAGCCC GAAGGACAAG TTCA------------------------------------------------------------
I n s e r t  5 ---------------------------------------------------------------------------------------------------------------------
I n s e r t  6 CCTGGAGCCC GAAGGACAAG TTCAGC-------------------------------------------------------
RanBPM 9 CTGCGGGTGC
AGTTCGAGCC
AAGTAAAAAT
TCTGCTCAAG
ATATGGTTAC
GACAACCTTA
GTTAATCTTA
AGGTATTGCT
TTCAAACACC
GTGTTTGATA
ACAGATAGAT
TGATACAAAA
ACAGCAGAGG
AGCTTCCATT
GAATGGGAGA
GAAAGAAATC
AATGGTGAAT
CAAAGTCTCA
AGTATGAGCC
AGGAAGCACC
ACTACAAAGG
ACGCATCCAA
TGTCAGTAAG
GTGTGAACAT
CATGGGGATG
TGGACCAACT
TCAACAATAC
TTCACTGACC
AGGAGAAGTG
TAGAAGACTA
CGATTTCCTA
AATGGTTTCA
CCTTTGCCAG
AAGAATAGAC
AGCCATTGAA
CTAATCTCCT
GGTACAGATA
AGACAGTTAT
CCAGCCATGG
GCACATTTTT
TCATGGCAAA
TACCAGCAGC
GGAAGAGATG
GAATAGACTA
ATGGACATTC
TTCACTACTG
CTGCTTTTAC
TACCGCCAAA
GTCGATGCCA
TATGCGGGAG
TCGGAGATCG
TCTTATTTAG
ATCTACAGAC
AAAGAATTCA
ACAACACAAC
TTTCACATTA
GTGAAGTACG
CCTGTTAGTC
AATGAATATC
CAGGTTTTGA
ACCCCAAAAG
CTGTGGGATT
GTTACATGGG
CCAGGTTGGG
GTTTTGTTCT
GTGATGTCAT
ACCAAGAATG
TTTGTATCCT
ATTTTGGGCA
TGGAGAACCA
AGAAGGAGAA
TCCACCATGG
CAGACCGTTC
GAAATTGGTA
AGTTATACCC
AAAGTGCGTC
ATGTTTGGGA
CTCGACCTTT
CACAATTTAG
AAGTTGTAGT
ATGCCGCGTC
TATTATTTTG
AATTGGTCTT
ATAAGCATTC
TCTGGAACTG
TGGCTGTTGT
GACATAGTTT
ACTGTGGGGC
ACATCCTTTC
AAATCCAGGC
TGGCAGACCA
GTACTGTGCC
TAGAAGAATT
TTAGCAGGAA
AAGTTTACTT
AGTTTATAGA
GGCCGAAGTC
TAGTAGTCCA
CATCAGGCAA
AATGGTGTAA
3 5 0
4 0 0
4 5 0
5 0 0
5 5 0
6 0 0
6 5 0
7 0 0
7 5 0
8 0 0
8 5 0
9 0 0
9 5 0
1000
1 0 5 0
1 1 0 0
1 1 5 0
1200
1 2 5 0
1 3 0 0
99
TATCAAATAA
TCCAACTTGA
GCAAGTTAAT
ACTCCAATGG
TCTAAACATG
TTCAAGTCAG
AAAGAATGAT
AGGAGAGACT
ATTCAGTCTA
AGCTTGACCC
ATATTAGAAA
GGGACAGGCC
CCTGCGCATT
AGAGCTCACA
TCTGCTGATT
TTTGTCGCTT
CTAACTTAGT
CTAAGAGTTA
ATCCTTTAAA
GGGGGAGGGG
AGCATGTGGG
AGCACATCAA
ATGTACCAGA
AACTTCACCA
AGTTGGAGAA
ACCACGAAAT
TTGAGACGCC
CCACTTTGGA
GTGGCAAGAA
CTAGCATATT
GATTCAGAGA
CCCACAATCT
ACACAATGTC
TGCCACAGTG
CTTATATTGT
TGAAATTTAG
TACATTGCTT
GTTAGGAGAA
AATATTACTG
ACAATTACCT
GGAGAGAGGG
TGATGTAAAC
TCATATTGCC
ACTAAACAGT
GTAATGATGT
ACTTCATCCA
GGAAGATTGT
AGTTGTGTGG
CGAGAGCTGC
CACTGCAAAC
CAGATCCCTG
GAACCTGTGT
GCCAAAGCAA
TAGGACTGAT
GAAGACTACC
GGCATATAGT
ATTTTTTAAA
CCTAGTTTAC
ATTATTTTCC
AATTTCAGAC
AAAAGAAACC
GAAGGAAATG
TTCAAATTGG
ATAGTAATAA
ATAAATATGT
AGACATGGAA
ATGGTTTCCT
GACACCGAAA
AGGAAGTCAG
AAGCAATGAG
AAAAAAATGT
GAACAGCCCA
GCTCAGCTCT
CCTCCACTTG
GGCTCGATCA
TACATTAGCT
CAACATGGAA
TTATGTACTG
AGCATGATGC
ATCTTTAACC
GTTCAAATTG
AAAAATCCTG
GAACAAGTTG
GAGATGTTCC
ACACCAGTCA
CAAGATCACA
ACAGATCACT
AAATGGTAGC
TGGAAGTTGA
GCCGCCATAG
TGAACAGCTA
TGAAGGATGC
GTTGGAAATC
TAACAGTGCA
CCCTAGCAAT
GGAATTGGAT
ATGCATTTCA
GTAGACCAGC
GGGACAGGTT
AAATGATTTT
TCTTAGTTGT
ATCATCACAA
CCTTCTTTGT
TGTTTGTGTT
GACCCC
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Figure 4.9 Sequence alignment of inserts demonstrating 
homology to the RanBPM9 protein. The nucleotide sequences of 
inserts demonstrating homology with RanBPM9 have been aligned 
with the RanBPM9 nucleotide sequence. The RanBPM9 sequence 
is shown in black and the insert is shown in blue, with * marking the 
regions of insert sequence that do not align with RanBPM9.
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K IA A 0 1 6 0 CTCTGAGGAG
CCCTCTCCTC
GGTTGGTATT
AGGCAGGAAC
CCAGCGCGGG
CTTCGGGCGG
CCTCCTCCTC
TGGAGCACGT
TCTATAGATT
CTTACATGTC
ATATGTTATC
ATTTGCAGCT
AAAATGAACA
ACACTTTTTT
CCCTCTCTCC
GCAGGCGCTT
CGCGATGGCG
GTCCGGGGGA
CAAATCCGGC
CGCGGCGGCA
CCAGGCTGAC
TCTTCGAACT
TCATCGAAAC
AAAAGTAGAG
TACGTTTACT
AAATTCTGTT
TTTCCTCCCT
TCCTTCCCCC
GCTCTCCGGG
CCTCAGAAGC
GGCGGCTTCG
GGCGGGAGCT
GCGGCGGGGG
CACGAGCTTT
CGGAATCTCA
TCCAGAACAA
AAAATGAAAG
GGTTTCTTCC
ACCCTGGAAG
CCTTCCCTCC
CTCGGTCCGC
GCCGCCCGGC
ACGGCGGTGG
GGGGTTCGGC
GTGGAGGGGG
CTGCGGTGTT
TCCTCCAGGC
TAGCACCAAT
ACATCAAAAG
GAGAGCAAGA
ACAAAAATGA
TCCTGCTTGT
TCTCCTCCTC
CGGAGCCTGC
GGGTAGCTGG
GGGAGGGGGC
GGCGGTGGCG
TGGCAGTTAC
ACCGGTGAAG
CTTTGAGAAG
ATTTTTGCAC
GAAAACATTT
ATCTCATAGC
TAAGCCATCA
GAAAGTTTGC
CCTTCCCTTC
TGGGGCGAGC
CGGGGGGAGG
GGCTCGGGGC
GCGGCGACGG
TCGGCCTCCT
AAGCCGAAAA
CCAACACAGA
AGAACTCTTA
AAAGTTGATG
TTGTCAGCTC
CCAAACTCAG
CACAAAAAAA
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GAAAGGATGT AAGTTGTCCA ATAAGGCAAG TTCCCACAGG TAAAAAGCAG GTGCCTTTGA 8 4 0
GAAAGGATGT A*GTTGTCCA ATAAGGCAAG TTCCCACAGG TAAAAAGCAG GTGCCTTTGA
TTCCTGACCT CAATCAAACA AAACCCGGAA ATTTCCCGTC CCTTGCAGTT TCCAGTAATG 9 0 0
TCCTGACCTT CAATCAAACA AAACC*GGAA ATTTCCCGTC CCTTGCAGTT TCCAGTAATG
AATTTGAACC TAGTAACAGC CATATGGTGA AGTCTTACTC GTTGCTATTT AGAGTGACTC 9 6 0
AATTTGAACC TAGTAACAGC CA*ATGGTGA AGTCTTACT* GTTGCTATTT AGAGTGACTC
GTCCAGGAAG AAGAGAGTTT AATGGAATGA TTAATGGAGA AACCAATGAA AATATTGATG 1020
GTCC*GGAAG AAGAGAGTTT AATGGAATGA TTAATGGAGA AACC*ATGAA AATATTGATG
TCAATGAAGA GCTTCCAGCC AGAAGAAAAC GAAATCGTGA GGATGGGGAA AAGACATTTG 1 0 8 0
TCA*TGAAGA GCTTCCAGCC AGAAGAAAAC GAAA*CGTGA GGATGGGGAA AAGACATTTG
TTGCACAAAT GACAGTATTT GATAAAAACA GGCGCTTACA GCTTTTAGAT GGGGAATATG 1 1 4 0  
TTGCACAAAT GACAGTATTT GATAAAAACA GG---------------------------------------------------------------
AAGTAGCCAT
CTATTCTTGA
AGTTCACTCT
CTCTTGCCAC
CTACTCAAAC
AGGATACTCC
ACAATACAAG
ACTGCCGCAA
TCAACTATGT
ATGGCTCCTA
GCAACGGACC
CAAAAGCAAG
CATATAGTAG
CACAAGAAAT
CCATTACACA
TCTGGAATCT
GTATGCTGTT
TCATGCTTCA
AAGCTGTTAC
CTGCAAACGA
ACTCAAAAGA
AACAAAAACT
GTTAGATGAA
TATGCAGCAT
CATGAAAAGC
TTGATCTAGA
TTTCTACTTT
TTTAGAAATT
AGGATTTTTA
GAAATCATTT
TTTTACAATT
TCACATTGTT
TGCTTGTTTT
CTTTAAATTA
TAAGGGGAGA
CAAGGATGTC
AATCATTTTG
ATTTTCTCCA
ATTCCAACTC
ATATTGCATT
TTTAATTTTA
GGGATATATA
GCAGGAAATG
TGGGAAGAGG
TCGTTGGACA
TAGAAATTCA
TATTGCTGTT
AAATGAAAAC
GCAACAAACT
ACTTTATAGT
TTATCATCCA
TGCAGGAAAT
AGTTAAGAGA
CATGTCTGAA
TGGCCACAAT
GGAAGTAGAT
AATTGAAGAG
CCATGTCATG
TGTAGAAAAT
TCTAGTCAGC
CAAGCTCCGT
AGAAATAACT
GAAAGCTTTG
CTGAAAAGCT
GTAAATGATT
TACATGTATA
AATATTTCAA
AATTATTTCA
GTAATTGTGA
GAAGTGGTCT
TGAAATTATA
GTCAATTCGG
AAAAAATAGC
GACAGTGAAA
GTTTTTCTTT
GGATTGCAAA
AGTGTTCTTA
TTTGTAATGT
AGCAATTTTG
ACAGAAAGTG
CGAGCACTGT
TTCATATTCT
AAATTTCATT
AGCTTTCTAA
GAAGAATGTC
CTGCCTCCAT
GGAGAGACCA
GAGAGTCTCC
AAAGAATCAT
CGACAAAAAT
GAAGCAAGAG
TTACTCAAGC
AAAGGTGCTA
CCTCAGGATA
ACACCTATCA
TTTCTTGAAT
CGTCTGTATT
AGTGAAGATG
TTTTCTGATG
AAGCATGGGT
TATGGACAGA
ATGCATGACT
GAAATGCAGC
GAAGAACAAA
GAAACAGATA
CTAACCCCAT
TCAACAAGGA
TCACTTTTAT
AGTATTTTTA
TATATAAATC
GACATTTTCT
TCATATGTCA
TTGCATTACT
AATGAAAAAT
ACTTCTTCAT
TGCTATGTTG
TTTAATTAGA
CCAAGGAAAG
AAAAGTCAAC
GTTTCATGAA
CCCTGTGTTA
GATTCACTAC
GGTTGAGTAA
TTATTTATAA
CCACCACCAT
TGGTGTCTTC
CAATAAGCAA
TCGAAACATT
ATGATAAATC
ATCAGGAAAA
TGACTACAGA
TAAGAATATT
ATGACCTGCA
ATCTTAAACT
GGATAGATGT
TTCATCGCCA
CACATATTCT
CTGAAGATGG
TCCATAGTGA
AAAAGGATCC
TTAATGAAGG
TTATTGCTGA
AAATAATTAA
TTAATCTTAT
AAAAATTAGA
ATGGGACAGC
GTGTCTCAGG
GTTATGGACA
TATTTGTATC
TGATGTCATT
AACTCAACAA
AGAATTTTTT
TGGGGAGGGA
ACTACAGAAA
ATTTGCAGTC
TATAATGTAA
CTTATGCCTG
GTTTATAAGA
TAATCACACG
AACGCATTTG
CAGAAAACTG
TAGAATATCC
TATGTGTTTC
TGGCACATTA
CATCACCTCA
AGGATCAATG
CAGATGCAGT
AGAAATTTAT
GAAAAGAGCA
TTCTCAGGGA
TACGGCTCCT
CAAGCCTGGT
TCTACAAACA
TTATCAGTTT
TTGCCCTTGG
CTGCCATAGC
TTCTATCAAT
ACCTGGATTT
TGTGTGCAGG
GGAAGTAGAA
TACCTGCTTA
TGAATGGCTA
AGAGAAAGAA
CAATCAAATG
GAAGAATTTA
TAGCATAATG
AAAGGGGGAA
AAATGGATTT
GGTTTCAAAA
AACACTGAAA
AGGGTTCTAC
AAAACATTCT
ATGTCATCAA
TGCATTTATG
AAATTGGAAT
AGGAAAAAAA
AAACTTTGAT
TTTTACATTA
TTTGAGAAGA
TTACAGACCA
GAAAATTAAG
AGATTTTAAG
TTATGCCTTT
AATAGAGATA
ACGCACATAT
ACAAGCACCA
ATTTTTTATT
CTGCTGTAAA
TCCCTATTTT
AAAATGTAAA
ACATGGGAGA
CCTACGTTGC
ATTGCCAAAC
TCAGTTAAAC
AGAAAAGAAA
CTCTATAACA
TGTACTCTGA
AGATTTATCT
GAGTGTTATG
GCTTTTAGTC
CCAAAACGAA
CAGCAAAGAA
CCTCTCCGTC
AGAGAAAAAA
GTGATGAAAC
AATCATGCCT
TGTCGAAACT
TCAATAGATA
TCTGCTTCCC
AGTGAAATTA
CAGAGCAAAA
TTACATTTTA
TTCACTTCAT
GTACTTTAAG
ATATGTTGAA
AACGGCTGTT
GGTTCCCTTT
TAGAAATTGA
CCTTGTTTTT
CATAAGTTCC
TATTAAATTT
TTTGTTTTCA
CTGTTCATAT
ATGTCACTTA
TATTTGTTTG
AGCTGACTTG
TTGCAGTTGG
ATAGGTTTTT
ATCCTTAAAG
TACAGGTATT
GTTTAATGAA
TACTGATTTG
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1 2 6 0
1 3 2 0
1 3 8 0
1 4 4 0
1 5 0 0
1 5 6 0
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1 7 4 0
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1 8 4 0
1 9 2 0
1 9 8 0
2 0 4 0
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3 0 6 0
3 1 8 0
3 2 4 0
3 3 0 0
3 3 6 0
3 4 2 0
3 4 8 0
3 5 4 0
3 6 0 0
3 6 6 0
3 7 2 0
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ACTGGTCTTT AAGATGTGTT TAACTGTGAG GCTATTTAAC GAATAGTGTG GATGTGATTT 3 8 4 0
GTCATCCAGT ATTAAGTTCT TAGTCATTGA TTTTTGTGTT TAAAAAAAAA TAGGAAAGAG 3 9 0 0
GGAAACTGCA GCTTTCATTA CAGATTCCTT GATTGGTAAG CTCTCCAAAT GATGAGTTCT 3 9 6 0
AGTAAACTCT GATTTTTGCC TCTGGATAGT AGATCTCGAG CGTTTATCTC GGGCTTTAAT 4 0 2 0
TTGCTAAAGC TGTGCACATA TGTAAAAAAA AAAAAAAAAA GATTATTTTA GGGGAGATGT 4 0 8 0
AGGTGTAGAA TTATTGCTTA TGTCATTTCT TAAGCAGTTA TGCTCTTAAT GCTTAAAAGA 4 1 4 0
AGGCTAGCAT TGTTTGCACA AAAAGTTGGT GATTCCCACC CCAAATAGTA ATAAAATTAC 4 2 0 0
TTCTGTTGAG TAAACTTTTT ATGTCATCGT AAAAGCTGGA AAAATCCCTT TGTTTCTATT 4 2 6 0
TATAAAAAAA GTGCTTTTCT ATATGTACCC TTGATAACAG ATTTTGAAGA AATGGTGTAA 4 3 2 0
ATGATAAAG CATTTGAATG GTACAGTAGA TGTAAAAAAA ATTCAGTTTA AAAGAACATT 4 3 8 0
TGTTTTTACA TTAAATGTTT ATTTGAAATC AAATGATTTT GTACATAAAG TTCAATAATA 4 4 4 0
T 4 4 4 1
Figure 4.10 Sequence alignment of the insert that demonstrated 
homology to human mRNA for the KIAA0160 gene. The
nucleotide sequence of the insert, demonstrating homology to the 
human KIAA0160 gene have been aligned with the nucleotide 
sequence for the mRNA from KIAA0160. The KIAA0160 mRNA 
sequence is shown in black and the insert is shown in blue, with * 
marking the regions o f insert sequence that do not align with 
KIAA0160.
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4.2.10 Attempt to confirm protein-protein interaction by co- 
immunoprecipitation
The next step was to try and provide independent confirmation of the putative 
interactions between PDE4A7 and CBP. This was attempted in mammalian cells {in vivo) 
by using the biochemical method of co-immunoprécipitation (Materials and Methods 
2.2.2). It was impossible to check the PDE4A7-RanBPM9 or the PDE4A7-KIAA0160 
interactions as no antibodies were available for the detection of these proteins. Therefore, 
only the PDE4A7-CBP interaction could be tested by co-immunoprecipitation.
COS-1 cells were either mock transfected or transfected to express VSV-tagged 
PDE4A7, lysates from these cells were homogenised and clarified hy low speed 
centrifugation (Materials and Methods 2.2.2). The resultant supernatants were firstly 
incubated with protein A beads to check that PDE4A7 did not bind non-specifically to the 
beads alone. Next, the supernatants were incubated with either the polyclonal anti-CBP 
antibody or with control rabbit IgG (which acted as a negative control), followed by 
incubation with protein A beads. Resultant immunoprecipitates were analysed by 10% 
SDS-PAGE and inimunoprobed with the polyclonal anti-VS V antibody for detection of the 
PDE4A7 protein. Although PDE4A7 (32±2kDa) was detected in the immunoprecipitate 
where the CBP antibody was used {figure 4.11, lane 4), it was also found to associate non- 
specifically with the protein A beads {figure 4.11, lane 2) and also the control rabbit IgG 
{figure 4.11, lane 3). No PDE4A7 was detected in the control, mock-ti'ansfected COS-1 
cells {figure 4.11, lane 5). The data from this study did not provide conclusive evidence 
that PDE4A7 interacts specifically with the CBP protein as PDE4A7 was also detected in 
the immunoprecipitates from the controls. A possible reason why PDE4A7 was detected 
in the immunoprecipitate with CBP was because the intial clarification step was not 
performed at a high enough centrifugation speed. Therefore, to ensure complete 
clarification in the future the lysate should be centrifuged at 14000rpm for 10 minutes 
instead of 3000rpm for 10 minutes.
The lysis buffer used for harvesting the cells contained triton detergent, which 
breaks open the membranes in the cell and therefore PDE4A7 should be released into the 
supernatant fraction. However, the majority of PDE4A7 was detected within the pellet 
generated fr om the preliminary low speed spin {figure 4.11, lane 1). It is possible that not 
all nuclei have been broken open by this method of lysis and have therefore been pelleted 
in this low speed centrifugation step. Alternatively, it is likely that 2EL is associating with 
a protein that is triton insoluble. For example, early studies performed on 3T3 fibroblast- 
cells demonstrated that after cell lysis, the triton insoluble fraction contained nuclear and
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cytoskeletal components [Trotter et al., 1978]. That 2EL is nuclear in COS-1 cells might 
explain why it is found majorly within the triton insoluble fraction. Once cellular 
membranes are broken open, many proteins are brought together. This can result in the 
foiTnation of aggi'egates, which will also be pelleted by low speed centrifugation. The 
PDE4A7 that is found to associate with the control IgG immunoprecipitate and the protein 
A beads control may actually be residual PDE4A7 left over from the initial low speed spin 
or it may be that PDE4A7 is simply a ‘sticky’ protein. It was concluded that this method 
was not suitable for testing the PDE4A7 and CBP interaction. Alternative methods that 
could be used to test this interaction in the future would be to perform confocal analyses to 
check if  these two proteins co-localise with each other, or, one could attempt a ‘pull down 
assay’.
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Figure 4.11 Testing for the in vivo interaction of CBP with PDE4A7.
COS-1 cells were either mock transfected or transfected to over-express 
PDE4A7. After a 48 hour incubation period these cells were lysed, disrupted 
and centrifuged at a low speed to remove any cellular debris. Lysates were 
then immunoprecipitated with protein A beads alone followed by either 
control rabbit IgG or anti-GBP polyclonal antibody. Immunoprecipitates 
were subjected to 10% SDS-PAGE before immunoprobing with the 
polyclonal anti-VSV antibody. Lanes 1-5 were taken from the same gel. 
The migration of the standard protein molecular weight standards are 
indicated on the left and the data are representative of two separate 
experiments. PDE4A7 was detected in the cellular debris pellet (Jane 1). 
Lysates from COS-1 cells over-expressing PDE4A7 immunoprecipitated with 
protein A beads alone {lane 2), immunoprecipitated with control rabbit IgG 
(lane 3), immunoprecipitated with anti-CBP polyclonal antibody (lane 4). 
Lysates from mock transfected COS-1 cells immunoprecipitated with anti- 
CBP polyclonal antibody {lane 5).
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4.2.11 Re-evaluating the possible Interaction of PDE4A7 with RanBPM and 
CBP using the small scale Y2H
Putative interactions between PDE4A7 and either CBP or RanBPM were re­
evaluated using small-scale yeast mating using the rescued library plasmids (Materials and 
Methods 2.4.6). Diploids produced from the mating were plated onto SD-Leu/-Trp and 
incubated for 2-4 days at 30°C before testing for (3-galactosidase activity (Materials and 
Methods 2.4.8). The details of the mating reactions perfoiined are described below.
AH109[empty-pGBKT7] mated with Y187[empty-pACT2] acted as the negative 
control and colonies produced from this mating remained white in colour. This is because 
the AD and DNA-BD cannot interact unless they are brought into physical proximity by 
interacting proteins. Therefore resultant diploids are incapable of activating the reporter 
genes {figure 4.12, a). AH109[pGBKT7-53] mated with Y187[pTDl-l] acted as the
positive control and these colonies were blue in colour. This is because BD-p53 interacts 
with AD-T-antigen to restore the GAL4 activity leading to transcriptional activation of the 
reporter genes {figure 4.12, g  and h). AH109[pGBKT7-PDE4A7] mated with 
Y187[empty-pACT2] remained white as expected because PDE4A7 alone cannot 
autonomously activate the reporter genes {figure 4.12, b). When AH109[empty-pGBKT7] 
were mated with Y187[pACT2-CBP] the colony was white as expected (figure 4.12, c) 
but, AH109[pGBKT7-PDE4A7] mated with Y187[pACT2-CBP] also remained white in 
colour {figure 4.12, d) which was unexpected as CBP was identified as a positive binding 
partner for PDE4A7 previously in the large scale Y2H screen. When AH109[empty- 
pGBKTV] were mated with Y187[pACT2-RanBPM9] the colony turned blue when tested 
for p-galactosidase indicating that RanBPM9 alone was capable of autonomously 
activating the reporter genes (figure 4.12, e). However, when AH109[pGBKT7-PDE4A7] 
were mated with Y187[pACT2-RanBPM9] these colonies unexpectedly remained white, as 
if  the presence of PDE4A7 abolished the ability of RanBPM9 to autonomously activate the 
reporter genes {figure 4.12, f .  RanBPM9 is an example of an AD/library protein that can 
activate the reporter genes without the DNA-BD target protein present. This data suggested 
that both RanBPM9 and CBP were both artefacts. No conclusions were made regarding 
the KIAA0160 gene as its interaction with PDE4A7 was not re-tested.
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Figure 4.12 Re-testing the interaction of PDE4A7 with RanBPM 
and CBP. (a) AH109[pGBKT7/PDE4A7] mated with Y187[empty- 
pACT2], (b) AH109[empty-pGBKT7] mated with Y187[empty- 
pACT2] (negative control), (c) AH109[pGBKT7/PDE4A7] mated 
with Y187[pACT2/CBP], (d) AH109[empty-pGBKT7] mated with 
Y187[pACT2-CBP], (e) AH109[pGBKT7-PDE4A7] plasmid mated 
with Y187[pACT2/RanBPM], (f) AH109[empty-pGBKT7] mated 
with Y187[pACT2/RanBPM], (g) and (h) AH109[pGBKT7/p53] 
mated with Y187[pTDl-l] (positive control). Each of these 
combinations were mated using small scale yeast mating (Materials 
and methods) and were plated out onto SD-Trp/-Leu and and tested 
for B-galactosidase activity.
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4.3 Discussion
The Y2H system was used to probe a human brain library with PDE4A7 in the 
hope of identifying possible binding partners for PDE4A7. The Y2H screen identified 
CBP, RanBPM9 and inRNA from the human KIAA0160 gene as binding partners for 
PDE4A7. However, when these interactions were re-tested by small-scale yeast mating 
CBP was no longer found to interact with PDE4A7 as the reporter genes remained 
inactive. Upon re-testing, RanBPM9 was found able to autonomously activate the reporter 
genes, but the presence of PDE4A7 seemed to ablate this interaction. There are many 
proteins that are classified as common false positives in the Y2H, including heat shock 
proteins (hsps), ribosomal proteins, mitochondrial proteins and zinc finger proteins 
[Golemis et al., 1997] to name a few. That RanBPM9 is a zinc finger containing protein 
may explain why this protein was able to activate the reporter genes in the absence of a 
DNA-BD-bait protein. As antibodies were available to the CBP protein I decided to test 
whether the PDE4A7-CBP interaction could be detected in vivo by using co- 
immunoprecipitation. The results of this study suggested that PDE4A7 was not 
specifically interacting with CBP, as PDE4A7 was found to bind non-specifically to the 
protein A beads and the control rabbit IgG. I concluded that this method was not suitable 
for the study of this interaction and that in the future the alternative approaches of confocal 
analysis and ‘pull-down assays’ should be attempted instead. The overall conclusion was 
that CBP and RanBPM were artefacts produced in the PDE4A7 Y2H screen. The potential 
interaction of PDE4A7 with KIAA0160 still needs to be evaluated as I did not have time to 
test this further. This is because my efforts were focussed on evaluating the other species 
because they were established examples of nuclear localised proteins.
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Chapter 5
Assessing the potential effects of PDE4A7 (2EL) on
gene regulation
5.1 Introduction
As the function of PDEs is to degrade the cyclic nucleotides into inactive 5’ 
nucleoside monophosphates, it was surprising to find that the PDE4A gene also encoded a 
splice variant called PDE4A7 (2EL) that was incapable of hydrolysing either one o f these 
second messengers. This raised the question of what possible fimction such a catalytically 
inactive product of the PDE4A gene may have within the cell. Many proteins that have 
been found to be devoid of catalytic activity, such as GRB2 [Taii et al., 2001] or AKAPs 
[Michel and Scott, 2002], act as scaffold proteins that bring important signalling proteins 
into complexes. Therefore, one possible function of PDE4A7 may be to mediate the 
interaction of other PDEs with important signalling proteins. However, that recombinant 
PDE4A7 was found localised to the nucleus of COS-1 cells might indicate that PDE4A7 
could be involved in transcriptional regulation. This might provide a further route by which 
PDE4A gene products affect the transcription of various genes, for cAMP regulates the 
expression of various proteins through the action of CREB, with PDEs functioning to tailor 
cAMP levels.
Microairay has provided scientists with a method of analysing the expression 
patterns of thousands of genes in parallel. The micro array is a glass slide containing 
thousands of spots with each one representing a single gene. RNA is extracted from the 
test samples and reverse transcribed into fluorescently labelled cDNA by using fluor- 
derivatised nucleotides. Using different fluorescent dyes means that mRNA from the test 
sample and the control sample can be labelled in different colours, for example the control 
sample can be labelled with Cyanine 3 (CY3) (gi'een) whereas the test sample can be 
labelled in Cyanine 5 (CY5) (red). These labelled cDNAs can be mixed and hybridised to 
the same microarray slide, which leads to competition between the test and the control 
cDNAs for the immobilised probes on the DNA chip. cDNA containing sequence that is 
complementary to the DNA on a given spot, will bind and be detected by its fluorescence 
when excited by a laser. The differences in mRNA levels between the control and test 
samples are calculated fiom the differences in the intensities of either CY3 or CY5
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measured on each spot. Therefore, if  RNA from the control sample (labelled with CY3) is 
most abundant, the spot will be green and indicates this gene has been down-regulated by 
experimental treatment; if  the RNA from the experimental sample (labelled with CY5) is 
abundant the spot will be red and indicates that this gene has been up-regulated in response 
to experimental treatment. If both bind equally well to a spot it means there has been no 
effect on the regulation of that particular gene and the spot will be yellow. Finally, if 
neither bind then the spot will be black.
Studies perfomied on the PDE4A7 protein so far have been earned out using COS- 
1 cells as the model system, however, the slides available for the micro array study had 
been spotted with human cDNA. Therefore, the COS-1 cell system was not suitable for 
such analyses and had to be changed to a cell type of human origin. HEK-293 cells were 
used for this study, as they are well established as being readily transfectable, which was 
then confirmed here for PDE4A7 (see below). The major aim of the following study was 
to deteimine which genes are regulated in response to the over-expression of recombinant 
PDE4A7 using the techniques of gene microairay and RT-PCR.
5.2 Results
5.2.1 Expression of PDE4A7 in HEK-293 cells
HEK-293 cells were transiently transfected with a range of PDE4A7 plasmid DNA 
concentrations (0.5|ig/pl, Ipg/pl, 2pg/pl and 5pg/pl) to determine whether it was possible 
to over-express PDE4A7 in this cell type and if so, the concentiation of PDE4A7 plasmid 
DNA required to produce adequate expression of the PDE4A7 protein (Materials and 
Methods 2.1.3). The PDE4A7-transfected cell lysates were subjected to 10% SDS-PAGE 
before immunoprobing with the polyclonal anti-VSV antibody. The reason for using the 
anti-VSV antibody to detect PDE4A7 expression was because this protein contains a 
truncated C-terminal, which means that its expression camiot be detected using the general 
PDE4A antisera (discussed previously). Thus, PDE4A7 was engineered to contain a VSV 
epitope tag (YTDIEMNRLGK) at its C-terminal, which allows its expression to be 
detected using the anti-VSV antibody. VSV identified the 33±2kDa immunoreactive band 
of PDE4A7 only in those cells that were transfected with Spg/pl of plasmid DNA (figure 
5.1). This demonstrated that PDE4A7 could be over-expressed in this cell type and that 
5pg/pl of DNA sufficed to produce detectable PDE4A7 expression by immunoblotting.
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Figure 5.1 Expression of PDE4A7 in HEK-293 cells. Four 
plates of HEK-293 cells were transiently transfected with 
different amounts of DNA (indicated above). The cells were 
harvested, homogenised and centrifuged to remove cellular 
debris. 20pg of protein from each cell lysate was subjected to 
10% SDS-PAGE electrophoresis, followed by immunoblotting 
with the polyclonal anti-VSV antibody. The immunoreactive 
band of PDE4A7 is indicated above. Mock transfected HEK- 
293 lysate was run alongside the PDE4A7-transfected HEK-293 
lysates as a negative control. Migration of standard molecular 
weight protein markers (in kDa) are shown on the left.
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5.2.2 Using microarray to detect changes in gene expression in response
to expression of recombinant PDE4A7
RNA was extracted from HEK-293 cells over-expressing either PDE4A7, which 
will be refeiTed to as the test sample, or pcDNA3, referred to as the reference sample 
(Materials and Methods 2.3.9.1). pcDNA3-transfected HEK-293 cells were ehosen as the 
negative control (reference sample) because PDE4A7 had previously been cloned into this 
vector. This meant that any changes observed in gene expression profiles could be 
attributed solely to the over-expression of PDE4A7 and also allowed us to correct for any 
expression changes that occur in response to the transfection procedure. The mRNA from 
the test sample was reverse transcribed to produce cDNA labelled with CY3, whereas the 
mRNA from the reference sample was used to generate cDNA labelled with CY5 
(Materials and Methods 2.5). Equal amounts of these labelled cDNAs were mixed before 
hybridising to the micro array slides (Materials and Methods 2.5). It has been noted that 
CY5 does not incorporate as well as CY3, therefore, to coixect for any incorporation bias, 
we prepared samples in which the test and control dyes were reversed. In this case the test 
sample was labelled with CY5 and the control sample with CY3. This process is referred 
to as ‘fluor flip’. Two independent hybridisations to different microanay slides were 
performed for each treatment, with each including a ‘fluor flip’. Results from the 
micro array study are shown as colour images whereby green represents the control sample 
data and red represents the test sample data and the two of these colour images are 
combined. Those genes demonstrating a similar response to the over-expression of 
PDE4A7 were grouped using the data analysis packages of CLUSTER and TREE VIEW 
[Schena, 1996 and Shalon et al., 1996]. These programmes enabled us to eliminate those 
genes that showed variability in their responses between the experiments, allowing us to 
focus on those genes that demonstrated consistent changes, in both the separate 
hybridisations and “fluor flip” process (normalisation and analysis of the gene microarray 
data was performed by Dr Steven Yarwood). The full data set generated from this 
micro array analysis is contained on the enclosed CD and can be accessed using Microsoft 
Excel.
Group A (figure 5.2) shows a cluster of those genes that were up-regulated in
response to over-expression of PDE4A7, whereas group B (figure 5.3) shows those genes
that were down-regulated in response to the over-expression of PDE4A7. Genes up-
regulated in response to PDE4A7 over-expression included those involved in the cell cycle
(e.g CDK5 and ETS) and those involved in G protein-mediated signalling (e.g GRK, Gz
and A2A receptor). Genes down-regulated in response to PDE4A7 over-expression
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included the A2B receptor and the ras-related C3 botulinum toxin substrate (C3), that are 
involved in generating cAMP and hydrolysing cGMP respectively. Before conclusions 
could be taken from this microaiTay analysis, I had to verify the gene expression changes 
using an alternative method.
1 1 3
Figure 5.2 Display of genes upregulated In response to over-expression 
of PDE4A7 in HEK-293 cells. HEK-293 cells were transfected with 
either pcDNA3 or PDE4A7 DNA and allowed to express for 48 hours. 
CY3- and CY5- labelled cDNAs were prepared from each of these samples 
and hybridised to a 1.7K human array (as described in Materials and 
Methods 2.5). Slides were subjected to confocal scanning and coloured 
images were generated. * mark those transcripts that were re-evaluated 
using RT-PCR analysis.
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Figure 5.3 Display of genes down-regulated in response to over­
expression of PDE4A7 in HEK-293 cells. HEK-293 cells were transfected 
with either pcDNA3 or PDE4A7 DNA and allowed to express for 48 hours. 
CY3- and CY5- labelled cDNAs were prepared from each o f these samples 
and hybridised to a 1.7K human array (as described in Materials and 
Methods 2.5). Slides were subjected to confocal scanning and coloured 
images were generated. * mark those transcripts that were re-evaluated using 
RT-PCR analysis.
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5.2.3 Using RT-PCR to detect changes in gene expression in response to 
PDE4A7 over-expression
Although gene microanay has provided researchers with a valuable tool for 
analysing the expression of thousands of genes simultaneously, this method is still in its 
infancy and problems exist with inegularities in spot shape and size, noise and data 
analysis, which are all pitfalls that can lead to misinterpretation o f the expression profiles 
of many genes [Schuchhardt et a l, 2000]. Nonnally micro array data is verified by using 
RT-PCR or Northern blotting to retest the expression changes of the candidate genes. Here, 
RT-PCR was used to verify the changes in gene expression detected in HEK-293 cells in 
response to the over-expression of PDE4A7. Seven candidate genes were chosen for 
further analysis, as it would not have been feasible to analyse large numbers of genes given 
the time available.
RNA was extracted from HEK-293 cells over-expressing either PDE4A7 or 
pcDNA3 (negative control) and each was reverse transcribed into cDNA, which served as 
a template in the subsequent PCR reactions, where gene specific primers were used to 
detect the target gene of interest (Materials and Methods 2.3.9.1, 2.3.9.2, 2.3.9.3). In 
addition each PCR reaction contained primers to detect the housekeeping gene of 
cyclophylin, an RNA that provides an internal control to which the target genes can be 
normalised. Other common housekeeping genes used as internal controls are 
glyceraldehyde-3-phosphate-dehydrogenase (GADPH) and (3-actin because their 
expression is normally constitutive and their levels remain unchanged despite any 
experimental treatments, providing ideal internal controls [Bustin, 2000]. To ensure the 
target gene was detected within the linear range of amplification, each PCR reaction was 
performed at increasing cycle numbers (15, 20, 25, 30 and 35 cycles).
5.2.4 Primer design
The primers for each target gene and the cyclophylin control were designed 
according to the nucleotide sequences provided by the National Centre for biotechnology 
Infoimation (NCBI) database(http://www.ncbi.nlm.nih.gov/). Primer pairs amplified each 
of the target genes as 350bp products and the internal control of cyclophylin as a 250bp 
product. The nucleotide sequence of target used to generate the primer pairs are shown in 
figures 5.4-5J l ,  with the sequence used to generate the sense (5’) and antisense (3’) 
primers highlighted in yellow and red, respectively. The actual primer pairs and the PCR
1 1 6
reaction conditions used for amplification of each of the target genes are shown in Table 
5.1.
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1 AATTTTCAGC TGTTCTTTGC TCAATAATAA CTTTTTTATC ACCAAGATAT CTCTCTAAGT
61 TTTTGACATA TTCCTCATTT GTTTTGATAA AAGTTTTCTT ATTTTCTTAG AAAAATAAGT
1 2 1  TACTAAAAGT CATATATCAT TGTATATCTT CAAAATATTG CTTAAAACTA GGACTTGTAT
1 8 1  TTAAATGTTT TTTCTTCTTA AAGACAATTT GCAGGTGCCC TCAGGAACCC TGAAGCTGGG
2 4 1  CTGAGCCATG ATGCTGCTGC CAGAACCCCT GCAGAGGGCC TGGTTTCAGG AGACTCAGAG
3 0 1  TCCTCTGTGA AAAAGCCCTT GGAGAGCGCC CCAGCAGGGC TGCACTTGGC TCCTGTGAGG
3 6 1  AAGGGGCTCA GGGGTCTGGG CCCCTCCGCC TGGGCCGGGC TGGGAGCCAG GCGGGCGGCT
4 2 1  GGGCTGCAGC AATGGACCGT GAGCTGGCCC AGCCCGCGTC CGTGCTGAGC CTGCCTGTCG
4 81  TCTGTGGCCA TGCCCATCAT GGGCTCCTCG GTGTACATCA CGGTGGAGCT GGCCATTGCT
5 4 1  GTGCTGGCCA TCCTGGGCAA TGTGCTGGTG TGCTGGGCCG TGTGGCTCAA CAGCAACCTG
6 0 1  CAGAACGTCA CCAACTACTT TGTGGTGTCA CTGGCGGCGG CCGACATCGC AGTGGGTGTG
6 6 1  CTCGCCATCC CCTTTGCCAT CACCATCAGC ACCGGGTTCT GCGCTGCCTG CCACGGCTGC
7 2 1  CTCTTCATTG CCTGCTTCGT CCTGGTCCTC ACGCAGAGCT CCATCTTCAG TCTCCTGGCC
7 8 1  ATCGCCATTG ACCGCTACAT TGCbfiTCCGC ATCCCGCTCC GGTACAATGj CTTGGTGACC
8 4 1  GGCACGAGGG CTAAGGGCAT CATTGCCATC TGCTGGGTGC TGTCGTTTGC CATCGGCCTG
9 0 1  ACTCCCATGC TAGGTTGGAA CAACTGCGGT CAGCCAAAGG AGGGCAAGAA CCACTCCCAG
9 6 1  GGCTGCGGGG AGGGCCAAGT GGCCTGTCTC TTTGAGGATG TGGTCCCCAT GAACTACATG
1 0 2 1  GTGTACTTCA ACTTCTTTGC CTGTGTGCTG GTGCCCCTGC TGCTCATGCT GGGTGTCTAT
1 0 8 1  TTGCGGATCT TCCTGGCGGC GCGACGACAG CTGAAGCAGA TGGAGAGCCA GCCTCTGCCG
1 1 4 1  GGGGAGCGGG CACGGTCCAC ACTGCAGAAG GAGGTCCATG CTGCCAAGTC ACTGGCCATC
1 2 0 1  ATTGTGGGGC TCTTTGCCCT CTGCTGGCTG CCCCTACACA TCATCAACTG CTTCACTTTC
1 2 6 1  TTCTGCCCCG ACTGCAGCCA CGCCCCTCTC TGGCTCATGT ACCTGGCCAT CGTCCTCTCC
1 3 2 1  CACACCAATT CGGTTGTGAA TCCCTTCATC TACGCCTACC GTATCCGCGA GTTCCGCCAG
1 3 8 1  ACCTTCCGCA AGATCATTCG CAGCCACGTC CTGAGGCAGC AAGAACCTTT CAAGGCAGCT
1 4 4 1  GGCACCAGTG CCCGGGTCTT GGCAGCTCAT GGCAGTGACG GAGAGCAGGT CAGCCTCCGT
1 5 0 1  CTCAACGGCC ACCCGCCAGG AGTGTGGGCC AACGGCAGTG CTCCCCACCC TGAGCGGAGG
1 5 6 1  CCCAATGGCT ACGCCCTGGG GCTGGTGAGT GGAGGGAGTG CCCAAGAGTC CCAGGGGAAC
1 6 2 1  ACGGGCCTCC CAGACGTGGA GCTCCTTAGC CATGAGCTCA AGAGAGTGTG CCCAGAGCCC
1 6 8 1  CCTGGCCTAG ATGACCCCCT GGCCCAGGAT GGAGCAGGAG TGTCCTGATG ATTCATGGAG
17 41  TTTGCCCCTT CCTAAGGGAA GGAGATCTTT ATCTTTCTGG TTGGCTTGAC CAGTCACGTT
1 8 0 1  GGGAGAAGAG AGAGAGTGCC AGGAGACCCT GAGGGCAGCC GGTTCCTACT TTGGACTGAG
18 61 AGAAGGGAGC CCCAGGCTGG AGCAGCATGA GGCCCAGCAA GAAGGGCTTG GGTTCTGAGG
1 9 2 1  AAGCAGATGT TTCATGCTGT GAGGCCTTGC ACCAGGTGGG GGCCACAGCA CCAGCAGCAT
1 9 8 1  CTTTGCTGGG CAGGGCCCAG CCCTCCACTG CAGAAGCATC TGGAAGCACC ACCTTGTCTC
2 0 4 1  CACAGAGCAG CTTGGGCACA GCAGACTGGC CTGGCCCTGA GACTGGGGAG TGGCTCCAAC
2 1 0 1  AGCCTCCTGC CACCCACACA CCACTCTCCC TAGACTCTCC TAGGGTTCAG GAGCTGCTGG
2 1 6 1  GCCCAGAGGT GACATTTGAC TTTTTTTCCA GGAAAAATGT AAGTGTGAGG AAACCCTTTT
2 2 2 1  TATTTTATTA CCTTTCACTC TCTGGCTGCT GGGTCTGCCG TCGGTCCTGC TGCTAACCTG
2 2 8 1  GCACCAGAGC CTCTGCCCGG GGAGCCTCAG GCAGTCCTCT CCTGCTGTCA CAGCTGCCAT
2 3 4 1  CCACTTCTCA GTCCCAGGGC CATCTCTTGG AGTGACAAAG CTGGGATCAA GGACAGGGAG
2 4 0 1  TTGTAACAGA GCAGTGCCAG AGCATGGGCC CAGGTCCCAG GGGAGAGGTT GGGGCTGGCA
24  61  GGCCACTGGC ATGTGCTGAG TAGCGCAGAG CTACCCAGTG AGAGGCCTTG TCTAACTGCC
2 5 2 1  TTTCCTTCTA AAGGGAATGT TTTTTTCTGA GATAAAATAA AAACGAGCCA CA
Figure 5.4 Nucleotide sequence of the A2AR (NCBI: S46950). The
nucleotide sequence used to generate the sense (5’) and antisense (3’) 
primers for the amplification of the A2AR transcript are highlighted in 
yellow and red respectively. The actual nucleotide sequence of the primers 
used are shown in Table 5.1.
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1 GTACCAGGCC CATTTCCTCT TCTGTTACAT CTTCCTAATG GACAAACCAT GCCTGTTGCT
61 ATTCCTGCAT CAATTACAAG TTCTAATGTG CATGTTCCAG CTGCAGTCCC ACTCGTTCGA
1 2 1  CCAGTCACCA TGGTGCCTAG TGTTCCAGGA ATCCCAGGTC CTTCCTCTCC CCAACCAGTA
1 8 1  CAGTCAGAAG CAAAAATGAG ATTAAAAGCT GCTTTGACCC AGCAACATCC TCCAGTTACC
2 4 1  AATGGTGATA CTGTCAAAGG TCATGGTAGC GGATTGGTTA GGACTCAGTC AGAGGAATCT
3 0 1  CGACCGCAGT CATTACAACA GCCAGCCACA TCCACTACAG AAACTCCGGC TTCTCCAGCT
3 61 CACACAACTC CACAGACCCA AAGTACAAGT GGTCGTCGGA GAAGAGCAGC TAACGAAGAT
4 2 1  CCTGATGAAA AAAGGAGAAA GTTTTTAGAG CGAAATAGAG CAGCAGCTTC AAGATGCCGA
4 8 1  CAAAAAAGGA AAGTCTGGGT TCAGTCTTTA GAGAAGAAAG CTGAAGACTT GAGTTCATTA
5 4 1  AATGGTCAGC TGCAGAGTGA AGTCACCCTG CTGAGAAATG AAGTGGCACA GCTGAAACAG
6 0 1  CTTCTTCTGG CTCATAAAGA TTGCCCTGTA ACCGCCATGC AGAAGAAATC TGGCTATCAT
6 6 1  ACTGCTGATA AAGATGATAG TTCAGAAGAC ATTTCAGTGC CGAGTAGTCC ACATACAGAA
7 2 1  CTATACAGC ATAGTTCGGT CAGCACATCC AATGGAGTCA GTTCAACCTC CAAGGCAGAA 
7 8 1  GCTGTAGCCA CTTCAGTCCT CACCCAGATG GCGGAC|C ^ A  GTàCAGAGCC TGCTC’TTTCjil
8 4 1  K B a t c g t t a  TGGCTCCTTC CTCCCAGTCA CAGCCCTCAG GAAGTTGATT AAAAACCTGC
9 0 1  AGTACAACAG TTTTAGATAC TCATTAGTGA CTTCAAAGGG AAATCAAGGA AAGACCAGTT
9 6 1  TCCATTTATG CGAAATCTGT GGTTGTAAAT ACTTGAAATT AAATTTGGCT
1 0 2 1  CTAAAGTTGG TGTAGCAGCA GTTGATCAGA CTGAAAAACG GTTTTTAGTC TCTGGAAAAA
1 0 8 1  GACTGATTTT GCTTTTTTTA TAAATATTAT TAGATTTATT AATTTTTCTG TGCTCAATGT
1 1 4 1  GTAAATTGTA TTATAATTCA TTGTGATTTA TTTCACTTTT AATTTGCTGG TGTTTTAATA
1 2 0 1  AATGGGGGTG TTACTG
Figure 5.5 Nucleotide sequence of CREB protein (NCBI: M31630) The
nucleotide sequence used to generate the sense (5’) and antisense (S’) 
primers for the amplification of the CREB protein transcript are highlighted 
in yellow and red respectively. The actual nucleotide sequence of the 
primers used are shown in Table 5.1.
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1 CAGGACAAAA GATCCTTCAT CACCGAAGTG ACGTTTTAGA AACAGTGGTC CTGATCAACC
61 CTTCTGATGA AGCAGTCAGC ACCGAGGTGC GCTTAATGAT CACTGATGCT GCCCGACACA
1 2 1  AGCTGCTCGT GCTGACCGGG CAGTGCTTTG AAAATACCGG AGAGCTCATT CTCCAGTCCG
1 8 1  GCTCTTTCTC CTTCCAGAAC TTCATAGAGA TTTTCACCGA TCAAGAGATC GGGGAGTTAC
2 4 1  TAAGCACCAC CCATCCTGCC AACAAAGCCA GCTTAACCCT GTTCTGTCCT GAAGAAGGGG
3 0 1  ACTGGAAGAA CTCCAATCTT GACAGACACA ATCTCCAAGA CTTCATCAAT ATTAAACTCA
3 6 1  ATTCAGCTTC TATCTTGCCA GAAATGGAAG GACTTTCTGA GTTTACCGAG TATCTCTCAG
4 2 1  ^TCAGTGG A AGTCCCATCT CCCTTTfl|ACA TCTTGGAACC TCCCACATCG GGTGGATTTC
4 8 1  TGAAGCTCTC CAAGCCCTGC TGTTATATTT TTCCAGGAGG GAGGGGCGAT TCTGCCTTGT
5 4 1  TTGCAGTGAA TGGTTTCAAT ATGCTCATCA ATGGCGGATC AGAGAGAAAA TCCTGCTTCT
6 0 1  GGAAGCTCAT CCGACACTTA GACCGAGTGG ACTCCATCCT GCTCACCCAC ATTGGGGATG
6 6 1  ACAATTTGCC TGGAATAAAC AGCATGTTAC AGCGGAAAAT TGCAGAGCTC GAGGAAGAAC
7 2 1  AGTCCCAGGG CTCCACCACA AATAGTGACT GGATGAAAAA CCTCATCTCC CCTGACTTAG
7 8 1  GAGTTGTATT TCTCAATGTA CCTGAAAATC TCAAAAATCC AGAGCCAAAC ATCAAGATGA
8 4 1  AGAGAAGCAT AGAAGAAGCC TGCTTCACTC TCCAGTACCT AAACAAATTG TCCATGAAAC
9 0 1  CAGAACCTCT GTTTAGAAGT GTAGGCAATA CTATTGATCC TGTCATTCTT TTCCAAAAAA
9 6 1  TGGGAGTAGG TAAACTTGAG ATGTATGTGC TTAATCCAGT GAAGAGCAGC AAGGAAATGC
1 0 2 1  AGTATTTTAT GCAGCAGTGG ACTGGTACCA ACAAAGACAA GGCTGAATTC A T T C T -------
74  41  AGAGAGAGAG AGCGCGGGAG AGAGTGAGAG AGAGTGAGAG CACAAAGATA ACGCAGGAGA
7 5 0 1  GAGAGAGAGA AAGAATGAGA AAGAAAAGGA ATGCAAGAGA AGGAGATGTA ATGACAGAGA
7 5 6 1  GTTCTGGTGA GATACCCAGA GAGAAAAAGA GAGAGCAGGG TGGGGTAAGG AGGAGAAAAT
7 6 2 1  AAACCAACAA TTAGGTCTGC ATTTTCTCAG GCAGTAGGCA TTCTTTAGTC TACATAGGCA
7 6 8 1  AAGTTTTCCA TTTTTGTCAG TCTGAGTCAT CAAAAAGAGT CTTAATTTTC TAAAACAAGT
7 7 4 1  TGGCTAGAAG AAAGTAAAAA GAACAACACT TGTTATGAGG GCATGTGATA TTTTCACATC
7 8 0 1  TTAATTAAGC TCCTTCAGTT TGAAGGCTGC ACACTGACAT AATGTAGTGA GTGTAGACTG
7 8 6 1  GCCATGCAAG TGGTTTGGGC CCCATTCAGA ACTCTCAGAC TCTAAACACA CAAGTAGATT
7 9 2 1  GATCTAAGGC ATGCTCCCAG CATTGTCCAC CCACTTAGTC CACTCTGAGT CGATTAACCT
7 9 8 1  GCATGCAGCA ACACCCAAGT CCACCCCAAT TAACTGAAGC AAATACCAAA GCAGTTGGGA
8 0 4 1  GTACATATGG TAGACAATTT GCCTTAGGAA GTGACTTGAA TGTACAAAGA TACTTGATGC
8 1 0 1  ACTTATTTTT TAATGTGAGA CAGCAAGTTT ATAAAACATC CATATAGGAT TATAGATACT
8 1 6 1  TAAAGGAACA CGTGGGTGAG CGTGTGTGGG GGTACTAGAA GCTGATCTGA TTGGTCCAAC
8 2 2 1  AGTTTGATGC TGAGTCATGC GTGTTGAATC CCACTTCAGT GCACCTGTGG CCTCTCAGTC
8 2 8 1  AAACAAGTTG TGCCTTTCAC AGCTTCTTTA CTACTGCAAG TTCAAGACTG AAATGGCTTC
8 3 4 1  TATGATCAGA ACTGGGAAAA CAGTGAATCT TATGGTGGAA GAGGTTCTCA GCAAGTGTAC
84 01  AGTATTTAGC TTCCTTTGTC TTACATTGGC TTTTTAAATT TTCCATTAAT TTCAACATAA
84 61  TTATGGGAAC AAGTGTACAG AAGAATTTTT TTTTTAAGAT ATGTGAGAAC TTTTCATAGA
8 5 2 1  TGAACTTTTT AACAAATGTT TTCATTTACA GGAAATTGCA AAGAAAATTC TCAAGTGATA
8 5 8 1  GTCTTTTTTT TTAAGTGTTT CGTAAGACAA AAATTGAATA ATGTTTTTTG AAGTTCTGGC
8 6 4 1  AAGATTGAAG TCTGATATTG CAGTAATGAT ATTTATTAAA AACCCATAAC TACCAGGAAT
8 7 0 1  AATGATACCT CCCACCCCTT GATTCCCATA ACATAAAAGT GCTACTTGAG AGTGGGGGAG
87 61 AATGGCATGG TAGGCTACTT TTCAGGGCCT TGACAAGTAC ATCACCCAGT GGTATCCTAC
8 8 2 1  ATACTTCTTT CAAGATCTTC AACCATGAGG TAAAAGAGCC AAGTTCAAAG AACCCTAGCA
88 81 CAAATTTGCT TTGGGATTTT CTTTTCTGGA
Figure 5.6 Nucleotide sequence of the MAPIB protein (NCBI: XM 
003704). The nucleotide sequence used to generate the sense (5’) and 
anti sense (3’) primers for the amplification of the MAPIB transcript are 
highlighted in yellow and red respectively. The actual nucleotide sequence 
of the primers used are shown in Table 5.1.
120
1 ATGCAGGCCA TCAAGTGTGT GGTGGTGGGA GATGGGGCCG TGGGCAAGAC CTGCCTTCTC
61 ATCAGCTACA CCACCAACGC CTTTCCCGGA GAGTACATCC CCACCGTGTT TGACAACTAT
1 2 1  TCAGCCAATG TGATGGTGGA CAGCAAGCCA GTGAACCTGG GGCTGTGGGA CACTGCTGGG
1 8 1  CAGGAGGACT ACGACCGTCT CCGGCCGCTC TCCTATCCAC AGACGGACGT CTTCCTCATC
2 4 1  TGCTTCTCCC TCGTCAGCCC AGCCTCTTAT GAGAACGTCC GCGCCAAGTG GTTCCCAGAA
3 0 1  GTGCGGCACC ACTGCCCCAG CACACCCATC &TCCTGGTGG GCACCBAGCT GGACCT<g|CGG
3 6 1  GACGACAAGG ACACCATCGA GAAACTGAAG GAGAAGAAGC TGGCTCCCAT CACCTACCCG
4 2 1  CAGGGCCTGG CACTGGCCAA GGAGATTGAC TCGGTGAAAT ACCTGGAGTG CTCAGCCCTC
4 8 1  ACCCAGAGAG GCCTGAAAAC CGTGTTCGAC GAGGCCATCC GGGCCGTGCT GTGCCCTCAG
5 4 1  CCCACGCGGC AGCAGAAGCG GGGCTGCAGC CTCCTCTAG
Figure 5.7 Nucleotide sequence of the C3 protein (NCBI: M29871). The
nucleotide sequence used to generate the sense (5’) and antisense (3’) 
primers for the amplification of the C3 protein transcript are highlighted in 
yellow and red respectively. The actual nucleotide sequence of the primers 
used are shown in Table 5.1.
1 AGTTGTTGCT TATGATGTGT GAGTGAACAT ATGCCATGCC TGGCCTTTTT TGTGGTTAGC
61 TCCTTCTTGC CAACCAACCA TGAGCTCCCA GATTCGTCAG AATTATTCCA CCGACGTGGA
1 2 1  GGCAGCCGTC AACAGCCTGG TCAATTTGTA CCTGCAGGCC TCCTACACCT ACCTCTCTCT
1 8 1  GGGCTTCTAT TTCGACCGCG ATGATGTGGC TCTGGAAGGC GTGAGCCACT TCTTCCGCGA
2 4 1  ACTGGCCGAG GAGAAGCGCG AGGGCTACGA GCGTCTCCTG AAGATGCAAA ACCAGCGTGG
3 0 1  CGGCCGCGCT CTCTTCCAGG ACATCAAGAA GCCAGCTGAA GATGAGTGGG GTAAAACCCC
3 6 1  AGACGCCATG AAAGCTGCCA TGACCCTGGA GAAAAAGCTG A A C ^ G G Ç j B E S ï ^ H i
4 2 1  K A T G C C C #  GGTTCTGCCC GCACGGACCC CCATCTCTGT GACTTCCTGG AGACTCACTT
4 8 1  CCTAGATGAG GAAGTGAAGC TTATCAAGAA GATGGGTGAC CACCTGACCA ACCTCCACAG
5 4 1  GCTGGGTGGC CCGGAGGCTG GGCTGGGCGA GTATCTCTTC GAAAGGCTCA CTCTCAAGCA
6 0 1  CGACTAAGAG CCTTCTGAGC CCAGCGACTT CTGAAGGGCC CCTTGCAAAG TAATAGGGCT
6 6 1  TCTGCCTAAG CCTCTCCCTC CAGCCAATAG GCAGCTTTCT TAACTATCCT AACAAGCCTT
7 2 1  GGA
Figure 5.8 Nucleotide sequence of the FLCK protein (NCBI: M10119).
The nucleotide sequence used to generate the sense (5’) and anti sense (3’) 
primers for the amplification of the FLCK protein transcript are highlighted 
in yellow and red respectively. The actual nucleotide sequence of the 
primers used are shown in Table 5.1.
121
1 ATGAAATCGT TAGCACCTTA GGAGAGGGGA CCTTCGGCCG AGTTGTACAA TGTGTTGACC
61 ATCGCAGGGG TGGGGCTCGA GTTGCCCTGA AGATCATTAA GAATGTGGAG AAGTACAAGG
1 2 1  AAGCAGCTCG ACTTGAGATC AACGTGCTAG AGAAAATCAA TGAGAAAGAC CCTGACAACA
1 8 1  AGAACCTCTG TGTCCAGATG TTTGACTGGT TTGACTACCA TGGCCACATG TGTATCTCCT
2 4 1  TTGAGCTTCT GGGCCTTAGC ACCTTCGATT TCCTCAAAGA CAACAACTAC CTGCCCTACC
3 0 1  CCATCCACCA AGTGCGCCAC ATGGCCTTCC AGCTGTGCCA GGCTGTCAAG TTCCTCCATG
3 6 1  ATAACAAGCT GACACATACA GACCTCAAGC CTGAAAATAT TCTGTTTGTG AATTCAGACT
4 2 1  ATGAGCTCAC CTACAACCTA GAGAAGAAGC GAGATGAGCG CAGTGTGAAG AGCACAGCTG
4 81 TGCGGGTGGT AGACTTTGGC AGTGCCACCT TTGACCATGA jj^CCATAG C ACCATTGTCH
5 4 1  Ë cA dT dÈ CCA TTACCGAGCA CCAGAAGTCA TCCTTGAGTT GGGCTGGTCA CAGCCTTGTG
6 0 1  ATGTGTGGAG TATAGGCTGC ATCATCTTTG AATACTATGT GGGATTCACC CTCTTCCAGA
6 6 1  CCCATGACAA CAGAGAGCAT CTAGCCATGA TGGAAAGGAT CTTGGGTCCT ATCCCTTCCC
7 2 1  GGATGATCCG AAAGACAAGA AAGCAGAAAT ATTTTTACCG GGGTCGCCTG GATTGGGATG
7 8 1  AGAACACATC AGCTGGGCGC TATGTTCGTG AGAACTGCAA ACCGCTGCGG CGGTATCTGA
8 4 1  CCTCAGAGGC AGAGGAACAC CACCAGCTCT TCGATCTGAT TGAAAGCATG CTAGAGTATG
9 0 1  AACCAGCTAA GCGGCTGACC TTGGGTGAAG CCCTTCAGCA TCCTTTCTTC GCCCGCCTTC
9 6 1  GGGCTGAGCC GCCCAACAAG TTGTGGGACT CCAGTCGGGA TATCAGTCGG TGACGATCAG
1 0 2 1  GCCCTGGGCC CCCCTGCATC TTTTATAGCA GTGGGTGTCC AGTCCAGGAC ACTGGTGCTT
1 0 8 1  TTTTATACAA GAGAACGAGC CAGAGTTCAC TCCTTCCTCC TGGCTCTCTA TATACCTGTG
1 1 4 1  AATATGTGAA ATAGTGTAAA TATGAAAGAA CTTGTACCTA TCACTTCAAC CCCTGCCTTG
1 2 0 1  TACATAATAC TATTCCATCC ACACAGTTTC CACCCTCACC TGCCCCCTCA TACGGAGTTG
12 61 GATGGGGGCC GAGTGAGGTA ACCAGGTGGC ATCTACCCCA TGTTTTATAA GGAATTTTGT
1 3 2 1  ACAGTCTTTG TGAAATAAAA TAACGTGCTT CATTTGACCC CC
Figure 5.9 Nucleotide sequence of the CLK2 protein (NCBI: XM 
002188). The nucleotide sequence used to generate the sense (5’) and 
antisense (3’) primers for the amplification of the CLK2 protein transcript 
are highlighted in yellow and red respectively. The actual nucleotide 
sequence of the primers used are shown in Table 5.1.
122
1 GGGCAATTTG TTAGTTATCC GCCGCCACCA AGACGCGGCA CGGCGCCTGG ACCGGAGGGG
61 CCCCGCGCGG GCGCGAACTT TGGGCTCGGG CGAGTGGGTG GTGCTCCGCC CAGCCCGAGA
1 2 1  CGGGCGGGCG CGCGGGCCAA TGGGTGCCGC CTCTTGGCCG CGGGGGGCCC CGACCCGTGG
1 8 1  GTCCCGGCCA CCAGCGCCCC AGCCCCGAGG CTCAGAAGCG GCAGGCGGAG GCGCGGTCCG
2 4 1  GGCGCTATGG CCATGCCCGG CGGGTCTCAC GCGGCTGCCC CTCGCCCGGC GCGCCTTCGG
3 0 1  TAGGGGGCGC CCGGGGCCCA GCTGGCCCGG CCATGCTGCT GGAGACACAG GACGCGCTGT
3 61 ACGTGGCGCT GGAGCTGGTC ATCGCCGCGC TTTCGGTGGC GGGCAACGTG CTGGTGTGCG
4 2 1  CCGCGGTGGG CACGGCGAAC ACTCTGCAGA CGCCCACCAA CTACTTCCTG GTGTCCCTGG
4 8 1  CTGCGGCCGA CGTGGCCGTG GGGCTCTTCG CCATCCCCTT TGCCATCACC ATCAGCCTGG
5 4 1  GCTTCTGCAC TGACTTCTAC GGCTGCCTCT TCCTCGCCTG CTTCGTGCTG GTGCTCACGC
6 0 1  AGAGCTCCAT CTTCAGCCTT CTGGCCGTGG CAGTCGACAG ATACCTGGCC ATCTGTGTC|
6 6 1  P SC T C ftS G m  TAAAAGTTTG ^ GTCACQlGGGA CCCGAGCAAG AGGGGTCATT GCTGTCCTCT
7 2 1  GGGTCCTTGC CTTTGGCATC GGATTGACTC CATTCCTGGG GTGGAACAGT AAAGACAGTG
7 8 1  CCACCAACAA CTGCACAGAA CCCTGGGATG GAACCACGAA TGAAAGCTGC TGCCTTGTGA
8 4 1  AGTGTCTCTT TGAGAATGTG GTCCCCATGA GCTACATGGT ATATTTCAAT TTCTTTGGGT
9 0 1  GTGTTCTGCC CCCACTGCTT ATAATGCTGG TGATCTACAT TAAGATCTTC CTGGTGGCCT
9 6 1  GCAGGCAGCT TCAGCGCACT GAGCTGATGG ACCACTCGAG GACCACCCTC CAGCGGGAGA
1 0 2 1  TCCATGCAGC CAAGTCACTG GCCATGATTG TGGGGATTTT TGCCCTGTGC TGGTTACCTG
1 0 8 1  TGCATGCTGT TAACTGTGTC ACTCTTTTCC AGCCAGCTCA GGGTAAAAAT AAGCCCAAGT
1 1 4 1  GGGCAATGAA TATGGCCATT CTTCTGTCAC ATGCCAATTC AGTTGTCAAT CCCATTGTCT
12 01 ATGCTTACCG GAACCGAGAC TTCCGCTACA CTTTTCACAA AATTATCTCC AGGTATCTTC
12 61 TCTGCCAAGC AGATGTCAAG AGTGGGAATG GTCAGGCTGG GGTACAGCCT GCTCTCGGTG
1 3 2 1  TGGGCCTATG ATCTAGGCTC TCGCCTCTTC CAGGAGAAGA TACAAATCCA CAAGAAACAA
1 3 8 1  AGAGGACACG GCTGGTTTTC ATTGTGAAAG ATAGCTACAC CTCACAAGGA AATGGACTGC
1 4 4 1  CTCTCTTGAG CACTTCCCTG GAGCTACCAC GTATCTAGCT AATATGTATG TGTCAGTAGT
1 5 0 1  AGGCTCCAAG GATTGACAAA TATATTTATG ATCTATTCAG CTGCTTTTAC TGTGTGGATT
1 5 6 1  ATGCCAACAG CTTGAATGGA TTGTAACAGA CTCTTTTGTT TTTAAAAGTC TGCCTTGTTT
1 6 2 1  ATGGTGGAAA ATTACTGAAA CTATTTTACT GTGAAACAGT GTGAACTATT ATAATGCAAA
1 6 8 1  TACTTTTTAA CTTAGAGGCA ATGGAAAAAT AAAAGTTGAC TGTACTAAAA ATG
Figure 5.10 Nucleotide sequence of the A2BR (NCBI: X68487). The
nucleotide sequence used to generate the sense (5’) and antisense (3’) 
primers for the amplification of the A2BR transcript are highlighted in 
yellow and red respectively. The actual nucleotide sequence of the primers 
used are shown in Table 5.1.
123
1 GAATTCCCTT GTAAGGTTTT CTTAACAAAA CACCAGTCAC ATAAGTGCAT TTTATTTTAT
61 ATTTTTGTTT ATTTATTTGA GACGGAGTCT CTTGTCTCTC AGGCTGGAGT GCAGTGGCGC
1 2 1  CATCTCTGCT CGCTGCAACC TCCACCTCCT GGGTTCCAGC GATTCTCCTG CCTCAGCCTC
1 8 1  CCGAGGGGGT AGCTGGGACT ACAGGTGCGC ACCACCATGC CCAGCTAATT TTGTATTTTT
2 4 1  CGTAGAGATG GGGTTTCACC ATGTTGTCCA GGCTGGTCTT GAACTCCTGA CCTCAGGTGA
3 0 1  TCCTCCCGCC TCGGCCTCCC AAAGTGCTGG AATTACAGGC GTGATCCACC GCACCCGGCC
3 6 1  TATTTTTTGA GAGAGGGTCA CACTCTGTCG TCCCGGCTGG AATGCAGTGA TGCGATCACC
4 2 1  GCCCACTACA GCCTCGACCT CCGGGCTCAA GCAATCCTCC CCGCCCAGCC TCCTGAGTAG
4 81 CGAGCGCCTC GACGCCCAGC TAATTTTTAT TTTTATTTAT TTTTTTGTAG AGACGGCGTC
5 4 1  TCTCTAAGAT GCCCAGGCTG GTGGCCGGTG TCGAACTCCT AAGATGAAGC GATCCTCCCC
6 0 1  GGCCTTGGCC TCCGCGCCTC CTAAAGCGCC AGGTATGAGC CACCGCGCCT GGCCTACAAG
6 6 1  TGCATTTTAA TTAAAGTATT ATTAATGTCT TTGGGTGAAG AAATTCGCTT TTAAATTGTG
7 2 1  ACTTATCTTT CACCCAAAAA TCAAAGCACA ATTCAGCCCC GAGGCGGGGG CGGTAGGAGC
7 8 1  TGGGCGGGGC GGGGGCAGGG AAAGACCAGG AGCAGAGATT CAAAAAGAGT AAGAGGGCAA
8 4 1  AATGTGCATA ATGCATCTTC ACAGGTAAGA GCCTGGCCAG GCTCCTGTTT TAATGGCTTC
9 0 1  CTCCTGAAGA AGATTCAAGC AGAGTGTAAG ATATTTTCGG AAAGTAGAGC ATTTTGAAAG
9 6 1  CATTTCATAA TCTCTCAAAA CCGGAGACTG CTCCTGTCCC ACCTCGTTAG AGAAAACAGC
1 0 2 1  GATGCTCAAA GGCAACCTCC TTCCTGACAT TGCCTGGTAG GACGCGACGT GGTGTTTGCC
1 0 8 1  CGCGCGGAAT GCGGACGCAA GGCTGCTCCT AGGTCTCGGG GACGCGCCAT CCCCATTTCC
1 1 4 1  GCTCGCGGAG GCGTAGGGTC CGGGCGCGGG ACCCCAGTCG ACCTTGACTG GCGGCGCGAC
1 2 0 1  CTTGAGGCCT GCGTTCGCCT CAGTTGCCCC CTCTGTGCAA TGGGGAGACG CGCCTCATCG
12 61 CTTGACAACG GCCGAAGAGC CGCCGCGCTT CCGTCTCCCG CGTGCGCGCG CCATGCTGCC
1 3 2 1  CACCCCCGTT CCGCACTGAC CCTCCCCCGT GCCCCGCGTC CCGTACTGCC GCCCCGCCCC
1 3 8 1  GAGTCCCATG CCGCAGCCAC CGCGACGGAG CCCGCAGGCG GGAACCTGCC TCCGCGCGTT
1 4 4 1  AGCGCGCACG CGCGCCTCAT GTGTCGTCCC CATCAGCGCC GGCTTCCGTC TATAGGCCAG
1 5 0 1  ATGCACTGTC ACTCTGGCGA AGTCGCAGAC CCGATTGGCC GGGACGGAGG CGCGAGACCG
1 5 6 1  GGTTGCGGGC GGGGCCGAAC GTGGTATAAA ACGGGCGGGA GGCCAGGCTC GTGCCGTTTT
1 6 2 1  GCAGACGCCA CCGCCGAGGA AAACCGTGTA CTATTAGCCA TGGTCAACCC CACCGTGTTC
1 6 8 1  TTCGACATTG CCGTCGACGG CGAGCCCTTG GGCCGCGTCT CCTTTGAGGT CGGGCGGGCG
17 41  GCGGCGTGCG GGAATGGGGC CCAGAAAGTG GGCCGGGGTC GGGGTGGGTG GTAGCGCCCC
1 8 0 1  AAAGGCCCGG GCGCGGGGCG ACCCTGCTTG AGGGGCGAGC GCGGGCGGGC TGCGGCGCCA
18 61 TTTCCTGACG AGGGGCCATT TTGGGAGGTC CGCGAGTCGC GGGAGGAGGC CGGGACGCGG
1 9 2 1  CGGACAAAGG GAGGCGGGGG GGCTGCGAGG CCGTTGGGGG AGGGGGCCCG CGTGCGCGCG
1 9 8 1  CGCGCCTCAT GTGGCCGCGC CCTGTCCTGT CCGACGCACG TGCTCGGCGG CCGCGCTCAG
2 0 4 1  GTCCGCGCCT TGAGAGTCGT TGTCCGCCCT AGCTTGGCCT GGGCGCCGCA GACCGGAGCC
2 1 0 1  AGAAGCACGC TCGCGGGGGC TTGCGACCGC CTTCCTGGGA AGCTGTCCCC TGGCAGGCAT
2 1 6 1  GGGTGCTTTA CATCCTGAGC TGGGAAGCTG TTTGCTTGAG GGTTTTTCTC AAGGATCGAG
2 2 2 1  GCGCGGTGTG AGCCCGTCCA TGCTCGGTCC TGTAGATCCC GGGAGGCCAT GTTATAAAAG
2 2 8 1  GAGACTTGCT GGGATGTGAC GGGTTGCCAC TTGAAATATC TTCCATTTGG ATAAAGTAGG
2 3 4 1  AATATTTATA CATGTGCCCC AAACGTCCCT CCGTGTCCCC CACCCCCAAG CGGAAATGTG
24  01  AAAATGGGCC TTGCCTTTGC TGGTGCCCAA GGACCGCCTT CCACTGCAGT GACGGCGCTG
24  61 CTGGCCACAA GGCAGGCCTC TTCCGACCAA GGTGGATTAC CAGTGATTAC CTAATTAGTT
2 5 8 1  TTGAGAGCGT TAAATGAGTT CTTAAAGATC AGTTGTAATT ATAGCATAGT ATCTAAACTT
2 6 4 1  GGCGCGTGTC TTCAAAGTTA AATATTGAGT ACGATTCCGT TCCAGTTAAC ATGGATAGAC
27  01  CTTAGGGAGT AGCGAAATAG GATGTTAGTG GTTTTATTCC TTTAAATCAC ATCTCAAAAG
2 7  61 GCCACCAATG GCTAGTTTGG ATCTTATTCC GAAAATAGAT TGATCCTCAT GCAGTCTTCG
2 8 2 1  GAAACACTGC ATGTTAATCC ACACCCCACC CCACCTATGA GTGTAGTCAA AGCTGGTAAG
2 9 4 1  TGACAAGGGC TTTCGTGGAA ACTTGGCCTG ACCTAATGTT GGGCATCAGG TTACCCAAAG
3 0 0 1  AGCTTCAGGG AAATGAGAAA GGACTTGCAG GTCTTGATGA GAATGGAGGG GTAACTGCCA
3 0 6 1  ATGAGGGCTT TGGCTTTAGC GAAAGTCTGA AAGGGAAGCC ATAGGAACTT AAACGTACCG
3 1 2 1  ACTATAAAGC TCTGAGAAAA GCTGATGTTT TAGAAAGACC ATACATTCTA GGTACAAATA
3 1 8 1  CCTAAAAACT AAAAAATAAG TACGTTGGCC AGGCGGGCGG ATCACGAAGT CAGGAGATTG
3 2 4 1  AGACCATCCT GGGCCCCTGG TGAAACCCCA CCTCTATTAA AAATACAAAA ATTAGCTGGG
3 3 0 1  CGTGGTGGCG CTTGCCTGTA ATCTCAGCTA CTCTAGAGGC TGAGGCAGGA GATCGCTTGA
124
3 3 6 1  ACCCCGGAGG CGGAGGCTGC AGTGAGCCGA GATCGTGCCA CTGCACTCCA GCCTGGTGAC 
3 4 2 1  AGCGAGACTC TTGTCTCAAA AAAAAAAAAG TACATTGCTA TAAGAGAAGT GCACACGGAT 
3 4  8 1  ACTAGTAGTT AATTCAGTCA CATCTGTGAA ATAGCTTATA AAATGCTACT TTTAAACAAG 
3 5 4 1  CTGTTTTTAT GAAAGGGCTT GTAAATGTTT ATGGTATTTA AGCTACCTCT CTAGCCATAA 
3 6 0 1  CGTATTATAC ATTCAAGAAA GGTTCAAAAC GAG AT AT ACT AGAAACCAAT CTTTATTTTT  
3 6 6 1  TACCCCACTA CTAGGTAAGG GCCTGGATAC CAAGAAGTGA CTGCTCATCT AATCCATAAA  
3 7 2 1  GCTATGTTAA CAGATTGGAG GTAGTAGCAT TTTCATTACA AGTGACTAAA AGAACAGCTG 
3 7 8 1  TTTACCCCTG ATCGTGCAGC AGTGCTTGCT GTTCCTTAGA ATTTTGCCTT GTAAGTTCTA 
3 8 4 1  GTGATGTACT AAAAGTTTGA GACACTTTCT AGAAGTCTCA CTATTTAAGT TATGACTAGT 
3 9 6 1  ATTGGATTTT TGGCATGTCT TTGGGTTTCA TGTTTCTTAA CCCAACTGCC TGCAGGGCCT 
4 0 2 1  TATGGCTGTC AGGAGCAGTT CTTGGGAATT AAAGTAATTA CTGAAGAAGT ATTCTAGTGA  
4 0 8 1  GAAAATGAAT TTATGACTCA GAAGCCCCTA AAGACATGGG TACTAAGCAA CAAAATAAGC 
4 1 4 1  AGATGTTAAT TAACTGTAAT TTTCTCTTAC AGCTGTTTGC AGACAAGGTC CCAAAGACAG 
4 2 0 1  CAGGTTGGTC CATTTTCTAA GTTTAACAAA GATGTTCCAA TTGTGACAGT TTGTGTGTGT 
4 2 6 1  GTGTGTATAT ATATATTTTT ATGTATGTAT ATATGTGTTT AATTTTTTTT TAAACAGAAA 
4 3 2 1  ATTTTCGTGC TCTGAGCACT GGAGAGAAAG GATTTGGTTA TAAGGGTTCC TGCTTTCACA 
4 3 8 1  GAATTATTCC AGGGTTTATG TGTCAGGTAC GAAATTTACT GAATTTTATT TTATTTGGGT 
4 4  4 1  TTCTACCATT CGGTTCTATT TAACCCTTCT ATTCAGTTTG AACTTGGGTT TAAAGTTTGA 
4 5 6 1  ACCTTGCAGA TTTGGCACAC TTCATGGTTA TGTTGTCAGA AGTGACATTT TTCCTATATG  
4 6 2 1  TTGACAGGGT GGTGACTTCA CACGCCATAA TGGCACTGGT GGCAAGTCCA TCTATGGGGA 
4 6 8 1  GAAATTTGAA GATGAGAACT TCATCCTAAA GCATACGGGT CCTGGCATCT TGTCCATGGC 
4 7 4 1  AAATGCTGGA CCCAACACAA ATGGTTCjCCA GTTTTTCATC TGCACTGCCA A G S g TGAGTG 
4 8 0 1  GTAAGGGTAC AACATGGCAC ACTAACCACC TGACTAAATG AAAAGTTGCC CTGGGGGGAA 
4 8 6 1  CGGAACAAAC ACTACTTTTC TTCAACCTTT GCTTCCACAG ACTTTTTCAT CCCTAAGATA 
4 9 2 1  TATGATAGAA ACTTGGCCCT TAGCTGGGTG GTTGAATTAG GTGCTACTTT TTTGAGATGG 
5 0 4 1  AGTTTTGCTC TGTTGCCAGG TTGGAGTGCA GTGGCACAAT CTGGGCTCAC TGCAACCTCT 
5 1 0 1  GCCTCCTGGG TTCAAGCGAT TCTCCTGCCT TGGCCTCCTG AGTAGCTGAG AATACAGATG 
5 1 6 1  TGTGCCAGCA TGCCTGGCTA ATTTTTTGTA TTTTTGTGGA GACGGGGTTT CATCATGTTG 
5 2 2 1  GCCAAGCTGG TCTTGAACTC GTGACTTAAG GTGAACCACC TGCCTTGGCC CCCCAAAGTG 
5 2  8 1  CTGGGATTTC AGGCATGAGC CACTGCGCCC AACCAATTAA GTGCTTTTTT -r,p,prp.p,p,j„j„p,p 
5 3 4 1  CTTTTCTCAG ACTGGATCTC GCTCTTATCT CCCAGGTTGG AGTGCAGTGG TGCCATCTCA 
5 4 0 1  GGAACTACAG GCATGCAGCA CCACTCCCAG CTAAATTGTG TATTATTAGT AGAGCGGGAT 
5 5 2 1  TTACCATGTT GTCCAGGCTG GTCTCGAACT CCTGGGCTCA AGTGATCTGC CTGCCTTGAC 
5 5 8 1  CCCCCCGAAG TGCTGGGATT ACAGGCATGA GCCACTGTGC CCACCCAATT AAGTGCTGCT 
5 6 4 1  TTTGTTTTGT TTGTTTTTGG GGGAGGGGGG CGCAATTCAT TCTATATGTG TAACTCTTTT
5 7  6 1  TTGAGATGGA GTTTCGCTCT GTCGCCCAGG CTGGAGTGCA GTGGCGCGAT CTGGGCTCAC 
5 8 2 1  TGCAAGCTCC GCCTCCCAGG TTCACGCCAT TCTCCTGCCT CAGCCTCCCG AGTAGCTGGG
5 8  8 1  ACTATAGGCA CATGCCACCA TGCCCGGCTA ATTTTTTGTA TTTTTAGTAG AGACAGGGTT 
5 9 4 1  TCACCGTGTT AGCCAGGATG GTCTCGATCT CCTGACCTCG TGATCCGCCC GCCTTGGCCT 
6 0 0 1  CCCAAAGTGC TGGGATTACA GGCGTGAGCC ACCGCACCCG GCCTATATGT GTAACTCTTT 
6 0 6 1  AATGGTAATT GGAGAATCAT GTTTAATGAC ATTTAGTACA AAAGGCTTCA GTTAAAAAAA 
6 1 2 1  AAAAAAAAAA GCTACCTTTC TCGTCTTGGT TCATGACACA TGGAGGCTGC TTGTTTGTGG 
6 1 8 1  TTGCCAGTCA TAATGATTGT TCTTCCTTTT CAAGGTTGGA TGGCAAGCAT GTGGTGTTTG 
6 2 4 1  GCAAAGTGAA AGAAGGCATG AATATTGTGG AGGCCATGGA GCGCTTTGGG TCCAGGAATG 
6 3 0 1  GCAAGACCAG CAAGAAGATC ACCATTGCTG ACTGTGGACA ACTCGAATAA GTTTGACTTG 
6 3 6 1  TGTTTTATCT TAACCACCAG ATCATTCCTT CTGTAGCTCA GGAGAGCACC CCTCCACCCC 
6 4 2 1  ATTTGCTCGC AGTATCCTAG AATCTTTGTG CTCTCGCTGC AGTTCCCTTT GGGTTCCATG 
6 4  8 1  TTTTCCTTGT TCCCTCCCAT GCCTAGCTGG ATTGCAGAGT TAAGTTTATG ATTATGAAAT 
6 5 4 1  AAAAACTAAA TAACAATTGT CCTCGTTTGA GTTAAGTGTT GATGTAGGCT TTATTTTAAG  
6 6 0 1  CAGTAATGGG TTACTTCTGA AACATCACTT GTTTGCTTAA TTCTACACAG TACTTAGATT 
6 6 6 1  TTTTTTACTTTCCAGTCCCAGGAAGTGTCAATGTTTGTTGAGTGGAATATT
Figure 5.11 Nucleotide sequence of cyclophylin (NCBI: X52851). The nucleotide 
sequence used to generate the sense (S’) and anti sense (3’) primers for the 
amplification of the cyclophylin transcript are highlighted in yellow and red 
respectively. Actual nucleotide sequence of the primers used are shown in Table 5.1.
Target Primer Fragment Cycle conditions
Gene S=Sense A=Antiseiise Size (bp) D A E
A2A receptor SA
GGGCTCCTCGGTGTACATCACGGTGGA
CCATTGTACCGGAGCGGGATGCGGATG 350 94 °C 15 secs
65«C 
15 secs
68°C 
1 min
A2B receptor SA
GCTGCTGGAGAGACAGGACGCGCTGTA
GGTGACCAAACTTTTATACGTGAGCGG 350
94“C 
15 secs
60°C 
15 secs
68°C 
1 min
cAMP response 
element binding protein
S
A
GAAAGTGTGGGTTCAGTCTTTAGAGAA
GTGTGAAAGAGCAGGGTCTGTAGTCTG 350
94“C 
15 secs
550C 
15 secs
68oQ 
1 min
Protein kinase 
CLK2
S
A
GATGTTTGACTGGTTTGACTACGATGG
GGAGTGGAGACAATGGTGCTATGGTGC 350
94°C 
15 secs
eooQ 
15 secs
680C 
1 min
Dup 1 ras-related 
C3 botulinum toxin
S
A
GCGATCAAGTGTGTGGTGGTGGGAGAT
CAGGTGGAGGTTGGTGGGCAGCAGGAT 350
94°C 
15 secs
60=C 
15 secs
68«C 
1 min
Ferritin light 
chain kinase
S
A
GAGGTGGGAGATTCGTGAGAATTATTG
CAGGGGATGAAGATGCAAAAGGGGGTG 350
94oC 
15 secs
6QoC 
15 secs 6 8= 01 min
Microtubule-associated 
protein IB
S
A
GATGGTGGGGGAGAGAAGCTGGTGGTG
GAAAGGGAGATGGGACTTCCACTGATT 350
94°C 
15 secs
60«C 
15 secs
68=0 
1 min
Cyclophylin S
A
GTGCTCTGAGGAGTGGAGAGAAAGGAT
GTCTTGGCAGTGGAGATGAAAAAGTGG 250
Conditions used for 
cyclophylin matched conditions 
for the transcript to be  
amplified
Table 5.1 Table showing primers and conditions for RT-PCR reactions.
Sequences of the sense (5 ) and antisense (3 ) RT-PCR primers are shown 
alongside the gene they detect. An initial 2 min dénaturation step at 94°C was 
performed for each transcript tested. The temperatures and hold times for the 
dénaturation (D), annealing (A) and elongation (E) stages of the PCR cycles are 
shown. A range of cycles were performed in each case ranging from 1 5 - 3 5  
cycles. The expected size of the fragments amplified are given in base pairs (bp)
1 2 6
5.2.5 Checking for PDE4A7 expression in HEK-293 cells
cDNA template was prepared from HEK-293 cells over-expressing either PDE4A7 
or pcDNA3 (Materials and Methods 2.3.9.2). However, before proceeding with RT-PCR 
analysis, it was important to determine that these transfections were successful by checking 
for PDE4A7 protein expression. Transfected HEK cell lysates were subjected to 10% 
SDS-PAGE electrophoresis before immunoprobing with the polyclonal anti-VSV antibody, 
which identified the 34kDa immunoreactive band of PDE4A7 only in those cells 
transfected with PDE4A7 (figure 5.12). Experiment 1 and experiment 2 show the results 
o f two separate sets of transfections. The cDNA produced from each of these experiments 
were used in the subsequent RT-PCR reactions.
For all the mRNA transcripts investigated two ethidium bromide gels are shown, 
demonstrating the results of two separate RT-PCR reactions in which the template cDNAs 
used were generated from the two separate transfected HEK cell populations (mentioned 
previously). These will be referred to as experiment 1 and experiment 2. Products from 
each of the RT-PCR reactions were separated by 1.5% agarose gel electrophoresis (figures 
5.13-5.18), The predicted and observed weights for each of the transcripts are shown in 
Table 5.2. Each of these bands were found to increase in intensity with increasing cycle 
number, indicating that all the products were detected within the linear range of 
amplification. Each RT-PCR reaction contains a negative control where cDNA template 
was replaced with sterile water. No bands were detected in any of the negative controls.
The adenosine A2A receptor (A2AR), cAMP response element binding protein
(CREB) and microtubule-associated protein IB (MAPIB) were genes seemingly up-
regulated in response to over-expression of PDE4A7, as detected by microarray analysis.
When re-evaluated with RT-PCR no changes were detected for either the A2AR or
MAPIB transcripts (figures 5.13 and 5.15, respectively). However, CREB appeared to be
down-regulated (visually) in response to the over-expression of PDE4A7 (figure 5.14),
which disagreed with the microanay data. The intensity of the CREB and cyclophylin
bands at cycle 30 were measured (using the Kodak 1 ID progiumme) for both the control
and experimental samples. When the ratio value (CREB:cyclophylin) fiom the
experimental sample (HEK-293 cells over-expressing PDE4A7) was compared to that of
the control sample (HEK-293 cells over-expressing pcDNA3), no significant difference
was found (data not shown). This was the case for both experiment 1 and experiment 2. It
was concluded that CREB expression was unaffected by the over-expression of PDE4A7.
Dup 1 ras-related C3 botulinum toxin (C3), ferritin light chain kinase (FLCK) and protein
kinase CLK2 (CLK2) were genes seemingly down-regulated in response to PDE4A7 over-
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expression using microaiTay analysis. However, when these gene expression changes were 
re-evaluated with RT-PCR analysis (figures 5.16, 5.17 and 5.18, respectively), only CLK2 
appeared to be down-regulated (visually) in response to PDE4A7 over-expression (at cycle 
30) in both experiment 1 and experiment 2 (figure J.78). The intensity of the CLK2 and 
cyclophylin bands at cycle 30 were measured (using the Kodak 1 ID programme) for both 
the control and experimental samples. When the ratio value (CLK2:cyclophylin) from the 
experimental sample (HEK-293 cells over-expressing PDE4A7) was compared with the 
ratio value (CLK2:cyclophylin) fi*om the control sample (HEK-293 cells over-expressing 
pcDNA3), no significant difference was found. This was the case for both experiments. 
Therefore, it was concluded that CLK2 expression remained unchanged in response to the 
over-expression of PDE4A7. The A2B receptor transcript could not be amplified, 
indicating a problem with the primer design (data not shown). A comparison of the gene 
expression changes observed in these candidate genes from both microarray analysis and 
RT-PCR analysis are listed in Table 5.2.
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Table 5.2 Comparison of the predicted and observed molecular sizes (in bp) for the 
target genes.
Target Gene Predicted Size (bp) Observed Size (bp)
Adenosine A2A receptor 350 347±11
cAMP response element 
binding protein
350 337+25
Microtubule-associated 
protein IB
350 339±16
Dup 1 ras-related C3 
botulinum toxin substrate
350 352+12
Ferritin light chain 350 363+10
Protein kinase CLK2 350 356±9
Cyclophylin 250 250+6
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Experiment 1 Experiment 2
PDE4A7
Figure 5.12 Detecting expression of PDE4A7 in cell lysates used 
for RT-PCR analysis. HEK-293 cells were transiently transfected 
with either PDE4A7 plasmid DNA or pcDNA3 plasmid DNA. 
These sets of transfections were performed on two separate 
occasions and the cell lysates separated on the same gel, labelled as 
experiment 1 or experiment 2 above. Cells were harvested in lysis 
buffer, homogenised and centrifuged to remove cellular debris. 
Lysates were subjected to 10% SDS-PAGE gel electrophoresis 
before immunoprobing with the anti-VSV polyclonal antibody. The 
immunoreactive band of PDE4A7 is indicated. Migration of the 
standard protein molecular weight markers (in kDa) are shown on 
the left.
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Figure 5.13 Changes in the adenosine A2A receptor (A2AR) 
transcript level in response to over-expression of PDE4A7. cDNA 
was generated from HEK-293 cells over-expressing either pcDNA3 or 
PDE4A7 plasmid DNA. PCR products were fractionated 
electrophoretic all y on 1.5% agarose gels, stained with ethidium bromide 
and visualised using a UV transilluminator. Two sets of primer pairs 
were included in each PCR reaction, one pair were designed to amplify a 
350bp fragment representing the A2A transcript and the other primer 
pair were designed to amplify a 250bp fragment representing the control 
transcript of cyclophylin. Both bands are clearly labelled on the above 
gels. The two gels labelled experiment 1 and experiment 2 show the 
data obtained from two separate studies. The upper panel of each gel 
shows the change in A2A transcript level in HEK-293 cells in response 
to over-expression of PDE4A7 plasmid DNA, whereas the lower panels 
illustrate changes in A2A transcript level in HEK-293 cells in response 
to the over-expression of pcDNA3 plasmid DNA (negative control). The 
molecular size standards (in bp) are shown on the left.
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Figure 5.14 Changes in cAMP response element binding protein 
(CREB) transcript level in response to over-expression of PDE4A7.
cDNA was generated from HEK-293 cells over-expressing either 
pcDNA3 or PDE4A7 plasmid DNA. PCR products were fractionated 
electrophoretic all y on 1.5% agarose gels, stained with ethidium 
bromide and visualised using a UV transilluminator. Two sets of 
primer pairs were included in each PCR reaction, one pair were 
designed to amplify a 350bp fragment representing the CREB 
transcript and the other primer pair were designed to amplify 
cyclophylin as a 250bp fragment. Both bands are clearly labelled on 
the above gels. The two gels labelled experiment 1 and experiment 2 
show the data obtained from two separate studies. The upper panel of 
each gel shows the change in CREB transcript level in HEK-293 cells 
in response to over-expression of PDE4A7 plasmid DNA, whereas the 
lower panels show the changes in CREB transcript level detected in 
HEK-293 cells in response to the over-expression of pcDNA3 plasmid 
DNA (negative control). The molecular size standards (in bp) are 
shown on the left.
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Figure 5.15 Changes in microtubule-associated protein IB (MAPIB) 
transcript level in response to over-expression of PDE4A7. cDNA 
was generated from HEK-293 cells over-expressing either pcDNA3 or 
PDE4A7 plasmid DNA. PCR products were analysed by 1.5% agarose 
gel electrophoresis. Two sets of primer pairs were included in each PCR 
reaction, one pair were designed to amplify MAP IB as a 350bp 
fragment and the other primer pair were designed to amplify cyclophylin 
as a 250bp fragment. Both bands are clearly labelled on the above gels. 
The two gels labelled experiment 1 and experiment 2 show the data 
obtained from two separate studies. The upper panel of each gel shows 
the change in MAP IB transcript level in HEK-293 cells caused by the 
over-expression of PDE4A7 plasmid DNA, whereas the lower panels 
show the changes in MAP IB transcript level caused by over-expression 
of pcDNA3 plasmid DNA in HEK-293 cells (negative control). The 
molecular size markers are indicated on the left.
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Figure 5.16 Changes in C3 botulinum toxin substrate (C3) 
transcript level in response to over-expression of PDE4A7. cDNA 
was generated from HEK-293 cells over-expressing either pcDNA3 or 
PDE4A7 plasmid DNA. PCR products were fractionated 
electrophoretic all y on 1.5% agarose gels, stained with ethidium 
bromide and visualised using a UV transilluminator. Two sets of 
primer pairs were included in each PCR reaction, one pair were 
designed to amplify a 350bp fragment representing the C3 transcript 
and the other primer pair were designed to amplify a 250bp fragment 
of the cyclophylin control transcript. Both bands are clearly labelled 
on the above gels. The two gels labelled experiment 1 and experiment 
2 show the data obtained from two separate studies. The upper panel 
of each gel shows the change in C3 transcript level in HEK-293 cells in 
response to over-expression of PDE4A7 plasmid DNA, whereas the 
lower panels show the changes in C3 transcript level detected in HEK- 
293 cells in response to the over-expression of pcDNA3 plasmid DNA 
(negative control). The molecular size standards (in bp) are shown on 
the left.
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Figure 5.17 Changes in ferritin light chain kinase (FLCK) transcript 
level in response to over-expression of PDE4A7. cDNA was generated 
from HEK-293 cells over-expressing either pcDNA3 or PDE4A7 
plasmid DNA. PCR products were analysed by 1.5% agarose gel 
electrophoresis. Two sets of primer pairs were included in each PCR 
reaction, one pair were designed to amplify FLCK as a 350bp fragment 
and the other primer pair were designed to amplify cyclophylin as a 
250bp fragment. Both bands are clearly labelled on the above gels. The 
two gels labelled experiment 1 and experiment 2 show the data obtained 
from two separate studies. The upper panel of each gel shows the change 
in FLCK transcript level in HEK-293 cells caused by the over­
expression of PDE4A7 plasmid DNA, whereas the lower panels show 
the changes in FLCK transcript level caused by over-expression of 
pcDNA3 plasmid DNA in HEK-293 cells (negative control). The 
molecular size standards (in bp) are shown on the left.
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Figure 5.18 Changes in protein kinase CLK2 (CLK2) transcript 
level in response to over-expression of PDE4A7. cDNA was 
generated from HEK-293 cells over-expressing either pcDNA3 or 
PDE4A7 plasmid DNA. PCR products were analysed by 1.5 % gel 
electrophoresis. Two sets of primer pairs were included in each PCR 
reaction, one pair were designed to amplify a 350bp fragment 
representing the CLK2 transcript and the other primer pair were 
designed to amplify cyclophylin as a 250bp fragment. Both bands are 
clearly labelled on the above gels. The two gels labelled experiment 
1 and experiment 2 show the data obtained from two separate studies. 
The upper panel of each gel shows the change in CLK2 transcript 
level in response to over-expression of PDE4A7 plasmid DNA in 
HEK-293 cells, whereas the lower panels shows the changes in CLK2 
transcript level detected in HEK-293 cells in response to the over­
expression of pcDNA3 plasmid DNA (negative control). The 
molecular size standards (in bp) are shown on the left.
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Table 5,3 Comparison of the gene expression changes 
detected using gene microarray and RT-PCR analysis.
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5.4 Discussion
In this study microanay analysis was used to detemiine the changes in the gene 
expression profile of HEK-293 cells caused by the over-expression of PDE4A7. A number 
of interesting genes were regulated in response to PDE4A7, which included the genes 
encoding for proteins involved in cAMP signalling such as the A2A receptor, A2B 
receptor, and CREB. Before making conclusions about gene regulation based on the data 
obtained from micro array analysis it was important to evaluate potential changes by using 
an alternative technique. This is because micro array teclinology has been criticised for 
generating false positive data. Problems associated with microarray that can lead to the 
production of misleading data include non-specific background, slide inliomogeneities 
caused by hybridisation occmring differently in different parts o f the slide and variations in 
pin geometry, which can cause the deposition of differing amounts of target DNA onto the 
slide.
RT-PCR was used to re-evaluate the expression changes detected for seven genes 
from the micro array study. Unfortunately 1 was unable to identify any major differences in 
transcript level between the control cells and those over-expressing PDE4A7 for any of the 
targets. This suggested that microarray had generated false positive data. An alternative 
explanation for the lack of data correlation from these two methods is that the RNA used 
for microarray analysis was extracted from a different population of PDE4A7-transfected 
HEK-293 cells to that RNA used for RT-PCR analysis. This made direct comparison of 
the data obtained from the two methods difficult as small differences in the transfection 
efficiency of PDE4A7, differences in the time when the cells were harvested and 
differences in RNA quality are all factors that could have influenced the differences in the 
gene expression profiles of the HEK-293 cells detected by microarray and RT-PCR 
analysis. A better approach would have been to generate HEK cells stably transfected with 
PDE4A7 on an inducible promoter and from these cells prepare enough RNA for use in 
both micro array and RT-PCR analysis. This would obiviate the problems of differences in 
transfection efficiency and would have allowed the direct comparison of gene micro array 
data with RT-PCR data.
In conclusion, 1 was unable to confirm the gene expression changes detected with 
microarray for the A2AR, CREB, MAPI A, C3, and FLCK genes by using RT-PCR 
analysis. That time only allowed me to re-evaluate the changes in a small number of the 
microarray candidates, leaves the possibility that other genes did demonstrate authentic 
changes.
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Another problem with this study was the presumption that by over-expressing 
PDE4A7 we would only detect gene expression changes in those genes specifically 
regulated by this protein. It is probable that the high expression levels of PDE4A7 might 
have upset many other biochemical processes in the cell, resulting in gene changes that 
may not have occun*ed as a direct influence of PDB4A7. A way of addressing the actions 
of endogenous PDE4A7 would be to identify a cell line that natively expresses this protein 
and then to specifically downregulate its expression. Such approaches have traditionally 
used antisense teclmologies, which have been found to be problematic and inefficient. 
However, recently researchers have described a method that could prevent this problem 
[Brummelkamp et al., 2002]. It was demonstrated that RNA interference could be 
achieved by using a mammalian expression vector (pSUPER vector) to suppress the 
expression of a desired gene. Therefore, an alternative approach to identify those genes 
specifically regulated by PDE4A7 would be to identify cell lines that express PDE4A7 
natively and then to treat those cells with a pSUPER vector designed to suppress the 
expression of the PDE4A7 gene. By comparing the gene expression profiles of cells 
expressing endogenous PDE4A7 (as positive control) to those cells treated with the 
pSUPER vector specific for PDE4A7 suppression using the methods of microanay and 
RT-PCR analysis, it would be possible to identify those genes specifically regulated by the 
PDE4A7 protein.
It is possible that PDE4A7 might interact with other transcription factors or affect 
regulatory transcriptional complexes that are involved in controlling the expression of 
other PDE4As. As PDE genes were not present on the gene microan-ay chip used for this 
study, this question remains unanswered. Therefore, useful future experiments would be to 
investigate the changes in the regulation of other PDE genes in response to either over­
expression of recombinant PDE4A7 or to the down-regulation of native PDE4A7 using 
either microarray or RT-PCR analysis. PDE4A mRNA levels have been found to increase 
in response to elevated cAMP levels in U937 human monocytic cells [Engels et al., 1994], 
Mono-Mac-6 cells [Verghese et al., 1995] and Jurkat cells [Engels et al., 1994] and in 
some cell types ean decrease PDE4A mRNA [Erdogan et al., 1997]. PDE4A7 may 
therefore have an active role to play in these processes.
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Chapter 6 
Partial characterisation of the novel cyclic AMP- 
specific phosphodiesterase PDE4A11 (TM3)
6.1 Introduction
As already discussed in the Introduction (section 1.4), the PDE4 enzyme family 
contains -18 isoforms encoded by four different genes (4A, 4B, 4C, 4D). PDE4 enzymes 
all possess a highly conserved catalytic core for the hydrolysis of cAMP and in addition 
possess two other highly conserved regions of sequence, located N-tenninal to the catalytic 
core. These regions are called UCRl and UCR2 for Upstream Conserved Region 1 and 2, 
respectively. Those PDE4 enzymes possessing both a UCRl and UCR2 region are 
refeiTed to as long isoforms, those lacking a UCRl region but contain an intact UCR2 
region are referred to as short isoforms and finally those containing a truncated UCR2 are 
termed super-short isoforms. In addition, each isoform contains a unique N-tenninal 
sequence, which has been shown to target these enzymes to specific intracellular locations.
The human PDE4A gene encodes the two long isoforms of PDE4A4B (PDE46) 
[Huston et al., 1996] and PDE4A10 [Rena et al., 2001], the supershort isoform called 
PDE4A1 (RDI) and the N- and C-terminally truncated isoform called PDE4A7 (2EL) 
[Horton et al., 1995]. As both PDE4A4B and PDE4A10 each have a unique N-terminal, 
exon 1 will differ between each of these long isoforms and for any other long forms 
identified in the future. Exon 14, which encodes for the C-temiinal tail should be the same 
for each of these PDE4A isoforms with the exception of PDE4A7, which undergoes 3’ 
splicing within exon 14 (figure 6.1). That PDEs within a particular gene group contain 
identical sequence in their C-tenninal tails is an attribute that has been utilised to generate 
antisera, which recognises a peptide sequence found only within the C-temiinal sequence 
specific to a particular gene family.
Here, 1 have attempted partial characterisation studies on the novel PDE4A11 
(TM3) isoform. It was suggested originally that ‘TM3’ may be C-terminally truncated and 
be catalytically inactive as was seen for PDE4A7. However, the TM3 construct contains 
sequence for a novel PDE4A together with extraneous sequence originating from a cloning 
artefact as this does not appear in the genomic sequence. Inspection of the PDE4A gene 
has allowed for the identification of a unique exon for a novel PDE4A, called PDE4A11
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(sequence given in figure 6.2). This contains some of the sequence seen in TM3 [Sullivan 
et ah, 1998].
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Figure 6.1 Structure of the PDE4A gene. The structure of 
the PDE4A gene is shown in at the top. The exons are shown 
as boxes, which are joined together by horizontal lines, which 
represent the introns. Initiation and stop codons are 
represented in this diagram by arrows and filled circles, 
respectively. This diagram was taken from [Rena et al., 
2001].
142
1 MARPRGLGRI PELQLVAFPV AVAAEDEAFL PEPLAPRAPR RPRSPPSSPV51 FFASPSPTFR RRLRLLRSCQ DLGRQAWAGA GFEAENGPTP SPGRSPLDSQ101 ASPGLVLHAG AATSQRRESF LYRSDSDYDM SPKTMSRNSS VTSEAHAEDL151 IVTPFAQVLA SLRSVRSNFS LLTNVPVPSN KRSPLGGPTP VCKATLSEET2 01 CQQLARETLE ELDWCLEQLE TMQTYRSVSE MASHKFKRML NRELTHLSEM2 51 SRSGNQVSEY ISTTFLDKQN EVEIPSPTMK EREKQQAPRP RPSQPPPPPV301 PHLQPMSQIT GLKKLMHSNS LNNSNIPRFG VKTDQEELLA QELENLNKWG351 LNIFCVSDYA GGRSLTCIMY MIFQERDLLK KFRIPVDTMV TYMLTLEDHY401 HADVAYHNSL HAADVLQSTH VLLATPALDA VFTDLEILAA LFAAAIHDVD451 HPGVSNQFLI NTNSELALMY NDESVLENHH LAVGFKLLQE DNCDIFQNLS501 KRQRQSLRKM VIDMVLATDM SKHMTLLADL KTMVETKKVT SSGVLLLDNY551 SDRIQVLRNM VHCADLSNPT KPLELYRQWT DRIMAEFFQQ GDRERERGME601 ISPMCDKHTA SVEKSQVGFI DYIVHPLWET WADLVHPDAQ EILDTLEDNR651 DWYYSAIRQS PSPPPEEESR GPGHPPLPDK FQFELTLEEE EEEEISMAQI701 PCTAQEALTA QGLSGVEEAL DATIAWEASP AQESLEVMAQ EASLEAELEA751 VYLTQQAQST GSAPVAPDEF SSREEFWAV SHSSPSALAL QSPLLPAWRT801 LSVSEHAPGL PGLPSTAAEV EAQREHQAAK RACSACAGTF GEDTSALPAP851 GGGGSGGDPT
Figure 6.2 Amino acid sequence of HSPDE4A11 (TM3). The unique 81 amino 
acid N-terminal region of HSPDE4A11 is shown in blue and the sequence that is 
shared by all other long form human PDE4As is shown in black.
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6.2 Results
6.2.1 Distinguishing between the different PDE4A long isoforms
Preliminary expression studies using SDS-PAGE analysis revealed that 
HSPDE4A11 migrates as a similar size to the other PDE4A long-fonns of HSPDE4A4B 
and HSPDE4A10. Indeed, this offered the potential for confusing the identity of these 
enzymes in SDS-PAGE analyses. However, this problem was encountered previously with 
HSPDE4A10 and HSPDE4A4B, but was overcome by producing antisera that specifically 
recognised peptide sequence contained only within the unique N-tenninal of one particular 
isofonn or another. This led to the production of a PDE4A4B N-terminal specific, affinity 
purified antibody (by Novartis), which recognises the peptide sequence of 
‘PPEEESRGPGHPPLPK’ found only within the unique N-terminal of HSPDE4A4B. We 
developed the PDE4A10 N-terminal specific antibody, which recognises the peptide 
sequence of ‘MAMPPTGPESLTHFPFSDED’ located only within the unique N-tenninal 
sequence of HSPDE4A10 [Rena et a l, 2001]. This has allowed us to distinguish between 
these two long fbnn PDE4A isoenzymes. As yet, there is no antibody available for the 
specific detection of the novel HSPDE4A11.
To check the HSPDE4A10- and HSPDE4A4B-specific antisera would not cross- 
react with HSPDE4A11, COS-7 cell lysates transfected with either pSV-SPORT4A4B or 
pcDNA3.1-4All were subjected to subcellular fractionation followed by 10% SDS-PAGE 
analysis (Materials and Methods 2.2.1). The nitrocellulose membrane was firstly 
immunoprobed with the HSPDE4A4B N-terminal specific antisera, which identified a 
125kDa immunoreactive band in all three fractions of those COS-7 cells transfected to 
express HSPDE4A4B (figure 6.3). No bands were detected for the HSPDE4A10 standard, 
or in those cell lysates over-expressing HSPDE4A11. This demonstrated that the 
HSPDE4A4B-specific antisera only detected HSPDE4A4B and did not cross-react with 
HSPDE4A11.
The same nitrocellulose membrane was next immunoprobed with the HSPDE4A10 
N-tenninal specific antisera, which detected a 121kDa immunoreactive species only in the 
lane containing the HSPDE4A10 standard (figure 6.4). This demonstrated that the 
HSPDE4A 10-specific antisera did not cross-react with HSPDE4A11.
Finally, the nitrocellulose was immunoprobed with the general PDE4A C-temiinal 
antisera, which recognises peptide sequence located within the C-tenninal of all known 
human PDE4As (with the exception of the C-tenninally tmncated PDE4A7 enzyme). 
Only when the general PDE4A antisera was used, did bands appear in the lanes containing
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those COS-7 lysates over-expressing HSPDE4A11 (figure 6.5). These analyses 
demonstrated that the PDE4A4B- and PDE4A10-specific antisera were suitable for 
distinguishing between these three long foim isoenzymes, until antisera is generated for the 
specific detection of HSPDE4A11.
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Figure 6.3 Immunoprobing HSPDE4A11 and 
HSPDE4A4B COS-7 cell lysates with the HSPDE4A4B- 
specifîc antisera. COS-7 cells were transfected with either 
pSV.SPORT4A4B or pcDNA3.1-TM3 and allowed to 
express for 48 hours. Cells were lysed, disrupted and 
subjected to subcellular fractionation. 15/rg of the S fraction 
and equal volumes of both the particulate fractions (PI and 
P2) were separated by 10% SDS-PAGE and immunoprobed 
using HSPDE4A4B N-terminal specific antisera. The 
migration of standard protein molecular mass markers are 
indicated on the left. All lanes came from the same gel.
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Figure 6.4 Immunoprobing HSPDE4A11 and 
HSPDE4A4B COS-7 cell lysates with the HSPDE4A10- 
specifîc antisera. The nitrocellulose membrane previously 
immunoprobed with the HSPDE4A4B N-terminal specific 
antibody was re-probed with HSPDE4A10 N-terminal 
specific antisera. Migration of the standard protein 
molecular weight markers are indicated on the left. All lanes 
came from the same gel.
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Figure 6.5 Immunoprobing HSPDE4A11 and 
HSPDE4A4B COS-7 cell lysates with general PDE4A 
antisera. The nitrocellulose membrane previously 
immunoprobed with both the HSPDE4A4B N-terminal 
specific antisera and HSPDE4A10 N-terminal specific 
antisera was re-probed with antisera specific for the common 
C-terminal region of human PDE4A iso forms.. Migration of 
the standard protein molecular weight markers are indicated 
on the left. All lanes came from the same gel.
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6.2.2 Localisation of HSPDE4A11 in transiently transfected COS-7 celts
1 4 9
Lysates from COS-7 cells transfected with either pSV-SPORT4A4B or pcDNAS.l- 
4A ll  were subjected to subcellular fractionation into a low speed particulate fi-action (PI), 
high speed soluble fraction (S2) and a high speed particulate fraction (P2), before being 
subjected to 10% SDS-PAGE analysis (Materials and Methods 2.2,1). HSPDE4A4B was 
included as an ‘internal control’ because the distribution of this enzyme has already been 
established. Immunoblotting was performed using the general PDE4A C-terminal specific 
antibody [Huston et al., 1996], which identified immunoreactive bands in all three cellular 
fractions o f those cells transfected with either pSV-SPORT4A4B or pcDNA3.1-4All 
(figure 6.6). From these immunoblots the molecular size for the novel HSPDE4A11 was ;
calculated from its RF values. The calculated molecular size for PDE4A11 was 118 ± 2 I(n=3; m ean± S.D.).
Quantitative immunoblotting analyses demonstrated that PDE4A11 was distributed 
equally between the soluble (S2) and particulate fractions (PI, P2) (Table 6.1). Similar 
results were obtained when the distribution of HSPDE4A11 activity (IpM  cAMP 
substrate) was calculated (Table 6.1). When the distributions of both HSPDE4A11 and 
HSPDE4A4B were compared they were found to be very similar (Table 6.1).
If time had peimitted LSCM would have been used to visualise the precise 
intracellular localisation in intact COS-7 cells as cellulai* dismption may cause the release 
of PDE4A11 from any protein that it may interact with. This has been shown in previous 
studies whereby cellular disruption analyses of COS-7 cells over-expressing either 
HSPDE4A4B and HSPDE4A10, suggested that both these enzymes were predominantly 
located within the soluble fraction [Huston et al., 1996; Rena et al., 2001]. In contrast,
LSCM studies actually demonstrated that HSPDE4A4B was found predominantly at the 
cell margins and with structures tlrroughout the cell body, and that HSPDE4A10 was 
localised mainly to the perinuclear region of COS-7 cells [Huston et al., 1996; Rena et al.,
2001]. Therefore, according to LSCM analyses these enzymes should have been 
associated with the particulate fr'actions of the COS-7 cells, which was clearly not the case 
after cellular disruption. This highlights the importance of performing LSCM analysis for 
HSPDE4A11.
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Table 6.1 Distribution of HSPDE4A11 and HSPDE4A4B in COS-7 cells
These data are given as means ± S.D. for three separate experiments.
Fraction Distribution of 
4 A ll
(quantitative
immunoblotting)
(%)
Distribution of 
4A ll  (activity) 
(%)
Distribution of 
4A4B
(quantitative
immunoblotting)
(%)
Distribution of 
4A4B (activity) 
(%)
Particulate
(P1,P2)
48.5 + 2.1 53 + 1.5 55 ± 6.6 60 ± 4.2
Soluble
(82)
51,5 + 2.1 47 + 1.5 45 ± 6.6 40 + 4.2
1 5 0
(kDa)
PDE4A4B 
M S P2
PDE4A11 
PÏ S P2
150—
100—
75—
50—
3 7 -
Figure 6.6 Subcellular distribution of HSPDE4A11. COS-7 
cells were transfected with either pSV.SPORT4A4B or 
pcDNA3.1-4All and allowed to express for 48 hours. Cell 
lysates were then subjected to subcellular fractionation and 
20/ig of the S fraction and equal volumes of both particulate 
fractions(Pl and P2) were separated by 10% SDS-PAGE and 
immunoprobed with the general PDE4A C-terminal specific 
antisera. The migration o f protein molecular mass markers are 
indicated on the left. This blot is representative o f results 
obtained from three separate experiments.
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6.3 Kinetic evaluation of HSPDE4A11
6.3.1 Km and relative Vmax values of HSPDE4A11 expressed in transfected 
COS-7 cells
Kinetic evaluation was performed on the HSPDE4A11 activity foimd in both the 
soluble (S2) and particulate (P1,P2) fractions of transfected COS-7 cells. To detennine the 
Km value for the PDE4A11 enzyme, PDE assays were performed (Materials and Methods 
2.4.6.2), except instead of using IpM cAMP a range of cAMP substrate concentrations 
were used (O.l-lOOpM). The data was analysed by computer fitting to the hyperbolic form 
of the Michaelis-Menton equation using the Ultrafit programme (Biosoft, Cambridge, 
U.K). These data showed that the HSPDE4A11 activity in both the soluble (S2) and 
particulate fractions (PI, P2) had very similar Km values (graphs of kinetic data for the 
soluble and particulate fractions shown in figures 6.6 and 6.7 respectively and data values 
are listed in Table 6.2). Also the Km values for HSPDE4A11 were very similar to those 
Km values that were obtained previously for the HSPDE4A4B and HSPDE4A4B enzymes 
[Huston et al., 1996; Rena et al., 2001]. Next, attempts were made to determine whether 
the relative Vmax values for HSPDE4A11 in these various fractions are different. To do 
this I determined the relative amount o f HSPDE4A11 protein found in each of the fractions 
by using quantitative immunoblotting. The relative Vmax for the HSPDE4A11 protein 
found in each of these fractions were calculated using the following equation (adaptation 
of Michaelis- Menton equation):
V -  Vmax rS1 
[S]+Km
The Vmax data demonstrated that particulate HSPDE4A11 protein was less active
than the soluble foim (Table 6.2). A possible explanation for this finding might be that the
association of HSPDE4A11 with the particulate fraction has altered the confonnation of
the catalytic unit. However, this would have to be addressed further by detennining the
I C 5 0  values for inliibition of HSPDE4A11 in the different fractions by rolipram. If the
forms of HSPDE4A11 found in the different fractions showed significant differences in
their sensitivity to rolipram, then it could be concluded that they exist in different
conformational states. Indeed, HSPDE4A4B has been found to exist in two
conformationally distinct states, whereby the particulate species is more sensitive to
rolipram than the soluble foim [Huston, Pooley et al., 1996]. When the Vmax for soluble
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(S2) HSPDE4A11 was compared with the Vmax for soluble (S2) HSPDE4A4B, 
HSPDE4A11 was found to be a less active enzyme (Table 6.3).
Table 6.2 Properties of HSPDE4A11 expressed in COS-7 cells
Values given are means with eiTors as S.D. for separate detenninations done on three 
separate experiments. The Vmax values are given relative to that for soluble HSPDE4A11, 
which is set as unity.
Assay Soluble (S2) HSPDE4A11 Particulate (P1,P2) HSPDE4A11
Km (pM) 2.5+ 0.4 2.44+ 0.7
Relative
V max
(1) 0.74 ± 0.6
Table 6.3 Comparison of the relative Vmax obtained for soluble (S2) HSPDE4A4B and 
HSPDE4A11
The relative Vmax of soluble HSPDE4A11 is compared with the Vmax of soluble 
HSPDE4A4B (given here as unity). Values given are means with errors as S.D. for 
separate determinations done on two separate experiments.
Assay Soluble (S2) HSPDE4A4B Soluble (S2) HSPDE4A11
Relative
V max
(1) 0.41 ± 0.005
1 5 3
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Figure 6.7 Analysis of the for particulate PDE4A11 
expressed in COS-7 cells. COS-7 ceils were transfected with 
pcDNA3.1-4All and allowed to express for 48 hours. Cells 
were harvested, lysed and particulate fractions (PI and P2) 
were prepared as described in Materials and Methods. PDE 
activity was measured over a range of cAMP substrate 
concentrations. Data was analysed by computer fitting to the 
hyperbolic form of the Michaleis-Menton equation using the 
Ultrafit programme (Biosoft). Data shown are the means of 
three separate experiments done on different cell transfections 
with errors as SD.
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Figure 6.8 Analysis of the K^ , for soluble PDE4A11 
expressed in COS-7 cells. COS-7 cells were transfected with 
pcDNA3.1-4All and allowed to express for 48 hours. Cells 
were harvested, lysed and supernatant fractions (S2) were 
prepared as described in Materials and Methods. PDE activity 
was measured over a range of cAMP substrate concentrations. 
Data was analysed by computer fitting to the hyperbolic form 
of the Michaleis-Menton equation using the Ultrafit 
programme (Biosoft). Data shown are the means of two 
separate experiments done on different cell transfections with 
errors as SD.
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6.3 Discussion
In this study, I performed partial characterisation studies on a novel PDE4A long 
isoform called HSPDE4A11. I have demonstrated from subcellular analyses of transfected 
COS-7 cells that HSPDE4A11 has a similar distribution to that of the established 
HSPDE4A4B isoform. Obviously, to gain better insight into the intracellular localisation 
of this protein LSCM analysis would be required. This is because cellular disruption has 
already been shown to cause the release of particulate-associated proteins into the soluble 
fraction [Huston et al., 1996; Rena et a l, 2001]. 1 have also demonstrated that the Vmax of 
soluble HSPDE4A11 protein is similar to that of the particulate species. That the error 
values for Km and Vmax data are high and to reduce these errors experiments will have to 
be repeated.
1 5 6
Chapter 7 
General Discussion
cAMP is involved in regulating a diverse range of signalling processes. The 
enzymes that generate cAMP (adenylyl cyclases), detect cAMP (PKA) and degrade cAMP 
(PDEs) are all involved in controlling the levels of this key second messenger. The 
multiple isoforms of each of these enzymes and their distinct regulatory properties and 
intracellular locations all serve to produce a compartmentalised cell-specific cAMP 
response [Houslay and Milligan, 1997].
The PDE enzymes provide the sole means of degrading cyclic nucleotides in cells 
and, therefore, play a central role in the controlling the levels o f both cAMP and cGMP by 
hydrolysing them into 5’-nucleoside monophosphates. Without these PDE enzymes we 
would fail to see gradients of cAMP in cells and levels of cAMP would rise such that the 
sustained activation of PKA would ensue [Houslay and Milligan, 1997].
PDEs are cuiTently grouped into 11 gene families of which seven families (1, 2, 3, 
4 ,7 ,8 ,1 1 )  are able to functionally hydrolyse cAMP. The cAMP-specific PDE4 family are 
of particular interest within our laboratory as inhibitors of these enzymes have been found 
to serve as anti-inflammatory agents and anti-depressant agents, signifying not only that 
PDE4 enzymes provide targets for novel therapeutics, but also are functionally important 
species [Houslay, 2001]. Indeed, the high interspecies conseiwation of PDE4 enzymes, 
coupled with lack of polymorphisms in coding regions suggest a strong evolutionary 
pressure to keep intact this complex gene family.
PDE4 enzymes are encoded by four genes, which each generate multiple isofonns 
by alternative 5’ mRNA splicing. The distinct N-terminal regions of these enzymes can 
serve to target them to either distinct intracellulai' compartments or to interact with 
cytosolic signalling scaffold proteins as well as conferring regulatory properties on them 
[Houslay, 1996].
As the central role of PDEs within cells is to regulate the levels of cyclic 
nucleotides, it was surprising to find that the PDE4A gene encoded a splice variant, called 
PDE4A7 (2EL) that is devoid of any cAMP-specific PDE catalytic activity [Horton et al., 
1995].
This observation attracted my attention and caused me to investigate this protein
further. 1 began my study by focussing on its intracellular localisation, which then led me
on to attempt to gain insight into its possible functional role. Thus, in Chapter 3 I
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investigated the targeting of PDE4A7 using the methods of general subcellular 
fractionation and Laser Scanning Confocal Microscopy (LSCM). I made the novel finding 
that this protein was located exclusively to the nuclear comp ailment when over-expressed 
in COS-1 cells. This came as a great surprise as previous work had shown that a core 
complex fonned from the catalytic unit and the C-tenninal region was cytosolic, with 
targeting to distinct membrane sites being achieved by the isofoim-specific N-terminal 
region [Shakur, Pryde et al., 1993]. I thus fully expected that the extensively truncated 
PDE4A7, consisting of a truncated catalytic core together with small, unique N- and C- 
teiTninai regions would also be a soluble, cytosolic protein.
I thus demonstrated that although PDE4A7 and PDE4A4B share an identical 
central core region they are localised to very different intracellular locations. The initial 
aim of my study was thus to determine whether the unique N- and C-temiinal regions of 
PDE4A7 underpinned its targeting to the nucleus. As a first attempt to address this 1 
studied chimeras that replaced these regions with those of a PDE4A construct that had a 
defined intracellular targeting. This was PDE4A4C, also known as h6.1, which is found in 
both the cytosolic S2 fraction as well as the particulate PI fraction, due, presumably to the 
action of its N-terminal region. The PDE4A7 chimeras generated were called hybl and 
hyb2. In hybl, the unique C-terminal o f PDE4A7 was replaced with the C-terminal region 
that is found in all PDE4A isoforms, including h6.1. I was able to show that the hybl 
constmct was located not only in the paificulate (PI and P2) fractions but, crucially, the S2 
fraction of COS-1 cells. In hyb2, the unique N-terminal o f PDE4A7 was replaced with the 
N-terminal region common to all PDE4A isoforms, including h6.1. Hyb2 was essentially 
located within the PI particulate fraction. This indicated that the addition of the PDE4A 
common C-terminal region conferred 82 targeting upon PDE4A7. 1 thus concluded that 
the signal responsible for allowing PDE4 isoforms to have extranuclear localisation and to 
appear in the cytosolic fraction was located within the C-terminal region found in all 
known catalytically active PDE4A long and short isoforms.
My next aim was to gain insight into the basis for nuclear targeting of PDE4A7. I
set out first to deteimine whether the unique N-teiminal of PDE4A7 was responsible for
directing it to the nucleus. To address this point two constructs were engineered. In one
construct the unique N- and C-teiminal domains of PDE4A7 were deleted, to yield a core
region and in the other constmct only the unique C-tenninal region of PDE4A7 was
removed. 1 expected that the central core alone would be a fully soluble species and would
become targeted only when the PDE4A7 N-terminal was present. However, this was not
the case. Instead both constmcts were found to associate with the PI particulate fraction.
From these analyses 1 concluded that the targeting signal responsible for the PI association
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of PDE4A7 was located within the central core and not the unique N- or C-terminal 
regions. These data also enforced the idea that the signal responsible for the cytosolic (S2) 
targeting of hybl arose from sequence located C-terminal to the central core. I thus 
attempted to identify the approximate region of where this signal was located in the 
PDE4A C-terminal region by using tmncation analyses of the hybl chimera. Two 
constructs were engineered to address this question. The first o f these, called, delta 328 
contained 19 amino acids of the C-terminal sequence of hybl (also shared by all active 
PDE4As) fused to the PDE4A7 core and N-terminal. The second of these, called, delta 
410 contained 101 amino acids of the PDE4A C-terminal sequence fused to the PDE4A7 
core and N-terminal region.
Subcellular analyses of transfected COS-1 cells showed that delta 328 was 
distributed between both the PI and S2 fractions whilst delta 410 was found to associate 
with the PI, S2 with a small amount foimd in the P2 fraction. From these studies I 
concluded that the minimal common PDE4A C-terminal sequence required to target the 
PDE4A7 central core to the S2 fraction was located between amino acids 309-328 of hybl. 
To try and identify the motif responsible for allowing extranuclear targeting, further 
truncations upstream of residue 328 in hybl would have to be engineered and evaluated. 
This would further localise the targeting motif, whose sequence could then be determined 
by point mutations.
Next, I attempted to elucidate the basis of nuclear entry of PDE4A7. The majority
of proteins that are imported into the nuclear compartment possess an NLS. These take the
form of either a stretch of 3-5 basic amino acid residues (monopartite) or of two basic
stretches of amino acids separated by 10 amino acids (bipartite) [Kalderon et al., 1984;
Robbins et al., 1991]. On this basis, PDE4A7 was found to contain two putative NLSs,
namely KKFR and KKVT, positioned between amino acids 72-75 and amino acids 229-
232 of the hybl sequence, respectively. That these signals are located within the central
core of PDE4A7 made sense, as in previous studies, 1 demonstrated that the central core of
PDE4A7 was able to target exclusively to the PI fraction, as with PDE4A7. However
FDE4A4B, which also harbours this sequence, is found outside the nucleus. This
suggested the possibility either that only in the extensively truncated PDE4A7 protein were
these NLSs exposed or, alternatively, that all PDE4As might have the ability to cycle
tlnough the nucleus. In order to cycle, most proteins contain both an NLS and an NES
[Mattaj et al., 1998]. 1 next hypothesised that if PDE4As were to contain an NES then it
would presumably be located in the common PDE4A C-terminal region. This is because
hybl is found within the S2 fraction whilst appropriate C-tenninal truncation of this
species led to ablation of cytosolic targeting. Thus, 1 analysed this common PDE4A C-
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terminal sequence for the presence of any putative NES s. However, the only putative NES 
that I was able to identify in PDE4A4B was indeed found in the C-terminal region of 
PDE4A4B. However, this motif (LEAELEAVYL) was found between amino acids 436 
and 445 of hybl (conesponding to amino acids 770-779 of PDE4A4B), rather than being 
located between residues 309-328 of hybl (coiTesponding to residues 643-662 of 
PDE4A4B) that were previously found to be responsible for S2 targeting. To deteimine 
whether these putative NLSs and NES were functional, I investigated the targeting of 
constructs whereby these signals were removed by mutation of key residues. However, 
mutation of the putative NLSs on PDE4A7 did not cause this protein to re-localise to the 
S2 fraction, which demonstrated that these motifs did not provide the basis for targeting to 
the nucleus. I had also hoped to examine whether mutation of the ‘LEAELEAVYL’ motif 
would cause hybl to acrue in the nucleus. However, unfortunately the NES mutant did not 
express. It is also possible that amino acids 309-328 of the hybl C-terminal 
(coiTesponding to amino acids 643-662 of PDE4A4B) contain a novel type of NES. To 
evaluate this further, truncation/mutation analyses need to be performed in order to pin 
down the exact requirements (as already suggested). It would then be useful to see if such 
an NES could sei*ve to retarget other nuclear localised proteins. From these various 
analyses I concluded that KKFR and KKVT were not acting as NLSs for PDE4A7 and that 
it gained entry into the nucleus by either passive diffusion or by piggy-backing on another 
protein that does contain an NLS. 1 have yet to prove whether PDE4A4B can cycle 
through the nucleus. Cycling could be addressed in the future by treating cells over­
expressing PDE4A4B with the CRM-1 export inhibitor Leptomycin B and seeing if 
PDE4A4B accumulates in the nucleus as a result. However, it is possible that the active 
PDE4As are too large to enter into the nuclear compartment, or that once synthesised in the 
cytosol they associate with other proteins in the S2 fraction.
In chapter 4, 1 attempted to identify binding partners for PDE4A7, in the hope that
this would give insight into both the functional role and nuclear import mechanism of
PDE4A7. Using the yeast two hybrid screening procedure, 1 identified tlnee possible
binding partners for the PDE4A7 protein; CREB-binding protein (CBP) is a nuclear
protein, which is involved in transcriptional activation of a number of genes [Chirvia,
Kwok et al., 1993]; K1AA0160, which is a new functional gene with no known function to
date [Nagase, Seki et al., 1995]; RanBPM9 was the most abundant insert identified.
RanBPM9 is a nuclear localised protein and has been found to exist in a laige complex of
more than 670kDa, although its precise function remains to be elucidated [Nishitani,
Hirose et al., 2001], That CBP is involved in transcriptional regulation of many different
genes suggested the potential of a similar role for PDE4A7. The interaction with
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RanBPM9 was of interest as it is possible PDE4A7 could be imported into the nucleus by 
piggy-backing on either RanBPM9 or one of the other proteins contained in the large 
RanBPM9 complex. Also uncovering the biological function of the RanBPM9 complex 
would give insight into another possible functional role of PDE4A7. However, upon 
further analysis I demonstrated that both CBP and RanBPM9 were false positives 
generated from the yeast two-hybrid screen whereby upon re-testing RanBPM9 was found 
to autonomously activate the reporter genes and CBP was no longer found to interact with 
PDE4A7. However, the possibility remains that KIAA0160 is an authentic binding partner 
for PDE4A7 and thus its potential interaction needs to be evaluated. Unfortunately I did 
not have time to study this further as I had focussed on evaluating the other species. This 
is because nothing is known of KIAA0160, whilst the other species provided established 
examples of nuclear localised proteins.
Yeast two-hybrid is one of the most popular methods for the detection of protein- 
protein interactions as it is simple, rapid and inexpensive. However, there are a number of 
disadvantages to this system. For example, the yeast system may not provide the post- 
translational modifications required for native folding, or for certain interactions to occur. 
Conversely, protein-protein interactions that occur in the yeast system may not occur in the 
proteins’ native environment. Also, the GAL4 domain may interfere with the ability of the 
fusion proteins to interact. The major disadvantage noted for this system is the tendency 
to produce false positives, which has occurred in this case. There are a number of common 
false positives, which include heat shock proteins (hsps), ribosomal proteins, mitochondrial 
proteins and zinc finger proteins [Golemis et al., 1997]. That RanBPM9 is a zinc finger 
containing protein may explain why it was able to activate reporter genes in the absence of 
a DNA-BD-bait protein. False positives can be generated if  the bait or prey proteins affect 
the colony viability, which in turn would allow colonies to grow even under selective 
conditions. However, few false positives can be explained mechanistically.
An alternative method that could be used in the future to identify binding partners 
for PDE4A7 is that of mass spectrometry, which allows the identification of protein 
complexes. There are four steps to this procedure. Step 1 is to construct a vector encoding 
tagged PDE4A7, which we already have. The tagged PDE4A7 would be transfected into 
the cell type of interest. Next, PDE4A7 would be immunopurified alongside its interacting 
partners and mass spectrometry would be used to unambiguously identify the binding 
partners (details of mass spectrometry method are given in Figeys et al., 2001.
That PDE4A7 was localised to the genomic centre o f the cell, I proposed that the
function of PDE4A7 might be to regulate the transcription of genes involved in cAMP
signalling. To address this 1 used the methods of gene micro array and RT-PCR. From the
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gene micro array analysis I demonstrated that over-expression of recombinant PDE4A7 
affected the regulation of many genes including the cAMP response element binding 
protein (CREB), adenosine A2A and adenosine A2B receptors (A2AR and A2BR, 
respectively). As micro array is a new technique and has been criticised for generating 
false-positive data, I decided to try and verify the changes of seven of the candidate genes 
using the method of RT-PCR. I was unable to confirm the gene expression changes 
identified in the gene microarray study using RT-PCR analysis. However, expression 
changes for a large number of genes were detected from gene micro array analysis and 
given the time available it would not have been possible to re-evaluate them all. Therefore 
it is possible that many of the expression changes in other candidate genes were authentic.
Researchers should be aware that the micro array method is new and there are still 
pitfalls associated with the methodology, therefore all data must be re-evaluated by an 
alternative means. To increase the reliability of microarray data it has been suggested that 
microarray experiments should be repeated between five and nine times. This is because 
data can vary greatly between experiments due to fluctuations in probe, target and array 
preparation, in the hybridization process, background and effects resulting from image 
processing. In this case, microairay experiments were only repeated twice. This was 
because the technique was being used only as an initial screening tool to assess which 
genes may be possible candidates to investigate by RT-PCR. In hindsight, it would have 
been better to increase the number of repeats as the resulting data was quite variable. 
Another point to note is that no statistical analysis was performed on the microarray data 
therefore, any change above baseline level was considered to be a genuine change. In 
contrast, many researchers choose to omit those genes that do not have their expression 
modified by 1.5 or 2.0 fold as they are classified insignificant. As already discussed RT- 
PCR did not confirm the micro an ay data, this is probably because RT-PCR is only 
sensitive enough to detect 1.5 to 2.0 fold changes in expression, however, those genes from 
microarray that were re-evaluated demonstrated changes in expression levels less than this 
threshold. In conclusion, RT-PCR was not sensitive enough to detect the small changes in 
gene expression found in microarray. In future, numerous replicates, stricter normalisation 
and statistical analysis of microarray results should produce more reliable data that can be 
verified independently by alternative methodology if  the changes are authentic.
In this study I have demonstrated that PDE4A7 is targeted exclusively to the
nuclear compartment. This has not been shown for any of the other PDE4s, suggesting
that PDE4A7 must have an important functional role within this compartment. The most
logical reason for this is that PDE4A7 affects gene transcription, perhaps by interacting
with a transcription factor per se or affecting a regulatory transcriptional complex. My
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studies have established a novel feature of PDE4A enzymes, namely that the cytosolic 
targeting is associated with a small portion of the C-tenninal region found in the 
catalytically active PDE4A species. However, as yet, the exact basis for both the nuclear 
targeting and cytosolic targeting remain to be established.
In the future, it would be interesting to determine the binding partners for PDE4A7 
by using mass spectrometry (as already discussed) as opposed to the yeast two-hybrid, 
which could help unravel the mystery behind the function of this protein and the basis of 
its targeting. It would also be interesting to deteimine whether PDE4A7 can affect the 
expression levels of other PDEs. This could be addressed by using the gene chips (now 
available) that have been spotted with PDE cDNAs. It has already been demonstrated that 
PDE4A7 is incapable of hydrolysing cAMP because o f its truncated catalytic site, 
however, it remains to be ascertained whether PDE4A7 is still able to bind cAMP. If 
proven to bind cAMP, then a potential role for PDE4A7 could be protect certain PDE 
isofonns from becoming activated. This could be evaluated by conducting a cAMP 
binding assay as described in Rannels et al., 1983.
Finally, in Chapter 6 ,1 performed preliminary characterisation studies on the novel 
PDE4A isoform, called HSPDE4A11. In this study, I demonstrated that HSPDE4A11 
migrates as a 118kDa protein in both the soluble and particulate fractions. The results from 
the biochemical analyses done on disrupted COS-7 cells suggest that the majority of 
HSPDE4A11 exists as a soluble species. However, as cellular disruption can cause the 
release of these proteins fr om their binding partners, it will be interesting to determine the 
distribution of this protein in intact cells by using LSCM analyses.
The soluble and particulate forms of HSPDE4A11 demonstrated similar Km values 
to each other and also to the other long human isoforms of HSPDE4A4B and 
HSPDE4A10. The soluble form of HSPDE4A11 was found to have a similar Vmax to that 
of the particulate form. In order to draw valid conclusions fr'om this data these 
experiments will have to be repeated to reduce the error values.
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